

MENDELIOME GENE PANEL DGD141114

| Gene | Median coverage | % covered > 10x | % covered > 20x | Associated Phenotype description and OMIM ID |
|-------------|------------------------|---------------------------|---------------------------|--|
| A4GALT | 116.3 | 100% | 100% | [Blood group, P1Pk system, p phenotype], 111400 [Blood group, P1Pk system, P(2) phenotype], 111400 NOR polyagglutination syndrome, 111400 |
| AAAS | 98.2 | 100% | 99% | Achalasia-addisonianism-alacrimia syndrome, 231550 |
| AAGAB | 121.3 | 99% | 95% | Keratoderma, palmoplantar, punctate type IA, 148600 |
| AARS | 91.7 | 98% | 95% | Charcot-Marie-Tooth disease, axonal, type 2N, 613287 |
| AARS2 | 86.4 | 99% | 96% | Combined oxidative phosphorylation deficiency 8, 614096 |
| AASS | 101.1 | 100% | 99% | Hyperlysinemia, 238700 Saccharopinuria, 268700 (1) |
| ABAT | 66.2 | 100% | 92% | GABA-transaminase deficiency, 613163 |
| ABCA1 | 86.2 | 100% | 99% | Tangier disease, 205400 HDL deficiency, type 2, 604091 {Coronary artery disease in familial hypercholesterolemia, protection against}, 143890 |
| ABCA12 | 104.6 | 100% | 99% | Ichthyosis, congenital, autosomal recessive 4A, 601277 Ichthyosis, autosomal recessive 4B (harlequin), 242500 |
| ABCA3 | 91.4 | 99% | 96% | Surfactant metabolism dysfunction, pulmonary, 3, 610921 |
| ABCA4 | 87.8 | 99% | 96% | Stargardt disease 1, 248200 Retinitis pigmentosa 19, 601718 Cone-rod dystrophy 3, 604116 Macular degeneration, age-related, 2, 153800 Fundus flavimaculatus, 248200 Retinal dystrophy, early-onset severe, 248200 |
| ABCB11 | 92.4 | 99% | 97% | Cholestasis, progressive familial intrahepatic 2, 601847 Cholestasis, benign recurrent intrahepatic, 2, 605479 |
| ABCB4 | 96.9 | 98% | 95% | Cholestasis, progressive familial intrahepatic 3, 602347 Cholestasis, intrahepatic, of pregnancy, 3, 614972 Gallbladder disease 1, 600803 |
| ABCB6 | 118.6 | 100% | 98% | Microphthalmia, isolated, with coloboma 7, 614497 [Blood group, Langereis system], 111600 Dyschromatosis universalis hereditaria 3, 615402 |

| | | | | |
|--------|-------|------|------|--|
| ABCB7 | 57.9 | 100% | 94% | Anemia, sideroblastic, with ataxia, 301310 |
| ABCC2 | 102.8 | 100% | 99% | Dubin-Johnson syndrome, 237500 |
| ABCC6 | 51.1 | 71% | 67% | Pseudoxanthoma elasticum, 264800 Pseudoxanthoma elasticum, forme fruste, 177850 Arterial calcification, generalized, of infancy, 2, 614473 |
| ABCC8 | 83.1 | 100% | 97% | Hyperinsulinemic hypoglycemia, familial, 1, 256450 Hypoglycemia of infancy, leucine-sensitive, 240800 Diabetes mellitus, transient neonatal 2, 610374 Diabetes mellitus, noninsulin-dependent, 125853 Diabetes mellitus, permanent neonatal, 6 |
| ABCC9 | 107.1 | 100% | 98% | Cardiomyopathy, dilated, 1O, 608569 Atrial fibrillation, familial, 12, 614050 Hypertrichotic osteochondrodysplasia, 239850 |
| ABCD1 | 31.8 | 73% | 64% | Adrenoleukodystrophy, 300100 Adrenomyeloneuropathy, adult, 300100 |
| ABCD4 | 100.4 | 100% | 97% | Methylmalonic aciduria and homocystinuria, cblJ type, 614857 |
| ABCG5 | 135.1 | 99% | 87% | Sitosterolemia, 210250 |
| ABCG8 | 90.7 | 97% | 96% | Sitosterolemia, 210250 Gallbladder disease 4, 611465 |
| ABHD12 | 61.0 | 98% | 83% | Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 |
| ABHD5 | 121.2 | 100% | 100% | Chanarin-Dorfman syndrome, 275630 |
| ABL1 | 96.2 | 99% | 97% | Leukemia, Philadelphia chromosome-positive, resistant to imatinib |
| ACAD8 | 92.1 | 99% | 94% | Isobutyryl-CoA dehydrogenase deficiency, 611283 |
| ACAD9 | 91.0 | 100% | 99% | ACAD9 deficiency, 611126 |
| ACADM | 147.3 | 100% | 100% | Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 |
| ACADS | 107.7 | 100% | 100% | Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 |
| ACADSB | 85.7 | 98% | 96% | 2-methylbutyrylglycinuria, 610006 |
| ACADVL | 87.5 | 100% | 98% | VLCAD deficiency, 201475 |
| ACAN | 116.2 | 93% | 90% | Spondyloepiphyseal dysplasia, Kimberley type, 608361 Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 Osteochondritis dissecans, short stature, and early-onset osteoarthritis, 165800 |
| ACAT1 | 109.9 | 100% | 98% | Alpha-methylacetoacetic aciduria, 203750 |

| | | | | |
|--------|-------|------|------|--|
| ACE | 90.1 | 97% | 95% | {Myocardial infarction, susceptibility to} {Alzheimer disease, susceptibility to}, 104300 {Microvascular complications of diabetes 3}, 612624 [Angiotensin I-converting enzyme, benign serum increase] {SARS, progression of} Renal tubular |
| ACO2 | 77.9 | 90% | 83% | Infantile cerebellar-retinal degeneration, 614559 |
| ACOX1 | 75.3 | 99% | 93% | Peroxisomal acyl-CoA oxidase deficiency, 264470 |
| ACP5 | 98.3 | 100% | 100% | Spondyloenchondrodysplasia with immune dysregulation, 607944 |
| ACSF3 | 77.6 | 100% | 99% | Combined malonic and methylmalonic aciduria, 614265 |
| ACSL4 | 67.4 | 100% | 97% | Mental retardation, X-linked 63, 300387 |
| ACSL6 | 86.9 | 100% | 99% | Myelodysplastic syndrome Myelogenous leukemia, acute |
| ACTA1 | 73.6 | 99% | 94% | Nemaline myopathy 3, autosomal dominant or recessive, 161800 Myopathy, actin, congenital, with excess of thin myofilaments, 161800 Myopathy, actin, congenital, with cores, 161800 Myopathy, congenital, with fiber-type disproportion 1, 255310 |
| ACTA2 | 84.6 | 100% | 99% | Aortic aneurysm, familial thoracic 6, 611788 Multisystemic smooth muscle dysfunction syndrome, 613834 Moyamoya disease 5, 614042 |
| ACTB | 60.1 | 97% | 90% | Dystonia, juvenile-onset, 607371 Baraitser-Winter syndrome 1, 243310 |
| ACTC1 | 82.8 | 100% | 93% | Cardiomyopathy, dilated, 1R, 613424 Cardiomyopathy, familial hypertrophic, 11, 612098 Atrial septal defect 5, 612794 Left ventricular noncompaction 4, 613424 |
| ACTG1 | 56.9 | 99% | 93% | Deafness, autosomal dominant 20/26, 604717 Baraitser-Winter syndrome 2, 614583 |
| ACTN1 | 92.2 | 99% | 97% | Bleeding disorder, platelet-type, 15, 615193 |
| ACTN4 | 95.0 | 99% | 96% | Glomerulosclerosis, focal segmental, 1, 603278 |
| ACVR1 | 91.8 | 100% | 97% | Fibrodysplasia ossificans progressiva, 135100 |
| ACVR1B | 105.2 | 98% | 92% | Pancreatic cancer, somatic |
| ACVR2B | 84.4 | 96% | 96% | Heterotaxy, visceral, 4, autosomal, 613751 |
| ACVRL1 | 55.3 | 93% | 86% | Telangiectasia, hereditary hemorrhagic, type 2, 600376 |
| ACY1 | 87.8 | 100% | 97% | Aminoacylase 1 deficiency, 609924 |
| ADA | 70.7 | 100% | 95% | Severe combined immunodeficiency due to ADA deficiency, 102700 Adenosine deaminase deficiency, partial, 102700 |

| | | | | |
|----------|-------|------|------|--|
| ADAM10 | 126.6 | 100% | 100% | Reticulate acropigmentation of Kitamura, 615537 {Alzheimer disease 18, susceptibility to} |
| ADAM17 | 112.3 | 99% | 98% | Inflammatory skin and bowel disease, neonatal, 614328 |
| ADAM9 | 118.1 | 100% | 98% | Cone-rod dystrophy 9, 612775 |
| ADAMTS10 | 74.9 | 97% | 92% | Weill-Marchesani syndrome 1, recessive, 277600 |
| ADAMTS13 | 57.7 | 94% | 84% | Thrombotic thrombocytopenic purpura, familial, 274150 |
| ADAMTS17 | 75.2 | 92% | 84% | Weill-Marchesani-like syndrome, 613195 |
| ADAMTS18 | 99.3 | 100% | 98% | Microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 |
| ADAMTS2 | 95.1 | 97% | 92% | Ehlers-Danlos syndrome, type VIIC, 225410 |
| ADAMTSL2 | 64.7 | 96% | 79% | Geleophysic dysplasia 1, 231050 |
| ADAMTSL4 | 95.1 | 100% | 96% | Ectopia lentis, isolated, autosomal recessive, 225100 Ectopia lentis et pupillae, 225200 |
| ADAR | 137.0 | 99% | 98% | Dyschromatosis symmetrica hereditaria, 127400 Aicardi-Goutieres syndrome 6, 615010 |
| ADAT3 | 48.3 | 100% | 99% | Mental retardation, autosomal recessive 36, 615286 |
| ADCK3 | 97.8 | 100% | 95% | Coenzyme Q10 deficiency primary 4 |
| ADCK4 | 68.6 | 100% | 91% | Nephrotic syndrome, type 9, 615573 (3) |
| ADCY5 | 83.2 | 98% | 94% | Dyskinesia, familial, with facial myokymia, 606703 |
| ADIPOQ | 144.6 | 100% | 100% | Adiponectin deficiency, 612556 |
| ADK | 123.9 | 94% | 94% | Hypermethioninemia due to adenosine kinase deficiency, 614300 |
| ADRB2 | 145.3 | 100% | 100% | {Asthma, nocturnal, susceptibility to}, 600807 {Obesity, susceptibility to}, 601665 Beta-2-adrenoreceptor agonist, reduced response to |
| ADSL | 127.7 | 100% | 98% | ade(-)I bifunctional Adenylosuccinase deficiency, 103050 |
| AFF2 | 70.4 | 98% | 95% | Mental retardation, X-linked, FRAXE type, 309548 |
| AFG3L2 | 76.4 | 95% | 91% | Spinocerebellar ataxia 28, 610246 Ataxia, spastic, 5, autosomal recessive, 614487 |
| AGA | 117.2 | 100% | 89% | Aspartylglucosaminuria |
| AGBL1 | 96.1 | 100% | 99% | Corneal dystrophy, Fuchs endothelial, 8, 615523 (3) |
| AGK | 106.6 | 100% | 100% | Sengers syndrome, 212350 Cataract 38, autosomal recessive, 614691 |

| | | | | |
|--------|-------|------|------|--|
| AGL | 145.6 | 100% | 100% | Glycogen storage disease IIIa, 232400 Glycogen storage disease IIIb, 232400 |
| AGPAT2 | 62.9 | 95% | 82% | Lipodystrophy, congenital generalized, type 1, 608594 |
| AGPS | 116.3 | 100% | 100% | Rhizomelic chondrodysplasia punctata, type 3, 600121 |
| AGRN | 80.7 | 97% | 90% | Myasthenia, limb-girdle, familial, 254300 |
| AGT | 122.9 | 100% | 100% | {Hypertension, essential, susceptibility to}, 145500 {Preeclampsia, susceptibility to} Renal tubular dysgenesis, 267430 |
| AGTR1 | 147.4 | 97% | 97% | Hypertension, essential, 145500 Renal tubular dysgenesis, 267430 |
| AGXT | 88.5 | 97% | 90% | Hyperoxaluria, primary, type 1, 259900 |
| AHCY | 70.6 | 92% | 73% | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 |
| AHI1 | 114.6 | 100% | 99% | Joubert syndrome-3, 608629 |
| AICDA | 81.0 | 100% | 99% | Immunodeficiency with hyper-IgM, type 2, 605258 |
| AIFM1 | 57.2 | 99% | 88% | Combined oxidative phosphorylation deficiency 6, 300816 Cowchock syndrome, 310490 |
| AIMP1 | 125.6 | 100% | 100% | Leukodystrophy, hypomyelinating, 3, 260600 |
| AIP | 94.0 | 96% | 91% | Pituitary adenoma, growth hormone-secreting, 102200 Pituitary adenoma, prolactin-secreting, 600634 Pituitary adenoma, ACTH-secreting, 219090 |
| AIPL1 | 88.9 | 100% | 100% | Leber congenital amaurosis 4, 604393 Retinitis pigmentosa, juvenile, 604393 Cone-rod dystrophy, 604393 |
| AIRE | 70.1 | 98% | 91% | Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 |
| AK1 | 86.6 | 100% | 98% | Hemolytic anemia due to adenylate kinase deficiency, 612631 |
| AK2 | 73.5 | 77% | 75% | Reticular dysgenesis, 267500 |
| AKAP9 | 131.6 | 100% | 99% | Long QT syndrome-11, 611820 |
| AKR1C2 | 76.9 | 96% | 75% | Obesity, hyperphagia, and developmental delay 46XY sex reversal 8, 614279 |
| AKR1D1 | 98.0 | 100% | 100% | Bile acid synthesis defect, congenital, 2, 235555 |

| | | | | |
|----------|-------|------|------|---|
| AKT1 | 121.7 | 100% | 97% | IGH Breast cancer, somatic, 114480 Colorectal cancer, somatic, 114500 Ovarian cancer, somatic, 167000 {Schizophrenia, susceptibility to}, 181500 (2) Proteus syndrome, somatic, 176920 Cowden syndrome 6, 615109 |
| AKT2 | 117.1 | 98% | 96% | Diabetes mellitus, type II, 125853 Hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 |
| AKT3 | 115.6 | 100% | 94% | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome, 603387 |
| ALAD | 83.5 | 100% | 95% | Porphyria, acute hepatic, 612740 {Lead poisoning, susceptibility to}, 612740 |
| ALAS2 | 41.0 | 87% | 79% | Anemia, sideroblastic, X-linked, 300751 Protoporphyrina, erythropoietic, X-linked, 300752 |
| ALB | 106.9 | 100% | 97% | Analbuminemia [Dysalbuminemic hyperthyroxinemia] [Dysalbuminemic hyperzincemia], 194470 (1) |
| ALDH18A1 | 91.9 | 97% | 91% | Cutis laxa, autosomal recessive, type IIIA, 219150 |
| ALDH1A3 | 83.5 | 99% | 93% | Microphthalmia, isolated 8, 615113 |
| ALDH2 | 87.4 | 98% | 93% | Alcohol sensitivity, acute, 610251 {Hangover, susceptibility to}, 610251 {Sublingual nitroglycerin, susceptibility to poor response to} {Esophageal cancer, alcohol-related, susceptibility to} |
| ALDH3A2 | 97.3 | 100% | 100% | Sjogren-Larsson syndrome, 270200 |
| ALDH4A1 | 69.4 | 94% | 89% | Hyperprolinemia, type II, 239510 |
| ALDH5A1 | 71.8 | 97% | 95% | Succinic semialdehyde dehydrogenase deficiency, 271980 |
| ALDH6A1 | 100.9 | 100% | 100% | Methylmalonate semialdehyde dehydrogenase deficiency, 614105 |
| ALDH7A1 | 64.9 | 90% | 87% | Epilepsy, pyridoxine-dependent, 266100 |
| ALDOA | 111.4 | 98% | 94% | Glycogen storage disease XII, 611881 |
| ALDOB | 106.5 | 100% | 98% | Fructose intolerance, 229600 |
| ALG1 | 47.7 | 45% | 45% | Congenital disorder of glycosylation, type I κ , 608540 |
| ALG11 | 154.3 | 100% | 100% | Congenital disorder of glycosylation, type I ρ , 613661 |
| ALG12 | 103.4 | 100% | 97% | Congenital disorder of glycosylation, type I η , 607143 |
| ALG13 | 58.2 | 93% | 85% | Congenital disorder of glycosylation, type I σ , 300884 |
| ALG2 | 115.0 | 100% | 97% | Congenital disorder of glycosylation, type I ι , 607906 |
| ALG3 | 83.7 | 100% | 93% | Congenital disorder of glycosylation, type I δ , 601110 |

| | | | | |
|---------|-------|------|------|--|
| ALG6 | 104.1 | 100% | 100% | Congenital disorder of glycosylation, type Ic, 603147 |
| ALG8 | 85.2 | 96% | 95% | Congenital disorder of glycosylation, type Ih, 608104 |
| ALG9 | 83.5 | 100% | 99% | Congenital disorder of glycosylation, type II, 608776 |
| ALMS1 | 195.4 | 98% | 98% | Alstrom syndrome, 203800 |
| ALOX12B | 101.5 | 100% | 99% | Ichthyosis, congenital, autosomal recessive 2, 242100 |
| ALOXE3 | 84.2 | 100% | 96% | Ichthyosis, congenital, autosomal recessive 3, 606545 |
| ALPL | 80.7 | 100% | 100% | Hypophosphatasia, infantile, 241500 Hypophosphatasia, childhood, 241510 Odontohypophosphatasia, 146300 Hypophosphatasia, adult, 146300 |
| ALS2 | 143.8 | 99% | 97% | Amyotrophic lateral sclerosis 2, juvenile, 205100 Primary lateral sclerosis, juvenile, 606353 Spastic paralysis, infantile onset ascending, 607225 |
| ALX1 | 161.4 | 100% | 100% | Frontonasal dysplasia 3, 613456 |
| ALX3 | 75.4 | 85% | 80% | Frontonasal dysplasia 1, 136760 |
| ALX4 | 80.4 | 100% | 98% | Parietal foramina 2, 609597 Frontonasal dysplasia 2, 613451 |
| AMACR | 82.8 | 100% | 100% | Alpha-methylacyl-CoA racemase deficiency, 614307 Bile acid synthesis defect, congenital, 4, 214950 |
| AMELX | 62.2 | 100% | 96% | Amelogenesis imperfecta, hypoplastic/hypomaturation type 1E, 301200 -3 |
| AMER1 | 67.4 | 100% | 98% | Osteopathia striata with cranial sclerosis |
| AMH | 33.2 | 84% | 71% | Persistent Mullerian duct syndrome, type I, 261550 |
| AMHR2 | 119.0 | 100% | 99% | Persistent Mullerian duct syndrome, type II, 261550 |
| AMN | 65.8 | 89% | 85% | Megaloblastic anemia-1, Norwegian type, 261100 |
| AMPD1 | 106.6 | 100% | 99% | Myoadenylate deaminase deficiency |
| AMT | 127.5 | 100% | 99% | Glycine encephalopathy, 605899 |
| ANG | 155.1 | 100% | 99% | Amyotrophic lateral sclerosis 9, 611895 |
| ANGPTL3 | 128.0 | 100% | 99% | Hypobetalipoproteinemia, familial, 2, 605019 |
| ANK1 | 95.6 | 99% | 96% | Spherocytosis, type 1, 182900 |
| ANK2 | 125.4 | 100% | 99% | Long QT syndrome-4, 600919 Cardiac arrhythmia, ankyrin-B-related, 600919 |
| ANKH | 110.5 | 100% | 99% | Craniometaphyseal dysplasia, 123000 Chondrocalcinosis 2, 118600 |
| ANKK1 | 100.2 | 100% | 99% | Dopamine receptor D2, reduced brain density of |
| ANKRD11 | 118.3 | 91% | 87% | KBG syndrome, 148050 |
| ANKRD26 | 119.9 | 100% | 97% | Thrombocytopenia 2, 188000 |

| | | | | |
|--------|-------|------|------|---|
| ANKS6 | 62.7 | 96% | 85% | Nephronophthisis 16, 615382 |
| ANO10 | 96.1 | 99% | 97% | Spinocerebellar ataxia, autosomal recessive 10, 613728 |
| ANO3 | 109.4 | 100% | 100% | Dystonia 24, 615034 |
| ANO5 | 103.4 | 100% | 100% | Gnathodiaphyseal dysplasia, 166260 Muscular dystrophy, limb-girdle, type 2L, 611307 Miyoshi muscular dystrophy 3, 613319 |
| ANO6 | 92.8 | 98% | 95% | Scott syndrome, 262890 |
| ANTXR1 | 83.3 | 97% | 91% | {Hemangioma, capillary infantile, susceptibility to}, 602089 GAPO syndrome, 230740 |
| ANTXR2 | 120.7 | 100% | 100% | Hyaline fibromatosis syndrome, 228600 |
| AP1S1 | 79.9 | 100% | 99% | MEDNIK syndrome, 609313 |
| AP1S2 | 95.3 | 100% | 100% | Mental retardation, X-linked syndromic, Fried type, 300630 |
| AP2S1 | 84.7 | 100% | 100% | Hypocalciuric hypercalcemia, familial, type III, 600740 |
| AP3B1 | 109.5 | 100% | 99% | Hermansky-Pudlak syndrome 2, 608233 |
| AP4B1 | 107.5 | 100% | 100% | Spastic paraplegia 47, autosomal recessive, 614066 |
| AP4E1 | 136.2 | 100% | 99% | Spastic paraplegia 51, autosomal recessive, 613744 |
| AP4M1 | 102.6 | 100% | 98% | Spastic paraplegia 50, autosomal recessive, 612936 |
| AP4S1 | 76.7 | 99% | 87% | Spastic paraplegia 52, autosomal recessive, 614067 |
| AP5Z1 | 75.3 | 96% | 90% | Spastic paraplegia 48, autosomal recessive, 613647 |
| APC | 150.5 | 100% | 100% | Adenomatous polyposis coli, 175100 Gastric cancer, somatic, 613659 Adenoma, periampullary, somatic Hepatoblastoma, somatic, 114550 Desmoid disease, hereditary, 135290 Colorectal cancer, somatic, 114500 Brain tumor-polyposis syndrom |
| APCDD1 | 123.4 | 100% | 99% | Hypotrichosis simplex, 605389 |
| APOA1 | 80.5 | 100% | 95% | ApoA-I and apoC-III deficiency, combined Hypoalphalipoproteinemia, 604091 Corneal clouding, autosomal recessive Amyloidosis, 3 or more types, 105200 |
| APOA2 | 83.7 | 100% | 100% | Apolipoprotein A-II deficiency {Hypercholesterolemia, familial, modification of}, 143890 |
| APOA5 | 129.6 | 100% | 100% | {Hypertriglyceridemia, susceptibility to}, 145750 Hyperchylomicronemia, late-onset, 144650 |

| | | | | |
|----------|-------|------|------|--|
| APOB | 162.5 | 99% | 99% | Ag linked Hypobetalipoproteinemia Hypobetalipoproteinemia, normotriglyceridemic Hypercholesterolemia, due to ligand-defective apo B, 144010 |
| APOC2 | 156.8 | 100% | 100% | Hyperlipoproteinemia, type Ib, 207750 |
| APOC3 | 99.8 | 100% | 100% | Hyperalphalipoproteinemia 2, 614028 |
| APOE | 43.5 | 82% | 73% | {Myocardial infarction, susceptibility to}, 608446 |
| APOE | 43.5 | 82% | 73% | Hyperlipoproteinemia, type III {Myocardial infarction susceptibility} Sea-blue histiocyte disease, 269600 Alzheimer disease-2, 104310 {?Macular degeneration, age-related}, 603075 Lipoprotein glomerulopathy, 611771 |
| APP | 89.0 | 100% | 99% | Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, 605714 Alzheimer disease 1, familial, 104300 |
| APRT | 47.5 | 100% | 91% | Adenine phosphoribosyltransferase deficiency, 614723 |
| APTX | 120.8 | 96% | 94% | Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 |
| AQP2 | 87.6 | 91% | 87% | Diabetes insipidus, nephrogenic, 125800 |
| AQP5 | 103.4 | 100% | 94% | Palmoplantar keratoderma, Bothnian type, 600231 |
| AR | 48.5 | 99% | 92% | Androgen insensitivity, 300068 Spinal and bulbar muscular atrophy of Kennedy, 313200 Androgen insensitivity, partial, with or without breast cancer, 312300 {Prostate cancer, susceptibility to}, 176807 Hypospadias 1, X-linked, 300633 |
| ARFGEF2 | 114.4 | 100% | 99% | Periventricular heterotopia with microcephaly, 608097 |
| ARG1 | 135.0 | 98% | 91% | Argininemia, 207800 |
| ARHGAP26 | 118.8 | 100% | 99% | Leukemia, juvenile myelomonocytic, 607785 |
| ARHGAP31 | 134.5 | 100% | 99% | Adams-Oliver syndrome 1, 100300 |
| ARHGEF10 | 92.9 | 98% | 94% | Slowed nerve conduction velocity, AD, 608236 |
| ARHGEF12 | 121.4 | 99% | 99% | Leukemia, acute myeloid, 601626 |
| ARHGEF6 | 54.8 | 97% | 93% | Mental retardation, X-linked 46, 300436 |

| | | | | |
|---------|-------|------|------|--|
| ARHGEF9 | 50.1 | 96% | 87% | Epileptic encephalopathy, early infantile, 8, 300607 |
| ARID1A | 102.5 | 99% | 95% | Mental retardation, autosomal dominant 14, 614607 |
| ARID1B | 122.4 | 100% | 98% | Mental retardation, autosomal dominant 12, 614562 |
| ARL13B | 126.0 | 99% | 95% | Joubert syndrome 8, 612291 |
| ARL2BP | 85.2 | 100% | 96% | Retinitis pigmentosa with or without situs inversus, 615434 |
| ARL6 | 160.1 | 100% | 100% | Bardet-Biedl syndrome 3, 209900 {Bardet-Biedl syndrome 1, modifier of}, 209900 Retinitis pigmentosa 55, 613575 |
| ARMC4 | 97.3 | 87% | 85% | Ciliary dyskinesia, primary, 23, 615451 |
| ARNT | 82.0 | 96% | 92% | Leukemia, acute myeloblastic |
| ARSA | 87.1 | 97% | 94% | Metachromatic leukodystrophy, 250100 |
| ARSB | 91.1 | 100% | 99% | Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 |
| ARSE | 49.9 | 90% | 75% | Chondrodysplasia punctata, X-linked recessive, 302950 |
| ARX | 31.5 | 76% | 62% | Epileptic encephalopathy, early infantile, 1, 308350 Lissencephaly, X-linked 2, 300215 Mental retardation, X-linked 29 and others, 300419 Proud syndrome, 300004 Partington syndrome, 309510 Hydranencephaly with abnormal genitalia, 30021 |
| ASAHI | 99.1 | 100% | 100% | Farber lipogranulomatosis, 228000 Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 |
| ASB10 | 73.1 | 92% | 86% | Glaucoma 1, open angle, F, 603383 |
| ASCC1 | 96.7 | 93% | 88% | Barrett esophagus/esophageal adenocarcinoma, 614266 |
| ASCL1 | 154.4 | 100% | 100% | Central hypoventilation syndrome, congenital, 209880 Haddad syndrome, 209880 |
| ASL | 81.3 | 99% | 96% | Argininosuccinic aciduria, 207900 |
| ASNS | 64.5 | 92% | 87% | temperature sensitive G1 mutant |
| ASPA | 112.8 | 100% | 99% | Canavan disease, 271900 |
| ASPM | 141.0 | 100% | 99% | Microcephaly 5, primary, autosomal recessive, 608716 |
| ASPSCR1 | 75.3 | 97% | 93% | Alveolar soft-part sarcoma, 606243 |
| ASS1 | 40.4 | 85% | 60% | Citrullinemia, 215700 |
| ASXL1 | 143.4 | 98% | 96% | Bohring-Opitz syndrome, 605039 Myelodysplastic syndrome, somatic, 614286 |
| ASXL3 | 157.3 | 100% | 99% | Bainbridge-Ropers syndrome, 615485 |
| ATCAY | 104.3 | 100% | 100% | Ataxia, cerebellar, Cayman type, 601238 |

| | | | | |
|----------|-------|------|------|--|
| ATIC | 115.4 | 100% | 99% | AICA-ribosiduria due to ATIC deficiency, 608688 |
| ATL1 | 108.5 | 100% | 99% | Spastic paraplegia 3A, autosomal dominant, 182600 Neuropathy, hereditary sensory, type ID, 613708 |
| ATL3 | 100.4 | 99% | 97% | Neuropathy, hereditary sensory, type IF, 615632 |
| ATM | 118.0 | 100% | 99% | Ataxia-telangiectasia, 208900 Lymphoma, B-cell non-Hodgkin, somatic {Breast cancer, susceptibility to}, 114480 Lymphoma, mantle cell T-cell prolymphocytic leukemia, somatic |
| ATN1 | 119.7 | 97% | 97% | Dentatorubro-pallidoluysian atrophy, 125370 |
| ATP13A2 | 81.3 | 97% | 91% | Parkinson disease 9, 606693 |
| ATP1A2 | 100.1 | 100% | 98% | Migraine, familial hemiplegic, 2, 602481 Alternating hemiplegia of childhood, 104290 Migraine, familial basilar, 602481 |
| ATP1A3 | 110.1 | 100% | 98% | Dystonia-12, 128235 Alternating hemiplegia of childhood 2, 614820 |
| ATP2A1 | 121.2 | 100% | 99% | Brody myopathy, 601003 |
| ATP2A2 | 120.5 | 100% | 100% | Darier disease, 124200 Acrokeratosis verruciformis, 101900 |
| ATP2C1 | 119.6 | 100% | 100% | Hailey-Hailey disease, 169600 |
| ATP5E | 159.8 | 100% | 100% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3, 614053 |
| ATP6V0A2 | 106.5 | 100% | 99% | Cutis laxa, autosomal recessive, type IIA, 219200 Wrinkly skin syndrome, 278250 |
| ATP6V0A4 | 77.6 | 99% | 93% | Renal tubular acidosis, distal, autosomal recessive, 602722 |
| ATP6V1B1 | 98.0 | 100% | 98% | Renal tubular acidosis with deafness |
| ATP7A | 60.3 | 100% | 97% | Menkes disease, 309400 Occipital horn syndrome, 304150 Spinal muscular atrophy, distal, X-linked 3, 300489 |
| ATP7B | 125.7 | 100% | 98% | Wilson disease, 277900 |
| ATP8B1 | 113.5 | 99% | 98% | Cholestasis, progressive familial intrahepatic 1, 211600 Cholestasis, benign recurrent intrahepatic, 243300 Cholestasis, intrahepatic, of pregnancy, 1, 147480 |
| ATPAF2 | 70.9 | 100% | 98% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1, 604273 |

| | | | | |
|----------|-------|------|------|---|
| ATR | 119.4 | 100% | 99% | Seckel syndrome 1, 210600 Cutaneous telangiectasia and cancer syndrome, familial, 614564 |
| ATRX | 73.1 | 100% | 98% | Alpha-thalassemia/mental retardation syndrome, 301040 Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 Mental retardation-hypotonic facies syndrome, X-linked, 309580 |
| ATXN1 | 89.1 | 100% | 100% | Spinocerebellar ataxia 1, 164400 |
| ATXN10 | 118.4 | 100% | 100% | Spinocerebellar ataxia 10, 603516 |
| ATXN2 | 97.6 | 89% | 80% | Spinocerebellar ataxia 2, 183090 {Amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 |
| ATXN3 | 125.6 | 100% | 100% | Machado-Joseph disease, 109150 |
| ATXN7 | 129.0 | 97% | 95% | Spinocerebellar ataxia 7, 164500 |
| AUH | 114.5 | 100% | 100% | 3-methylglutaconic aciduria, type I, 250950 |
| AURKC | 102.7 | 100% | 99% | Spermatogenic failure 5 |
| AVP | 39.8 | 93% | 68% | Diabetes insipidus, neurohypophyseal, 125700 |
| AVPR2 | 44.8 | 95% | 89% | Diabetes insipidus, nephrogenic, 304800 Nephrogenic syndrome of inappropriate antidiuresis, 300539 |
| AXIN1 | 127.5 | 97% | 92% | Hepatocellular carcinoma, somatic, 114550 Caudal duplication anomaly, 607864 |
| AXIN2 | 100.1 | 98% | 92% | Oligodontia-colorectal cancer syndrome, 608615 Colorectal cancer, somatic, 114500 |
| B2M | 163.4 | 100% | 100% | Hypoproteinemia, hypercatabolic, 241600 |
| B3GALNT2 | 79.9 | 90% | 87% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies type A 11 |
| B3GALT6 | 64.0 | 77% | 75% | Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 Ehlers-Danlos syndrome, progeroid type, 2, 615349 |
| B3GALT1 | 107.6 | 95% | 95% | Peters-plus syndrome, 261540 |
| B3GAT3 | 58.8 | 97% | 83% | Multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects, 245600 |
| B3GNT1 | 106.0 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 |
| B4GALNT1 | 80.3 | 95% | 86% | Spastic paraplegia 26, autosomal recessive, 609195 |
| B4GALT1 | 78.9 | 100% | 100% | Congenital disorder of glycosylation, type IIb, 607091 |
| B4GALT7 | 89.7 | 100% | 95% | Ehlers-Danlos syndrome, progeroid type, 1, 130070 |
| B9D1 | 83.9 | 100% | 93% | Meckel syndrome 9, 614209 |
| B9D2 | 49.9 | 100% | 98% | Meckel syndrome 10, 614175 |

| | | | | |
|--------|-------|------|------|--|
| BAAT | 123.0 | 100% | 99% | Hypercholanemia, familial, 607748 |
| BAG3 | 151.0 | 100% | 100% | Myopathy, myofibrillar, 6, 612954 Cardiomyopathy, dilated, 1HH, 613881 |
| BANF1 | 54.6 | 86% | 54% | Nestor-Guillermo progeria syndrome, 614008 |
| BAP1 | 88.2 | 100% | 98% | Tumor predisposition syndrome, 614327 |
| BAX | 88.3 | 99% | 95% | Colorectal cancer T-cell acute lymphoblastic leukemia |
| BBS1 | 114.8 | 100% | 98% | Bardet-Biedl syndrome 1, 209900 |
| BBS10 | 126.9 | 100% | 100% | Bardet-Biedl syndrome 10, 209900 |
| BBS12 | 144.1 | 100% | 100% | Bardet-Biedl syndrome 12, 209900 |
| BBS2 | 115.0 | 100% | 99% | Bardet-Biedl syndrome 2, 209900 |
| BBS4 | 91.7 | 95% | 91% | Bardet-Biedl syndrome 4, 209900 |
| BBS5 | 150.6 | 100% | 100% | Bardet-Biedl syndrome 5, 209900 |
| BBS7 | 130.1 | 100% | 99% | Bardet-Biedl syndrome 7, 209900 |
| BBS9 | 124.4 | 100% | 100% | Bardet-Biedl syndrome 9 |
| BCAP31 | 40.7 | 78% | 72% | Deafness, dystonia, and cerebral hypomyelination, 300475 (3) |
| BCHE | 164.2 | 100% | 100% | Apnea, postanesthetic |
| BCKDHA | 102.4 | 100% | 98% | Maple syrup urine disease, type Ia, 248600 |
| BCKDHB | 95.9 | 98% | 84% | Maple syrup urine disease, type Ib, 248600 |
| BCKDK | 128.2 | 100% | 100% | Branched-chain ketoacid dehydrogenase kinase deficiency, 614923 |
| BCL10 | 110.6 | 95% | 89% | Lymphoma, MALT, somatic, 137245 {Lymphoma, follicular, somatic}, 613024 {Male germ cell tumor, somatic}, 273300, {Sezary syndrome, somatic}, {Mesothelioma, somatic}, 156240 |
| BCL2 | 159.4 | 100% | 99% | Leukemia/lymphoma, B-cell, 2 |
| BCL7A | 73.1 | 96% | 86% | B-cell non-Hodgkin lymphoma, high-grade |
| BCO1 | 131.9 | 100% | 99% | Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 |
| BCOR | 61.1 | 99% | 93% | Microphtalmia, syndromic 2, 300166 |
| BCR | 76.7 | 84% | 83% | Leukemia, chronic myeloid, 608232 Leukemia, acute lymphocytic, 613065 |
| BCS1L | 148.6 | 100% | 100% | Mitochondrial complex III deficiency, nuclear type 1, 124000 Leigh syndrome, 256000 Bjornstad syndrome, 262000 GRACILE syndrome, 603358 |

| | | | | |
|---------|-------|------|------|---|
| BDNF | 189.2 | 100% | 96% | {Memory impairment, susceptibility to} Central hypoventilation syndrome, congenital, 209880 {Obsessive-compulsive disorder, protection against}, 164230 {Bulimia nervosa, age of onset of weight loss in}, 607499 {Anorexia nervosa, susceptibi |
| BEAN1 | 79.0 | 100% | 100% | Spinocerebellar ataxia 31 |
| BEST1 | 106.5 | 100% | 97% | Best macular dystrophy, 153700 Maculopathy, bull's-eye Vitelliform macular dystrophy, adult-onset, 608161 Bestrophinopathy, 611809 Vitreoretinochoroidopathy, 193220 Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 1 |
| BFSP1 | 124.0 | 100% | 100% | Cataract 33, 611391 |
| BFSP2 | 62.7 | 94% | 92% | Cataract 12, multiple types, 611597 |
| BICD2 | 93.3 | 99% | 96% | Spinal muscular atrophy, lower extremity-predominant, 2, AD, 615290 -3 |
| BIN1 | 54.9 | 85% | 75% | Myopathy, centronuclear, autosomal recessive, 255200 |
| BLK | 103.2 | 100% | 99% | Maturity-onset diabetes of the young, type 11, 613375 |
| BLM | 118.7 | 100% | 100% | Bloom syndrome |
| BLNK | 102.7 | 100% | 100% | Agammaglobulinemia 4, 613502 |
| BLOC1S3 | 31.0 | 79% | 68% | Hermansky-Pudlak syndrome 8, 614077 |
| BLOC1S6 | 117.5 | 99% | 92% | Hermansky-pudlak syndrome 9, 614171 |
| BLVRA | 85.8 | 100% | 99% | Hyperbiliverdinemia, 614156 |
| BMP1 | 98.8 | 97% | 95% | Osteogenesis imperfecta, type XIII, 614856 |
| BMP15 | 72.2 | 100% | 100% | Ovarian dysgenesis 2, 300510 Premature ovarian failure 4, 300510 |
| BMP2 | 115.8 | 100% | 100% | {HFE hemochromatosis, modifier of}, 235200 Brachydactyly, type A2, 112600 |
| BMP4 | 114.2 | 100% | 100% | Microphthalmia, syndromic 6, 607932 Orofacial cleft 11, 600625 -3 |
| BMPER | 122.1 | 97% | 97% | Diaphanospondylodysostosis, 608022 |
| BMPR1A | 59.0 | 78% | 63% | Polyposis, juvenile intestinal, 174900 Polyposis syndrome, hereditary mixed, 2, 610069 Juvenile polyposis syndrome, infantile form, 174900 |
| BMPR1B | 104.1 | 100% | 96% | Brachydactyly, type A2, 112600 Chondrodysplasia, acromesomelic, with genital anomalies, 609441 |

| | | | | |
|----------|-------|------|------|--|
| BMPR2 | 150.9 | 100% | 99% | Pulmonary hypertension, familial primary, 1, with or without HHT, 178600 Pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 Pulmonary venoocclusive disease, 265450 |
| BOLA3 | 54.7 | 100% | 99% | Multiple mitochondrial dysfunctions syndrome 2, 614299 |
| BPGM | 148.3 | 100% | 100% | Erythrocytosis due to bisphosphoglycerate mutase deficiency, 222800 |
| BRAF | 78.5 | 100% | 99% | Melanoma, malignant, somatic Colorectal cancer, somatic Adenocarcinoma of lung, somatic, 211980 Non small cell lung cancer, somatic Cardiofaciocutaneous syndrome, 115150 Noonan syndrome 7, 613706 LEOPARD syndrome 3, 613707 |
| BRAT1 | 76.2 | 100% | 98% | Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 |
| BRCA2 | 151.7 | 100% | 100% | {Breast-ovarian cancer, familial, 2}, 612555 Fanconi anemia, complementation group D1, 605724 Prostate cancer, 176807 {Breast cancer, male, susceptibility to}, 114480 Wilms tumor, 194070 {Medulloblastoma}, 155255 {Glioblastoma 3}, |
| BRIP1 | 130.4 | 100% | 100% | Breast cancer early-onset |
| BRWD3 | 62.9 | 98% | 96% | Mental retardation, X-linked 93, 300659 |
| BSCL2 | 110.4 | 100% | 100% | Lipodystrophy, congenital generalized, type 2, 269700 Silver spastic paraplegia syndrome, 270685 Neuropathy, distal hereditary motor, type V, 600794 |
| BSND | 116.3 | 100% | 98% | Bartter syndrome, type 4a, 602522 Sensorineural deafness with mild renal dysfunction, 602522 |
| BTD | 141.7 | 100% | 100% | Biotinidase deficiency, 253260 |
| BTK | 53.4 | 99% | 95% | Agammaglobulinemia, X-linked 1, 300755 Agammaglobulinemia and isolated hormone deficiency, 307200 |
| BUB1 | 118.0 | 98% | 94% | Colorectal cancer with chromosomal instability |
| BUB1B | 117.8 | 100% | 98% | Colorectal cancer, somatic, 114500 Mosaic variegated aneuploidy syndrome 1, 257300 [Premature chromatid separation trait], 176430 |
| C10orf11 | 91.1 | 100% | 100% | Albinism, oculocutaneous, type VII, 615179 |

| | | | | |
|-----------|-------|------|------|---|
| C10orf2 | 138.3 | 100% | 100% | Progressive external ophthalmoplegia, autosomal dominant, 3, 609286 Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 |
| C12orf57 | 77.6 | 100% | 96% | Temptamy syndrome, 218340 |
| C12orf65 | 174.3 | 100% | 100% | Combined oxidative phosphorylation deficiency 7, 613559 Spastic paraplegia 55, autosomal recessive, 615035 |
| C15orf41 | 85.9 | 87% | 82% | Dyserythropoietic anemia, congenital, type Ib, 615631 (3) |
| C19orf12 | 67.0 | 100% | 93% | Neurodegeneration with brain iron accumulation 4, 614298 |
| C1GALT1C1 | 86.6 | 100% | 99% | Tn polyagglutination syndrome, somatic, 300622 |
| C1QA | 126.3 | 100% | 98% | C1q deficiency, 613652 |
| C1QB | 101.5 | 96% | 86% | C1q deficiency, 613652 |
| C1QC | 137.1 | 94% | 80% | C1q deficiency, 613652 |
| C1QTNF5 | 101.7 | 98% | 91% | Retinal degeneration, late-onset, autosomal dominant, 605670 |
| C1S | 105.2 | 100% | 99% | C1s deficiency, 613783 |
| C2 | 19.2 | 80% | 46% | C2 deficiency, 217000 {Macular degeneration, age-related, reduced risk of}, 603075 |
| C21orf59 | 98.1 | 100% | 97% | Ciliary dyskinesia, primary, 26, 615500 (3) |
| C2orf71 | 105.5 | 99% | 96% | Retinitis pigmentosa 54, 613428 |
| C3 | 99.1 | 99% | 95% | C3 deficiency, 613779 {Hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 {Macular degeneration, age-related, 9}, 611378 |
| C4A | 1.2 | 3% | 2% | C4a deficiency, 614380 [Blood group, Rodgers], 614374 ?Systemic lupus erythematosus, susceptibility to or protection against}, 152700 (2) |
| C4B | 1.4 | 4% | 2% | C4B deficiency, 614379 |
| C4orf26 | 162.2 | 100% | 100% | Amelogenesis imperfecta, hypomaturation type, IIA4, 614832 |
| C5 | 100.4 | 100% | 99% | C5 deficiency, 609536 |
| C5orf42 | 129.8 | 100% | 99% | Joubert syndrome 17, 614615 |
| C6 | 114.8 | 100% | 99% | C6 deficiency, 612446 Combined C6/C7 deficiency |
| C7 | 95.3 | 98% | 93% | C7 deficiency, 610102 |
| C8A | 88.6 | 100% | 99% | C8 deficiency, type I, 613790 |
| C8B | 96.3 | 100% | 97% | C8 deficiency, type II, 613789 |
| C8orf37 | 95.2 | 100% | 100% | Retinitis pigmentosa 64, 614500 Cone-rod dystrophy 16, 614500 -3 |

| | | | | |
|----------|-------|------|------|---|
| C9 | 112.3 | 100% | 100% | C9 deficiency Macular degeneration, age-related, 15, susceptibility to |
| C9orf72 | 86.8 | 100% | 100% | Amyotrophic lateral sclerosis and/or frontotemporal dementia, 105550 -3 |
| CA12 | 74.1 | 100% | 100% | Hyperchlorhidrosis, isolated, 143860 |
| CA2 | 143.7 | 100% | 100% | Osteopetrosis autosomal recessive 3 with renal tubular acidosis |
| CA4 | 83.8 | 98% | 92% | Retinitis pigmentosa 17, 600852 |
| CA5A | 28.4 | 43% | 36% | Hyperammonemia due to carbonic anhydrase VA deficiency, 615751 (3) |
| CA8 | 83.5 | 100% | 100% | Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 |
| CABP2 | 47.4 | 84% | 72% | Deafness, autosomal recessive 93, 614899 |
| CABP4 | 64.3 | 100% | 100% | Night blindness, congenital stationary (incomplete), 2B, autosomal recessive, 610427 |
| CACNA1A | 80.9 | 98% | 90% | Migraine, familial hemiplegic, 1, 141500 Episodic ataxia, type 2, 108500 Spinocerebellar ataxia 6, 183086 Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 |
| CACNA1C | 97.3 | 98% | 95% | Timothy syndrome, 601005 Brugada syndrome 3, 611875 |
| CACNA1D | 115.7 | 100% | 98% | Sinoatrial node dysfunction and deafness, 614896 |
| CACNA1F | 42.5 | 94% | 85% | Night blindness, congenital stationary (incomplete), 2A, X-linked, 300071 Cone-rod dystrophy, X-linked, 3, 300476 Aland Island eye disease, 300600 |
| CACNA1S | 96.0 | 100% | 99% | Hypokalemic periodic paralysis, type 1, 170400 {Malignant hyperthermia susceptibility 5}, 601887 {Thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 |
| CACNA2D4 | 78.1 | 98% | 94% | Retinal cone dystrophy 4, 610478 |
| CACNB2 | 127.4 | 100% | 100% | Brugada syndrome 4, 611876 |
| CACNB4 | 92.9 | 100% | 93% | {Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 {Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 Episodic ataxia, type 5, 613855 |
| CACNG2 | 96.4 | 100% | 100% | Mental retardation, autosomal dominant 10, 614256 |
| CALM1 | 114.1 | 100% | 100% | Ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 -3 |
| CALR | 140.5 | 96% | 90% | distal to C3, near LDLR |
| CALR3 | 96.1 | 100% | 99% | Cardiomyopathy, familial hypertrophic, 19, 613875 |

| | | | | |
|----------|-------|------|------|--|
| CAMTA1 | 124.8 | 97% | 97% | Cerebellar ataxia, nonprogressive, with mental retardation, 614756 -3 |
| CANT1 | 93.1 | 99% | 97% | Desbuquois dysplasia, 251450 |
| CAPN3 | 115.4 | 99% | 97% | Muscular dystrophy, limb-girdle, type 2A, 253600 |
| CAPN5 | 78.6 | 100% | 95% | Vitreoretinopathy, neovascular inflammatory, 193235 |
| CARD11 | 97.9 | 100% | 98% | Persistent polyclonal B-cell lymphocytosis, 606445 Immunodeficiency 11, 615206 |
| CARD14 | 62.6 | 97% | 89% | {Psoriasis susceptibility 2}, 602723 Pityriasis rubra pilaris, 173200 |
| CARD9 | 60.9 | 100% | 97% | Candidiasis, familial, 2, autosomal recessive, 212050 |
| CASC5 | 145.0 | 98% | 98% | Microcephaly 4, primary, autosomal recessive, 604321 |
| CASK | 51.6 | 98% | 94% | Mental retardation and microcephaly with pontine and cerebellar hypoplasia, 300749 FG syndrome 4, 300422 Mental retardation, with or without nystagmus, 300422 |
| CASP10 | 110.7 | 100% | 100% | Autoimmune lymphoproliferative syndrome, type II, 603909 Non-Hodgkin lymphoma, somatic, 605027 Gastric cancer, somatic, 613659 |
| CASP8 | 118.6 | 100% | 98% | Immunodeficiency due to CASP8 deficiency, 607271 Hepatocellular carcinoma, somatic, 114550 {Breast cancer, protection against}, 114480 {Lung cancer, protection against}, 211980 |
| CASQ2 | 87.8 | 100% | 96% | Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 |
| CASR | 118.8 | 100% | 99% | Hypocalciuric hypercalcemia, type I, 145980 Hyperparathyroidism, neonatal, 239200 Hypocalcemia, autosomal dominant, 601198 Hypocalcemia, autosomal dominant, with Bartter syndrome, 601198 {Epilepsy idiopathic generalized, susceptibility to}, |
| CAT | 91.7 | 98% | 91% | Acatalasemia, 614097 |
| CATSPER1 | 102.9 | 99% | 98% | Spermatogenic failure 7, 612997 |
| CAV1 | 163.1 | 100% | 100% | Lipodystrophy, congenital generalized, type 3, 612526 Pulmonary hypertension, primary, 3, 615343 |
| CAV3 | 146.7 | 100% | 100% | Muscular dystrophy, limb-girdle, type IC, 607801 Rippling muscle disease, 606072 Creatine phosphokinase, elevated serum, 123320 Myopathy, distal, Tateyama type, 614321 Cardiomyopathy, familial hypertrophic, 192600 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Long QT syndrome-9, 6 |
| CBL | 127.5 | 100% | 99% | Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 |
| CBS | 73.6 | 98% | 89% | Homocystinuria, B6-responsive and nonresponsive types, 236200 Thrombosis, hyperhomocysteinemic, 236200 |
| CBX2 | 135.4 | 100% | 99% | 46XY sex reversal 5, 613080 |
| CC2D1A | 96.2 | 100% | 97% | Mental retardation, autosomal recessive 3, 608443 |
| CC2D2A | 92.9 | 98% | 97% | Joubert syndrome 9, 612285 Meckel syndrome 6, 612284 COACH syndrome, 216360 |
| CCBE1 | 93.2 | 97% | 89% | Hennekam lymphangiectasia-lymphedema syndrome, 235510 |
| CCDC103 | 106.0 | 100% | 100% | Ciliary dyskinesia, primary, 17, 614679 |
| CCDC114 | 77.5 | 100% | 98% | Ciliary dyskinesia, primary, 20, 615067 |
| CCDC39 | 104.7 | 100% | 100% | Ciliary dyskinesia, primary, 14, 613807 |
| CCDC40 | 84.4 | 97% | 93% | Ciliary dyskinesia, primary, 15, 613808 |
| CCDC50 | 131.9 | 99% | 96% | Deafness, autosomal dominant 44, 607453 |
| CCDC65 | 74.5 | 100% | 96% | Ciliary dyskinesia, primary, 27, 615504 |
| CCDC78 | 90.8 | 100% | 100% | Myopathy, centronuclear, 4, 614807 |
| CCDC8 | 130.3 | 100% | 100% | Three M syndrome 3, 614205 |
| CCDC88C | 90.9 | 99% | 96% | Hydrocephalus, nonsyndromic, autosomal recessive, 236600 |
| CCM2 | 96.5 | 95% | 92% | Cerebral cavernous malformations-2 |
| CCT5 | 80.0 | 94% | 81% | Neuropathy, hereditary sensory, with spastic paraparesis, 256840 |
| CD151 | 87.3 | 100% | 96% | Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 [Blood group, Raph], 179620 |
| CD19 | 78.8 | 100% | 98% | Immunodeficiency, common variable, 3, 613493 |
| CD247 | 87.8 | 100% | 100% | Immunodeficiency due to defect in CD3-zeta, 610163 |
| CD27 | 80.9 | 100% | 98% | Lymphoproliferative syndrome 2 |
| CD2AP | 116.4 | 100% | 99% | Glomerulosclerosis, focal segmental, 3, 607832 |
| CD320 | 79.5 | 97% | 88% | Methylmalonic aciduria due to transcobalamin receptor defect, 613646 |

| | | | | |
|--------|-------|------|------|---|
| CD36 | 138.8 | 100% | 100% | [Macrothrombocytopenia] (1) Platelet glycoprotein IV deficiency, 608404 {Malaria, cerebral, susceptibility to}, 611162 {Malaria, cerebral, reduced risk of}, 611162 {Coronary heart disease, susceptibility to, 7}, 610938 |
| CD3D | 83.6 | 100% | 99% | Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 |
| CD3E | 93.8 | 95% | 86% | Immunodeficiency due to defect in CD3-epsilon Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 |
| CD3G | 87.9 | 100% | 100% | Immunodeficiency due to defect in CD3-gamma |
| CD4 | 84.0 | 97% | 96% | Methylmalonic aciduria and homocystinuria, cblJ type, 614857 |
| CD4 | 84.0 | 97% | 96% | OKT4 epitope deficiency, 613949 |
| CD40 | 103.3 | 95% | 91% | Immunodeficiency with hyper-IgM, type 3, 606843 |
| CD40LG | 63.0 | 91% | 83% | Immunodeficiency X-linked with hyper-IgM |
| CD59 | 115.7 | 100% | 100% | Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 |
| CD79A | 75.4 | 98% | 85% | Agammaglobulinemia 3, 613501 |
| CD79B | 126.4 | 100% | 99% | Agammaglobulinemia 6, 612692 |
| CD81 | 61.1 | 97% | 87% | Immunodeficiency, common variable, 6, 613496 |
| CD8A | 82.1 | 95% | 93% | CD8 deficiency, familial, 608957 |
| CD96 | 119.4 | 100% | 100% | C syndrome, 211750 |
| CDAN1 | 91.2 | 99% | 96% | Anemia, congenital dyserythropoietic, type I, 224120 |
| CDC6 | 103.5 | 100% | 99% | Meier-Gorlin syndrome 5, 613805 |
| CDC73 | 150.1 | 100% | 100% | Hyperparathyroidism, familial primary, 145000 Hyperparathyroidism-jaw tumor syndrome, 145001 Parathyroid adenoma with cystic changes, 145001 Parathyroid carcinoma, 608266 |
| CDH1 | 117.6 | 100% | 99% | Endometrial carcinoma, somatic, 608089 Ovarian carcinoma, somatic, 167000 {Breast cancer, lobular}, 114480 Gastric cancer, familial diffuse, with or without cleft lip and/or palate, 137215 {Prostate cancer, susceptibility to}, 176807 |
| CDH15 | 80.2 | 100% | 98% | Mental retardation, autosomal dominant 3, 612580 |

| | | | | |
|----------|-------|------|------|---|
| CDH23 | 93.7 | 99% | 98% | Usher syndrome, type 1D, 601067 Deafness, autosomal recessive 12, 601386 Usher syndrome, type 1D/F digenic, 601067 |
| CDH3 | 96.9 | 97% | 92% | i Hypotrichosis, congenital, with juvenile macular dystrophy, 601553 Ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 |
| CDHR1 | 110.9 | 98% | 98% | Cone-rod dystrophy 15, 613660 Retinitis pigmentosa 65, 613660 -3 |
| CDK5RAP2 | 109.5 | 99% | 95% | Microcephaly 3, primary, autosomal recessive, 604804 |
| CDKL5 | 65.8 | 98% | 95% | Epileptic encephalopathy, early infantile, 2, 300672 Angelman syndrome-like, 105830 |
| CDKN1B | 130.0 | 100% | 100% | Multiple endocrine neoplasia, type IV, 610755 |
| CDKN1C | 39.5 | 91% | 82% | Beckwith-Wiedemann syndrome, 130650 IMAGE syndrome, 614732 |
| CDKN2A | 139.7 | 100% | 100% | {Melanoma, cutaneous malignant, 2}, 155601 Melanoma and neural system tumor syndrome, 155755 Pancreatic cancer/melanoma syndrome, 606719 Orolaryngeal cancer, multiple, -3 |
| CDON | 117.2 | 100% | 98% | Holoprosencephaly 11, 614226 |
| CDSN | 17.0 | 81% | 39% | Hypotrichosis simplex of scalp 1, 146520 Peeling skin syndrome, 270300 |
| CDT1 | 44.7 | 91% | 73% | Meier-Gorlin syndrome 4, 613804 |
| CEACAM16 | 92.3 | 97% | 90% | Deafness, autosomal dominant 4B, 614614 |
| CEBPA | 43.1 | 99% | 70% | Leukemia, acute myeloid, 601626 |
| CEBPE | 101.1 | 100% | 100% | Specific granule deficiency, 245480 |
| CECR1 | 89.9 | 98% | 97% | Polyarteritis nodosa, 615688 (3) |
| CEL | 57.3 | 64% | 61% | Maturity-onset diabetes of the young, type VIII, 609812 |
| CENPJ | 139.2 | 100% | 100% | Microcephaly 6, primary, autosomal recessive, 608393 Seckel syndrome 4, 613676 |
| CEP135 | 121.5 | 100% | 99% | Microcephaly 8, primary, autosomal recessive, 614673 |
| CEP152 | 131.9 | 99% | 99% | Microcephaly 9, primary, autosomal recessive, 614852 Seckel syndrome 5, 613823 |
| CEP164 | 76.6 | 98% | 92% | Nephronophthisis 15, 614845 |
| CEP19 | 165.5 | 100% | 100% | Morbid obesity and spermatogenic failure, 615703 (3) |

| | | | | |
|--------|-------|------|------|--|
| CEP290 | 101.5 | 100% | 98% | Joubert syndrome 5, 610188 Senior-Loken syndrome 6, 610189 Leber congenital amaurosis 10, 611755 Meckel syndrome 4, 611134 Bardet-Biedl syndrome 14, 209900 |
| CEP41 | 88.3 | 100% | 99% | Joubert syndrome 15, 614464 |
| CEP57 | 88.6 | 100% | 97% | Mosaic variegated aneuploidy syndrome 2, 614114 |
| CERKL | 137.2 | 100% | 100% | Retinitis pigmentosa 26, 608380 |
| CERS3 | 83.6 | 100% | 100% | Ichthyosis, congenital, autosomal recessive 9, 615023 |
| CES1 | 59.0 | 60% | 57% | Carboxylesterase 1 deficiency |
| CETP | 101.0 | 100% | 100% | Hyperalphalipoproteinemia, 143470 [High density lipoprotein cholesterol level QTL 10], 143470 |
| CFAP53 | 183.1 | 99% | 98% | Heterotaxy, visceral, 6, autosomal recessive, 614779 |
| CFC1 | 1.0 | % | % | Heterotaxy, visceral, 2, autosomal, 605376 Double-outlet right ventricle, 217095 Transposition of the great arteries, dextro-looped 2, 613853 |
| CFD | 50.3 | 96% | 86% | Complement factor D deficiency, 613912 |
| CFH | 107.3 | 95% | 92% | Basal laminar drusen |
| CFHR5 | 107.7 | 94% | 92% | Nephropathy due to CFHR5 deficiency, 614809 |
| CFI | 137.0 | 100% | 100% | Complement factor I deficiency, 610984 {Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 {Macular degeneration, age-related, 13, susceptibility to}, 615439 |
| CFL2 | 133.6 | 100% | 100% | Nemaline myopathy 7, autosomal recessive, 610687 |
| CFP | 48.6 | 97% | 85% | Properdin deficiency X-linked |
| CFTR | 123.1 | 95% | 95% | Cystic fibrosis, 219700 Congenital bilateral absence of vas deferens, 277180 Sweat chloride elevation without CF {Pancreatitis, idiopathic}, 167800 {Hypertrypsinemia, neonatal} {Bronchiectasis with or without elevated sweat chloride 1, |
| CHAT | 69.3 | 91% | 77% | Myasthenic syndrome, congenital, associated with episodic apnea, 254210 |
| CHD2 | 128.0 | 99% | 98% | Epileptic encephalopathy, childhood-onset, 615369 |
| CHD7 | 121.0 | 100% | 99% | CHARGE syndrome, 214800 {Scoliosis, idiopathic 3}, 608765 Hypogonadotropic hypogonadism 5 with or without anosmia, 612370 |

| | | | | |
|--------|-------|------|------|--|
| CHEK2 | 55.5 | 70% | 65% | Li-Fraumeni syndrome, 609265 Osteosarcoma, somatic, 259500 {Breast cancer, susceptibility to}, 114480 {Prostate cancer, familial, susceptibility to}, 176807 {Breast and colorectal cancer, susceptibility to} |
| CHKB | 91.1 | 93% | 91% | Muscular dystrophy, congenital, megaconial type, 602541 |
| CHM | 52.7 | 98% | 91% | Choroideremia, 303100 |
| CHMP1A | 81.5 | 95% | 89% | Pontocerebellar hypoplasia, type 8, 614961 |
| CHMP2B | 124.5 | 100% | 100% | Dementia, familial, nonspecific, 600795 Amyotrophic lateral sclerosis 17, 614696 |
| CHMP4B | 114.9 | 100% | 100% | Cataract 31, multiple types, 605387 |
| CHN1 | 140.2 | 100% | 96% | Duane retraction syndrome 2, 604356 |
| CHRDL1 | 63.2 | 99% | 94% | Megalocornea 1, X-linked 309300 |
| CHRM3 | 161.3 | 100% | 100% | Eagle-Barrett syndrome, 100100 |
| CHRNA1 | 101.6 | 100% | 98% | Myasthenic syndrome, slow-channel congenital, 601462 Myasthenic syndrome, fast-channel congenital, 608930 Multiple pterygium syndrome, lethal type, 253290 |
| CHRNA2 | 115.4 | 100% | 100% | Epilepsy, nocturnal frontal lobe, type 4, 610353 |
| CHRNA4 | 93.2 | 99% | 98% | Epilepsy, nocturnal frontal lobe, 1, 600513 {Nicotine addiction, susceptibility to}, 188890 |
| CHRNB1 | 102.5 | 98% | 94% | Myasthenic syndrome, slow-channel congenital, 601462 Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 |
| CHRNB2 | 142.5 | 95% | 93% | Epilepsy, nocturnal frontal lobe, 3, 605375 |
| CHRND | 94.6 | 97% | 91% | Myasthenic syndrome, slow-channel congenital, 601462 Myasthenic syndrome, fast-channel congenital, 608930 Multiple pterygium syndrome, lethal type, 253290 |
| CHRNE | 158.8 | 100% | 100% | Myasthenic syndrome, slow-channel congenital, 601462 Myasthenic syndrome, fast-channel congenital, 608930 Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 |
| CHRNG | 95.7 | 100% | 97% | Myasthenia gravis, neonatal transient (2) Escobar syndrome, 265000 Multiple pterygium syndrome, lethal type, 253290 |
| CHST14 | 130.2 | 100% | 100% | Ehlers-Danlos syndrome, musculocontractural type , 601776 |
| CHST3 | 67.2 | 100% | 100% | Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 |
| CHST6 | 123.3 | 100% | 100% | Macular corneal dystrophy, 217800 |

| | | | | |
|--------|-------|------|------|---|
| CHSY1 | 147.3 | 98% | 97% | Temptamy preaxial brachydactyly syndrome, 605282 |
| CHUK | 92.4 | 100% | 99% | Cocoon syndrome, 613630 |
| CIB2 | 103.6 | 100% | 100% | Deafness, autosomal recessive 48, 609439 Usher syndrome, type IJ, 614869 |
| CIITA | 99.1 | 98% | 96% | Bare lymphocyte syndrome type II complementation group A |
| CIRH1A | 107.2 | 100% | 100% | Cirrhosis, North American Indian childhood type, 604901 |
| CISD2 | 190.3 | 77% | 77% | Wolfram syndrome 2, 604928 |
| CITED2 | 108.4 | 99% | 97% | Ventricular septal defect 2, 614431 Atrial septal defect 8, 614433 |
| CLCF1 | 43.5 | 81% | 75% | Cold-induced sweating syndrome 1, 610313 |
| CLCN1 | 91.2 | 100% | 97% | Myotonia congenita, recessive, 255700 Myotonia congenita, dominant, 160800 Myotonia levior, recessive |
| CLCN2 | 107.0 | 100% | 99% | {Epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 {Epilepsy, juvenile absence, susceptibility to, 2}, 607628 {Epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 |
| CLCN5 | 84.2 | 99% | 94% | Dent disease, 300009 Nephrolithiasis, type I, 310468 Hypophosphatemic rickets, 300554 Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 |
| CLCN7 | 80.7 | 100% | 98% | Osteopetrosis, autosomal recessive 4, 611490 Osteopetrosis, autosomal dominant 2, 166600 |
| CLCNKA | 87.2 | 83% | 79% | Bartter syndrome, type 4b, digenic, 613090 |
| CLCNKB | 74.1 | 86% | 80% | Bartter syndrome, type 3, 607364 Bartter syndrome, type 4b, digenic, 613090 |
| CLDN1 | 104.5 | 100% | 100% | Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 |
| CLDN14 | 66.2 | 100% | 99% | Deafness, autosomal recessive 29, 614035 |
| CLDN16 | 126.8 | 98% | 95% | Hypomagnesemia 3, renal, 248250 |
| CLDN19 | 69.3 | 100% | 93% | Hypomagnesemia 5, renal, with ocular involvement, 248190 |
| CLEC7A | 103.1 | 100% | 100% | Candidiasis, familial, 4, autosomal recessive, 613108 {Aspergillosis, susceptibility to}, 614079 |
| CLIC2 | 33.1 | 92% | 63% | Mental retardation, X-linked, syndromic 32, 300886 |
| CLK1 | 151.4 | 100% | 99% | 3MC syndrome 2 |
| CLMP | 99.8 | 97% | 97% | Congenital short bowel syndrome, 615237 |
| CLN3 | 86.5 | 100% | 99% | Ceroid lipofuscinosis, neuronal, 3, 204200 |

| | | | | |
|---------|-------|------|------|---|
| CLN5 | 139.7 | 100% | 90% | Ceroid lipofuscinosis, neuronal, 5, 256731 |
| CLN6 | 63.7 | 98% | 81% | Ceroid lipofuscinosis, neuronal, 6, 601780 Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300 |
| CLN8 | 133.8 | 100% | 100% | Ceroid lipofuscinosis, neuronal, 8, 600143 Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 |
| CLPP | 90.1 | 97% | 91% | Perrault syndrome 3, 614129 |
| CLRN1 | 165.5 | 100% | 100% | Usher syndrome, type 3A, 276902 Retinitis pigmentosa 61, 614180 -3 |
| CNBP | 106.4 | 100% | 95% | Myotonic dystrophy 2 |
| CNGA1 | 119.8 | 91% | 90% | Retinitis pigmentosa 49, 613756 |
| CNGA3 | 146.7 | 100% | 99% | Achromatopsia-2, 216900 |
| CNGB1 | 84.8 | 96% | 90% | Retinitis pigmentosa 45, 613767 |
| CNGB3 | 108.7 | 100% | 98% | Achromatopsia-3, 262300 Macular degeneration, juvenile, 248200 -3 |
| CNNM2 | 136.5 | 100% | 99% | Hypomagnesemia 6, renal, 613882 |
| CNNM4 | 170.4 | 99% | 96% | Jalili syndrome, 217080 |
| CNTN1 | 109.4 | 100% | 99% | Myopathy, congenital, Compton-North, 612540 |
| CNTNAP2 | 100.2 | 100% | 99% | Cortical dysplasia-focal epilepsy syndrome, 610042 {Autism susceptibility 15}, 612100 Pitt-Hopkins like syndrome 1, 610042 |
| COA5 | 84.9 | 99% | 96% | Mitochondrial complex IV deficiency, 220110 |
| COASY | 123.7 | 100% | 100% | Neurodegeneration with brain iron accumulation 6, 615643 |
| COCH | 119.2 | 100% | 98% | Deafness, autosomal dominant 9, 601369 |
| COG1 | 121.0 | 100% | 98% | Congenital disorder of glycosylation, type IIg, 611209 |
| COG4 | 86.4 | 98% | 95% | Congenital disorder of glycosylation, type IIj, 613489 |
| COG5 | 101.6 | 97% | 94% | Congenital disorder of glycosylation, type III, 613612 |
| COG6 | 101.9 | 97% | 95% | Congenital disorder of glycosylation, type III, 614576 Shaheen syndrome, 615328 |
| COG7 | 77.0 | 100% | 96% | Congenital disorder of glycosylation, type Ile, 608779 |
| COG8 | 116.5 | 100% | 100% | Congenital disorder of glycosylation, type IIh, 611182 |
| COL10A1 | 93.3 | 100% | 99% | Metaphyseal chondrodysplasia, Schmid type, 156500 |
| COL11A1 | 99.4 | 98% | 97% | Stickler syndrome, type II, 604841 Marshall syndrome, 154780 {Lumbar disc herniation, susceptibility to}, 603932 Fibrochondrogenesis, 228520 |

| | | | | |
|---------|-------|-----|-----|---|
| COL11A2 | 14.4 | 61% | 17% | Stickler syndrome, type III, 184840 Otospondylomegaepiphyseal dysplasia, 215150 Weissenbacher-Zweymuller syndrome, 277610 Deafness, autosomal dominant 13, 601868 Deafness, autosomal recessive 53, 609706 Fibrochondrogenesis 2, 614524 |
| COL17A1 | 82.4 | 97% | 89% | Epidermolysis bullosa, junctional, non-Herlitz type, 226650 |
| COL18A1 | 86.0 | 96% | 90% | Knobloch syndrome, type 1, 267750 |
| COL1A1 | 112.0 | 99% | 97% | Osteogenesis imperfecta, type I, 166200 OI type II, 166210 OI type III, 259420 OI type IV, 166220 Ehlers-Danlos syndrome, type I, 130000 Ehlers-Danlos syndrome, type VIIA, 130060 {Osteoporosis}, 166710 Caffey disease, 114000 |
| COL1A2 | 93.1 | 99% | 96% | Ehlers-Danlos syndrome, type VIIIB, 130060 Osteogenesis imperfecta, type IV, 166220 Osteogenesis imperfecta, type III, 259420 Osteogenesis imperfecta, type II, 166210 {Osteoporosis, postmenopausal}, 166710 Ehlers-Danlos syndrome, cardi |
| COL2A1 | 85.2 | 99% | 95% | Stickler syndrome, type I, 108300 Kniest dysplasia, 156550 Achondrogenesis, type II or hypochondrogenesis, 200610 SED congenita, 183900 SMED Strudwick type, 184250 Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 Sp |
| COL3A1 | 72.7 | 97% | 95% | Ehlers-Danlos syndrome, type IV, 130050 Ehlers-Danlos syndrome, type III, 130020 |
| COL4A1 | 87.4 | 99% | 96% | Porencephaly 1, 175780 Brain small vessel disease with hemorrhage, 607595 Angiopathy, hereditary, with nephropathy, aneurysms, and muscle, 611773 Brain small vessel disease with Axenfeld-Rieger anomaly, 607595 {Hemorrhage, intracerebral, s |

| | | | | |
|--------|-------|------|-----|---|
| COL4A2 | 80.1 | 99% | 97% | Porencephaly 2, 614483 {Hemorrhage, intracerebral, susceptibility to}, 614519 |
| COL4A3 | 74.2 | 97% | 94% | Alport syndrome, autosomal recessive, 203780 Hematuria, benign familial, 141200 Alport syndrome, autosomal dominant, 104200 |
| COL4A4 | 92.0 | 100% | 97% | Alport syndrome, autosomal recessive, 203780 Hematuria,familial benign |
| COL4A5 | 38.2 | 94% | 78% | Alport syndrome, 301050 |
| COL5A1 | 97.1 | 98% | 95% | Ehlers-Danlos syndrome, type II, 130010 Ehlers-Danlos syndrome, type I, 130000 |
| COL5A2 | 85.0 | 97% | 92% | Ehlers-Danlos syndrome, type I, 130000 |
| COL6A1 | 81.8 | 98% | 96% | Bethlem myopathy, 158810 Ullrich congenital muscular dystrophy, 254090 {Ossification of the posterior longitudinal spinal ligaments}, 602475 (2) |
| COL6A2 | 82.7 | 99% | 97% | Bethlem myopathy, 158810 Ullrich congenital muscular dystrophy, 254090 Myosclerosis, congenital, 255600 |
| COL6A3 | 123.2 | 99% | 99% | Bethlem myopathy, 158810 Ullrich congenital muscular dystrophy, 254090 |
| COL7A1 | 101.1 | 100% | 98% | Epidermolysis bullosa dystrophica, AD, 131750 Epidermolysis bullosa dystrophica, AR, 226600 Epidermolysis bullosa, pretibial, 131850 EBD, Bart type, 132000 EBD, localisata variant Transient bullous of the newborn, 131705 Epidermoly |
| COL8A2 | 62.8 | 97% | 94% | Corneal dystrophy, Fuchs endothelial, 1, 136800 Corneal dystrophy polymorphous posterior, 2, 609140 |
| COL9A1 | 108.1 | 100% | 96% | Epiphyseal dysplasia, multiple, 6, 614135 Stickler syndrome, type IV, 614134 |
| COL9A2 | 72.9 | 98% | 93% | Epiphyseal dysplasia, multiple, 2, 600204 {Intervertebral disc disease, susceptibility to}, 603932 Stickler syndrome, type V, 614284 |
| COL9A3 | 70.4 | 99% | 89% | Epiphyseal dysplasia, multiple, 3, 600969 Epiphyseal dysplasia, multiple, with myopathy {Intervertebral disc disease, susceptibility to}, 603932 |
| COLQ | 73.9 | 100% | 90% | Endplate acetylcholinesterase deficiency, 603034 |

| | | | | |
|--------|-------|------|------|---|
| COMP | 86.2 | 100% | 98% | Pseudoachondroplasia, 177170 Epiphyseal dysplasia, multiple 1, 132400 |
| COQ2 | 75.5 | 99% | 96% | Coenzyme Q10 deficiency, primary, 1, 607426 {Multiple system atrophy, susceptibility to}, 146500 |
| COQ6 | 109.2 | 99% | 95% | Coenzyme Q10 deficiency, primary, 6, 614650 |
| COQ9 | 86.6 | 91% | 83% | Coenzyme Q10 deficiency, primary, 5, 614654 |
| CORIN | 114.4 | 100% | 99% | Preeclampsia/eclampsia 5, 614595 |
| CORO1A | 88.6 | 85% | 84% | Immunodeficiency 8, 615401 |
| COX10 | 130.3 | 100% | 97% | Encephalopathy, progressive mitochondrial, with proximal renal tubulopathy due to cytochrome c oxidase deficiency |
| COX14 | 127.5 | 100% | 100% | Mitochondrial complex IV deficiency, 220110 |
| COX15 | 75.0 | 100% | 93% | Leigh syndrome due to cytochrome c oxidase deficiency, 256000 Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2, 615119 |
| COX20 | 59.4 | 88% | 88% | Mitochondrial complex IV deficiency, 220110 |
| COX4I2 | 56.1 | 99% | 89% | Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 |
| COX7B | 32.8 | 76% | 67% | Aplasia cutis congenita, reticulolinear, with mmicrocephaly, facial dysmorphism and other congenital anomalies, 300887 |
| CP | 90.4 | 99% | 92% | [Hypoceruloplasminemia, hereditary], 604290 Cerebellar ataxia, 604290 Hemosiderosis, systemic, due to aceruloplasminemia, 604290 |
| CPA6 | 122.8 | 100% | 100% | Epilepsy, familial temporal lobe, 5, 614417 Febrile seizures, familial, 11, 614418 |
| CPN1 | 77.9 | 100% | 99% | Carboxypeptidase N deficiency, 212070 |
| CPOX | 85.2 | 100% | 97% | Coproporphyria, 121300 Harderoporphyrin, 121300 |
| CPS1 | 107.5 | 100% | 99% | Carbamoylphosphate synthetase I deficiency, 237300 {Pulmonary hypertension, neonatal, susceptibility to}, 615371 {Venoocclusive disease after bone marrow transplantation} |
| CPT1A | 96.1 | 100% | 98% | CPT deficiency, hepatic, type IA, 255120 |
| CPT2 | 109.4 | 92% | 91% | Myopathy due to CPT II deficiency, 255110 CPT deficiency, hepatic, type II, 600649 CPT II deficiency, lethal neonatal, 608836 {Encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 |
| CR2 | 119.6 | 100% | 100% | {Systemic lupus erythematosus, susceptibility to, 9}, 610927 Immunodeficiency, common variable, 7, 614699 |

| | | | | |
|--------|-------|------|------|---|
| CRADD | 128.0 | 100% | 98% | Mental retardation, autosomal recessive 34, 614499 |
| CRB1 | 165.3 | 100% | 100% | Retinitis pigmentosa-12, autosomal recessive, 600105 Leber congenital amaurosis 8, 613835 Pigmented paravenous chorioretinal atrophy, 172870 |
| CRBN | 145.0 | 100% | 100% | Mental retardation, autosomal recessive 2, 607417 |
| CREB1 | 97.2 | 100% | 100% | Histiocytoma, angiomatoid fibrous, somatic, 612160 |
| CREBBP | 83.1 | 99% | 97% | Rubinstein-Taybi syndrome, 180849 |
| CRELD1 | 83.7 | 100% | 93% | {Atrioventricular septal defect, susceptibility to, 2}, 606217 Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 |
| CRLF1 | 56.0 | 90% | 82% | Cold-induced sweating syndrome, 272430 |
| CRTAP | 98.4 | 100% | 100% | Osteogenesis imperfecta, type VII, 610682 |
| CRTC1 | 89.7 | 97% | 91% | Mucoepidermoid salivary gland carcinoma |
| CRX | 152.8 | 100% | 100% | Cone-rod retinal dystrophy-2, 120970 Leber congenital amaurosis 7, 613829 |
| CRYAA | 108.4 | 100% | 100% | Cataract 9, multiple types, 604219 |
| CRYAB | 133.3 | 100% | 100% | Myopathy, myofibrillar, 2, 608810 Cataract 16, multiple types, 613763 Myopathy, myofibrillar, fatal infantile hypertrophy, alpha-B crystallin-related, 613869 Cardiomyopathy, dilated, 1II, 615184 |
| CRYBA1 | 91.0 | 100% | 100% | Cataract 10, multiple types, 600881 |
| CRYBA4 | 79.0 | 100% | 100% | Cataract 23, 610425 |
| CRYBB1 | 56.9 | 100% | 94% | Cataract 17, multiple types, 611544 |
| CRYBB2 | 111.3 | 100% | 100% | Cataract 3, multiple types, 601547 |
| CRYBB3 | 110.5 | 100% | 100% | Cataract 22, autosomal recessive, 609741 |
| CRYGB | 69.4 | 100% | 93% | Cataract 39, multiple types, autosomal dominant, 615188 |
| CRYGC | 84.1 | 100% | 96% | Cataract 2, multiple types, 604307 |
| CRYGD | 76.2 | 90% | 77% | Cataract 4, multiple types, 115700 |
| CRYGS | 92.6 | 98% | 90% | Cataract 20, multiple types, 116100 |
| CRYM | 75.1 | 100% | 99% | Deafness, autosomal dominant 40 |
| CSF1R | 79.2 | 99% | 95% | Leukoencephalopathy, diffuse hereditary, with spheroids, 221820 |
| CSF2RA | .0 | % | % | Surfactant metabolism dysfunction, pulmonary, 4, 300770 |
| CSF2RB | 102.4 | 100% | 98% | Surfactant metabolism dysfunction, pulmonary, 5, 614370 |
| CSF3R | 81.0 | 100% | 98% | Neutrophilia, hereditary, 162830 |
| CSNK1D | 97.8 | 88% | 85% | Advanced sleep-phase syndrome, familial, 2, 615224 |
| CSPP1 | 121.7 | 100% | 99% | Joubert syndrome 21, 615636 |

| | | | | |
|--------|-------|------|------|---|
| CSRP3 | 107.3 | 100% | 95% | Cardiomyopathy, dilated, 1M, 607482 Cardiomyopathy, familial hypertrophic, 12, 612124 |
| CST3 | 56.2 | 100% | 99% | Cerebral amyloid angiopathy, 105150 Macular degeneration, age-related, 11, 611953 |
| CSTA | 105.8 | 100% | 100% | Exfoliative ichthyosis, autosomal recessive, ichthyosis bullosa of Siemens-like, 607936 |
| CSTB | 166.9 | 100% | 99% | Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 |
| CTC1 | 95.5 | 100% | 99% | Cerebroretinal microangiopathy with calcifications and cysts, 612199 |
| CTCF | 113.2 | 100% | 98% | Mental retardation, autosomal dominant 21, 615502 |
| CTDP1 | 69.8 | 89% | 87% | Congenital cataracts, facial dysmorphism, and neuropathy, 604168 |
| CTH | 130.2 | 100% | 100% | Cystathioninuria, 219500 Homocysteine, total plasma, elevated -3 |
| CTHRC1 | 87.2 | 100% | 92% | Barrett esophagus/esophageal adenocarcinoma, 614266 |
| CTNNA3 | 116.2 | 98% | 97% | Arrhythmogenic right ventricular dysplasia, familial, 13, 615616 |
| CTNNB1 | 113.6 | 100% | 99% | Mental retardation, autosomal dominant 19, 615075 Colorectal cancer, somatic, 114500 Pilomatricoma, somatic, 132600 Ovarian cancer, somatic, 167000 Hepatocellular carcinoma, somatic, 114550 |
| CTNS | 114.9 | 97% | 94% | ? Cystinosis, nephropathic, 219800 Cystinosis, ocular nonnephropathic, 219750 Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 Cystinosis, atypical nephropathic, 219800 -3 |
| CTSA | 92.8 | 100% | 98% | Galactosialidosis, 256540 |
| CTSC | 86.4 | 100% | 100% | Papillon-Lefevre syndrome, 245000 Haim-Munk syndrome, 245010 Periodontitis 1, juvenile, 170650 |
| CTSD | 96.2 | 100% | 100% | Ceroid lipofuscinosis, neuronal, 10, 610127 |
| CTSF | 109.8 | 96% | 82% | Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 |
| CTSK | 129.9 | 100% | 100% | Pycnodysostosis, 265800 |
| CUBN | 88.4 | 99% | 96% | Megaloblastic anemia-1, Finnish type, 261100 |
| CUL3 | 103.8 | 99% | 96% | Pseudohypoaldosteronism, type IIE, 614496 |
| CUL4B | 61.8 | 100% | 92% | Mental retardation, X-linked, syndromic 15 (Cabezas type), 300354 |
| CUL7 | 99.0 | 100% | 99% | 3-M syndrome 1, 273750 |
| CXCR4 | 226.9 | 100% | 100% | WHIM syndrome, 193670 Myelokathexis, isolated |
| CYB5A | 48.4 | 100% | 94% | Methemoglobinemia, type IV, 250790 |

| | | | | |
|---------|-------|------|------|---|
| CYB5R3 | 77.9 | 97% | 94% | Methemoglobinemia, type I, 250800 Methemoglobinemia, type II, 250800 |
| CYBA | 43.3 | 93% | 84% | Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 |
| CYBB | 53.3 | 88% | 81% | Chronic granulomatous disease, X-linked, 306400 Atypical mycobacteriosis, familial, X-linked 2, 300645 |
| CYC1 | 81.4 | 95% | 79% | Mitochondrial complex III deficiency, nuclear type 6, 615453 |
| CYCS | 49.5 | 100% | 92% | Thrombocytopenia 4, 612004 |
| CYLD | 114.3 | 100% | 100% | Cylindromatosis, familial, 132700 Brooke-Spiegler syndrome, 605041 Trichoepithelioma, multiple familial, 1, 601606 |
| CYP11A1 | 89.8 | 100% | 97% | Adrenal insufficiency congenital with 46XY sex reversal partial or complete |
| CYP11B1 | 128.0 | 98% | 94% | anti-Lepore-like Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 Aldosteronism, glucocorticoid-remediable, 103900 |
| CYP11B2 | 104.9 | 98% | 91% | Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 {Low renin hypertension, susceptibility to} Aldosterone to renin ratio raised |
| CYP17A1 | 105.5 | 99% | 96% | 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 17,20-lyase deficiency, isolated, 202110 |
| CYP19A1 | 131.0 | 100% | 100% | Aromatase deficiency, 613546 Aromatase excess syndrome, 139300 -3 |
| CYP1B1 | 103.3 | 100% | 99% | Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 Peters anomaly, 604229 |
| CYP21A2 | 5.2 | 17% | 10% | Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 |
| CYP24A1 | 105.8 | 100% | 97% | Hypercalcemia, infantile, 143880 |
| CYP26B1 | 66.2 | 100% | 97% | Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 |
| CYP26C1 | 59.2 | 100% | 91% | Focal facial dermal dysplasia 4, 614974 |
| CYP27A1 | 118.1 | 100% | 96% | Cerebrotendinous xanthomatosis, 213700 |
| CYP27B1 | 107.1 | 100% | 98% | Vitamin D-dependent rickets, type I, 264700 |

| | | | | |
|---------|-------|------|------|---|
| CYP2A6 | 29.3 | 54% | 42% | Coumarin resistance, 122700 {Nicotine addiction, protection from}, 188890 {Lung cancer, resistance to}, 211980 |
| CYP2B6 | 105.6 | 88% | 88% | Efavirenz, poor metabolism of, 614546 {Efavirenz central nervous system toxicity, susceptibility to}, 614546 |
| CYP2C19 | 103.4 | 98% | 96% | Clopidogrel impaired responsiveness to |
| CYP2C8 | 133.7 | 100% | 100% | Rhabdomyolysis, cerivastatin-induced |
| CYP2C9 | 108.6 | 100% | 97% | Tolbutamide poor metabolizer Warfarin sensitivity, 122700 |
| CYP2R1 | 107.1 | 99% | 96% | Rickets due to defect in vitamin D 25-hydroxylation, 600081 |
| CYP2U1 | 108.4 | 100% | 99% | Spastic paraplegia 56, autosomal recessive, 615030 |
| CYP4F22 | 98.9 | 100% | 100% | Ichthyosis, congenital, autosomal recessive 5, 604777 |
| CYP4V2 | 124.7 | 100% | 99% | Bietti crystalline corneoretinal dystrophy, 210370 |
| CYP7B1 | 97.1 | 100% | 96% | Bile acid synthesis defect, congenital, 3, 613812 Spastic paraplegia 5A, autosomal recessive, 270800 |
| D2HGDH | 57.7 | 96% | 86% | D-2-hydroxyglutaric aciduria, 600721 |
| DAG1 | 145.4 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818 |
| DARS | 131.4 | 100% | 100% | Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 |
| DARS2 | 116.2 | 100% | 100% | Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 |
| DBH | 99.0 | 100% | 97% | [Dopamine-beta-hydroxylase activity levels, plasma] Dopamine beta-hydroxylase deficiency, 223360 |
| DBT | 111.7 | 100% | 100% | Maple syrup urine disease, type II, 248600 |
| DCAF17 | 102.4 | 99% | 94% | Woodhouse-Sakati syndrome, 241080 |
| DCC | 120.1 | 99% | 99% | Mirror movements 1, 157600 Colorectal cancer, somatic, 114500 Esophageal carcinoma, somatic 133239 |
| DCHS1 | 99.4 | 100% | 98% | Van Maldergem syndrome 1, 601390 (3) |
| DCLRE1C | 106.1 | 97% | 97% | Severe combined immunodeficiency, Athabascan type, 602450 Omenn syndrome, 603554 |
| DCN | 121.3 | 100% | 100% | Corneal dystrophy, congenital stromal, 610048 |
| DCTN1 | 112.7 | 99% | 95% | Neuropathy, distal hereditary motor, type VIIIB, 607641 {Amyotrophic lateral sclerosis, susceptibility to}, 105400 Perry syndrome, 168605 |
| DCX | 60.2 | 100% | 94% | Lissencephaly, X-linked, 300067 Subcortical laminar heteropia, X-linked, 300067 |

| | | | | |
|--------|-------|------|------|--|
| DDB2 | 97.1 | 100% | 99% | Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 |
| DDC | 88.8 | 100% | 98% | Aromatic L-amino acid decarboxylase deficiency, 608643 |
| DDHD1 | 141.9 | 100% | 97% | Spastic paraplegia 28, autosomal recessive, 609340 |
| DDHD2 | 105.4 | 100% | 100% | Spastic paraplegia 54, autosomal recessive, 615033 |
| DDOST | 97.6 | 100% | 98% | Congenital disorder of glycosylation, type Ir, 614507 |
| DDR2 | 127.4 | 100% | 100% | Spondylometaphyseal dysplasia, short limb-hand type, 271665 |
| DDX11 | 10.2 | 18% | 13% | Warsaw breakage syndrome, 613398 |
| DDX59 | 153.0 | 100% | 100% | Orofaciodigital syndrome V, 174300 |
| DEPDC5 | 114.0 | 99% | 99% | Epilepsy, familial focal, with variable foci, 604364 |
| DES | 92.8 | 96% | 88% | Myopathy, myofibrillar, 1, 601419 Cardiomyopathy, dilated, 1I, 604765 Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 ?Muscular dystrophy, limb-girdle, type 2R, 615325 |
| DFNA5 | 100.4 | 99% | 95% | Deafness, autosomal dominant 5, 600994 |
| DFNB31 | 85.0 | 100% | 98% | Deafness autosomal recessive 31 |
| DFNB59 | 127.4 | 100% | 100% | Deafness autosomal recessive 59 |
| DGKE | 111.9 | 100% | 99% | Nephrotic syndrome, type 7, 615008 |
| DGUOK | 99.3 | 100% | 100% | Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 |
| DHCR24 | 86.6 | 99% | 97% | Desmosterolosis, 602398 |
| DHCR7 | 115.9 | 100% | 97% | Smith-Lemli-Opitz syndrome, 270400 |
| DHDDS | 70.3 | 100% | 90% | Retinitis pigmentosa 59, 613861 |
| DHFR | 51.9 | 81% | 58% | Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 |
| DHH | 77.9 | 100% | 100% | 46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 46XY sex reversal 7, 233420 |
| DHODH | 100.6 | 100% | 99% | Miller syndrome, 263750 |
| DHTKD1 | 103.3 | 100% | 98% | 2-amino adipic 2-oxoadipic aciduria, 204750 Charcot-Marie-Tooth disease, axonal, type 2Q, 615025 |
| DIABLO | 114.0 | 97% | 90% | Deafness autosomal dominant 64 |
| DIAPH1 | 80.8 | 99% | 91% | Deafness, autosomal dominant 1, 124900 |
| DIAPH2 | 57.7 | 95% | 93% | Premature ovarian failure, 300511 |
| DIAPH3 | 111.8 | 97% | 93% | Auditory neuropathy, autosomal dominant, 1, 609129 |
| DICER1 | 119.3 | 100% | 100% | Pleuropulmonary blastoma, 601200 Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, 138800 |
| DIP2B | 100.8 | 100% | 97% | Mental retardation, FRA12A type, 136630 |
| DIS3L2 | 133.8 | 99% | 94% | Perlman syndrome, 267000 |
| DKC1 | 50.0 | 99% | 91% | Dyskeratosis congenita, X-linked, 305000 |

| | | | | |
|----------|-------|------|------|---|
| DLAT | 107.0 | 100% | 100% | Pyruvate dehydrogenase E2 deficiency, 245348 |
| DLC1 | 148.3 | 100% | 99% | Colorectal cancer, somatic |
| DLD | 143.7 | 100% | 100% | Dihydrolipoamide dehydrogenase deficiency, 246900 |
| DLG3 | 39.5 | 90% | 77% | Mental retardation, X-linked 90, 300850 |
| DLL3 | 70.3 | 94% | 81% | Spondylocostal dysostosis, autosomal recessive, 1, 277300 |
| DLX3 | 75.6 | 98% | 91% | Trichodontosseous syndrome, 190320 Amelogenesis imperfecta, hypomaturation-hypoplastic type, with taurodontism, 104510 |
| DMD | 57.8 | 98% | 95% | Duchenne muscular dystrophy, 310200 Becker muscular dystrophy, 300376 Cardiomyopathy, dilated, 3B, 302045 |
| DMGDH | 116.6 | 97% | 96% | Dimethylglycine dehydrogenase deficiency, 605850 |
| DMP1 | 110.0 | 100% | 100% | Hypophosphatemic rickets, AR, 241520 |
| DMPK | 94.8 | 100% | 99% | Myotonic dystrophy 1, 160900 |
| DNA2 | 115.7 | 100% | 100% | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 6, 615156 |
| DNAAF1 | 120.8 | 100% | 99% | Ciliary dyskinesia primary 13 |
| DNAAF2 | 113.0 | 100% | 100% | Ciliary dyskinesia primary 10 |
| DNAAF3 | 73.3 | 96% | 81% | Ciliary dyskinesia, primary, 2, 606763 |
| DNAH11 | 115.8 | 100% | 99% | Ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 |
| DNAH5 | 96.0 | 99% | 98% | Ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 |
| DNAI1 | 124.5 | 100% | 100% | Ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 |
| DNAI2 | 109.7 | 98% | 93% | Ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 |
| DNAJB2 | 107.5 | 100% | 96% | Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 |
| DNAJB6 | 42.4 | 85% | 78% | Muscular dystrophy, limb-girdle, type 1E, 603511 |
| DNAJC19 | 57.8 | 79% | 78% | 3-methylglutaconic aciduria, type V, 610198 |
| DNAJC5 | 69.7 | 91% | 79% | Ceroid lipofuscinosis, neuronal, 4, Parry type, 162350 |
| DNAJC6 | 95.2 | 100% | 97% | Parkinson disease 19, juvenile-onset, 615528 |
| DNAL1 | 118.6 | 100% | 100% | Ciliary dyskinesia, primary, 16, 614017 |
| DNASE1L3 | 86.9 | 100% | 100% | Systemic lupus erythematosus 16, 614420 |
| DNM1L | 104.9 | 100% | 100% | Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission, 614388 |
| DNM2 | 80.0 | 100% | 96% | Charcot-Marie-Tooth disease, dominant intermediate B, 606482 Myopathy, centronuclear, 160150 Charcot-Marie-Tooth disease, axonal, type 2M, 606482 Lethal congenital contracture syndrome 5, 615368 |

| | | | | |
|---------|-------|------|------|---|
| DNMT1 | 101.5 | 99% | 96% | Neuropathy, hereditary sensory, type IE, 614116 Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, 604121 |
| DNMT3B | 93.8 | 100% | 99% | Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 |
| DOCK6 | 89.4 | 99% | 95% | Adams-Oliver syndrome 2, 614219 |
| DOCK8 | 83.4 | 100% | 98% | Mental retardation, autosomal dominant 2, 614113 Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 |
| DOK7 | 54.1 | 95% | 85% | Myasthenia, limb-girdle, familial, 254300 Fetal akinesia deformation sequence, 208150 |
| DOLK | 145.3 | 100% | 100% | Congenital disorder of glycosylation type Im |
| DPAGT1 | 90.9 | 99% | 95% | Congenital disorder of glycosylation, type Ij, 608093 Myasthenic syndrome, congenital, with tubular aggregates 2, 614750 |
| DPM1 | 157.7 | 100% | 100% | Congenital disorder of glycosylation, type Ie, 608799 |
| DPM2 | 59.9 | 98% | 88% | Congenital disorder of glycosylation, type Iu, 615042 |
| DPM3 | 101.1 | 100% | 100% | Congenital disorder of glycosylation, type Io, 612937 |
| DPP6 | 91.8 | 98% | 90% | Ventricular fibrillation, paroxysmal familial, 2, 612956 |
| DPY19L2 | 22.8 | 24% | 20% | Spermatogenic failure 9, 613958 |
| DPYD | 119.1 | 98% | 96% | Dihydropyrimidine dehydrogenase deficiency, 274270 5-fluorouracil toxicity, 274270 |
| DPYS | 60.6 | 100% | 98% | Dihydropyrimidinuria, 222748 |
| DRC1 | 75.1 | 100% | 97% | Ciliary dyskinesia, primary, 21, 615294 |
| DRD2 | 112.3 | 100% | 98% | Dystonia, myoclonic, 159900 |
| DRD4 | 40.7 | 92% | 67% | Autonomic nervous system dysfunction [Novelty seeking personality], 601696 (1) {Attention deficit-hyperactivity disorder}, 143465 |
| DRD5 | 18.0 | 60% | 47% | {Blepharospasm, primary benign}, 606798 Dystonia, primary cervical {Attention deficit-hyperactivity disorder, susceptibility to}, 143465 |
| DSC2 | 104.3 | 100% | 99% | Arrhythmogenic right ventricular dysplasia 11, 610476 Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 |
| DSC3 | 100.6 | 99% | 99% | Hypotrichosis and recurrent skin vesicles, 613102 |
| DSG1 | 150.0 | 100% | 100% | pemphigus foliaceus antigen Keratosis palmoplantaris striata I, 148700 |
| DSG2 | 132.4 | 100% | 98% | Arrhythmogenic right ventricular dysplasia 10, 610193 Cardiomyopathy, dilated, 1BB, 612877 |
| DSG4 | 134.5 | 99% | 96% | Hypotrichosis, localized, autosomal recessive, 607903 |

| | | | | |
|---------|-------|------|------|---|
| DSP | 130.6 | 99% | 98% | Keratosis palmoplantaris striata II, 612908 Dilated cardiomyopathy with woolly hair and keratoderma, 605676 Arrhythmogenic right ventricular dysplasia 8, 607450 Skin fragility-woolly hair syndrome, 607655 Epidermolysis bullosa, lethal acan |
| DSPP | 139.2 | 98% | 96% | Dentinogenesis imperfecta, Shields type II, 125490 Deafness, autosomal dominant 36, with dentinogenesis, 605594 Dentinogenesis imperfecta, Shields type III, 125500 Dentin dysplasia, type II, 125420 -3 |
| DST | 145.9 | 100% | 99% | Neuropathy, hereditary sensory and autonomic, type VI, 614653 Epidermolysis bullosa simplex, sutosomal recessive 2, 615425 |
| DTNA | 102.0 | 100% | 97% | Left ventricular noncompaction 1, with or without congenital heart defects, 604169 |
| DTNBP1 | 112.3 | 100% | 100% | {Schizophrenia}, 181500 (2) Hermansky-Pudlak syndrome 7, 614076 |
| DUOX2 | 92.8 | 94% | 92% | Thryoid dyshormonogenesis 6, 607200 |
| DUOXA2 | 93.5 | 100% | 99% | Thyroid dyshormonogenesis 5, 274900 |
| DUSP6 | 146.1 | 100% | 100% | Hypogonadotropic hypogonadism 19 with or without anosmia, 615269 |
| DYM | 102.2 | 100% | 99% | Dyggve-Melchior-Clausen disease, 223800 Smith-McCort dysplasia, 607326 |
| DYNC1H1 | 117.4 | 99% | 96% | Charcot-Marie-Tooth disease, axonal, type 20, 614228 Mental retardation, autosomal dominant 13, 614563 Spinal muscular atrophy, lower extremity-predominant, AD, 158600 |
| DYNC2H1 | 116.8 | 100% | 99% | Asphyxiating thoracic dystrophy 3, 613091 Short rib-polydactyly syndrome, type III, 263510 Short rib-polydactyly syndrome, type IIB, 615087 |
| DYRK1A | 146.9 | 99% | 99% | Mental retardation, autosomal dominant 7, 614104 |
| DYSF | 98.6 | 99% | 99% | Muscular dystrophy, limb-girdle, type 2B, 253601 Myopathy, distal, with anterior tibial onset, 606768 Miyoshi muscular dystrophy 1, 254130 |
| DYX1C1 | 93.9 | 100% | 100% | {Dyslexia, susceptibility to}, 127700 |
| EARS2 | 70.5 | 93% | 91% | Combined oxidative phosphorylation deficiency 12, 614924 |
| EBP | 43.9 | 94% | 73% | Chondrodysplasia punctata, X-linked dominant, 302960 |
| ECE1 | 93.4 | 97% | 97% | Hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 {Hypertension, essential, susceptibility to}, 145500 |
| ECEL1 | 62.0 | 96% | 79% | Arthrogryposis, distal, type 5D, 615065 |

| | | | | |
|---------|-------|------|------|--|
| ECM1 | 108.5 | 100% | 99% | Urbach-Wiethe disease, 247100 |
| EDA | 47.2 | 96% | 86% | Ectodermal dysplasia 1 hypohidrotic X-linked |
| EDAR | 80.1 | 100% | 99% | Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant, 129490 Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive, 224900 [Hair morphology 1, hair thickness], 612630 -3 |
| EDARADD | 115.9 | 100% | 95% | Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, 614940 |
| EDN1 | 129.1 | 100% | 100% | [High density lipoprotein cholesterol level QTL 7] |
| EDN3 | 93.8 | 100% | 100% | Waardenburg syndrome, type 4B, 613265 Central hypoventilation syndrome, congenital, 209880 {Hirschsprung disease, susceptibility to, 4}, 613712 |
| EDNRA | 122.3 | 100% | 100% | Migraine, resistance to, 157300 |
| EDNRB | 161.7 | 100% | 99% | {Hirschsprung disease, susceptibility to, 2}, 600155 ABCD syndrome, 600501 Waardenburg syndrome, type 4A, 277580 |
| EFEMP1 | 123.5 | 100% | 94% | Doyne honeycomb degeneration of retina, 126600 |
| EFEMP2 | 100.1 | 100% | 100% | Cutis laxa, autosomal recessive, type IB, 614437 |
| EFNB1 | 60.2 | 100% | 96% | ? Craniofrontonasal dysplasia, 304110 |
| EFTUD2 | 89.7 | 98% | 97% | Mandibulofacial dysostosis, Guion-Almeida type, 610536 |
| EGF | 113.7 | 99% | 98% | Hypomagnesemia 4, renal, 611718 |
| EGFR | 97.6 | 100% | 100% | Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 {Nonsmall cell lung cancer, susceptibility to}, 211980 |
| EGLN1 | 88.7 | 80% | 74% | Erythrocytosis, familial, 3, 609820 |
| EGR2 | 73.9 | 100% | 98% | Neuropathy, congenital hypomyelinating, 1, 605253 Charcot-Marie-Tooth disease, type 1D, 607678 Dejerine-Sottas disease, 145900 |
| EHMT1 | 99.8 | 98% | 95% | Kleefstra syndrome, 610253 |
| EIF2AK3 | 115.2 | 93% | 92% | Wolcott-Rallison syndrome, 226980 |
| EIF2AK4 | 107.6 | 99% | 98% | Pulmonary venoocclusive disease 2, 234810 (3) |
| EIF2B1 | 113.5 | 97% | 93% | Leukoencephalopathy with vanishing white matter, 603896 |
| EIF2B2 | 89.8 | 100% | 98% | Leukoencephalopathy with vanishing white matter, 603896 Ovarioleukodystrophy, 603896 |

| | | | | |
|--------|-------|------|------|---|
| EIF2B3 | 86.3 | 100% | 99% | Leukoencephalopathy with vanishing white matter, 603896 |
| EIF2B4 | 121.8 | 100% | 100% | Leukoencephaly with vanishing white matter, 603896 Ovarioleukodystrophy, 603896 |
| EIF2B5 | 96.4 | 100% | 99% | Leukoencephalopathy with vanishing white matter, 603896 Ovarioleukodystrophy, 603896 |
| EIF4A3 | 71.3 | 100% | 98% | Robin sequence with cleft mandible and limb anomalies, 268305 (3) |
| EIF4G1 | 103.1 | 100% | 99% | Parkinson disease 18, 614251 |
| ELAC2 | 85.6 | 100% | 100% | {Prostate cancer, hereditary, 2, susceptibility to}, 614731 Combined oxidative phosphorylation deficiency 17, 615440 |
| ELANE | 113.7 | 97% | 80% | Neutropenia, cyclic, 162800 Neutropenia, severe congenital 1, autosomal dominant, 202700 |
| ELN | 66.9 | 99% | 96% | Supravalvar aortic stenosis, 185500 Cutis laxa, AD, 123700 |
| ELOVL4 | 102.9 | 100% | 100% | Stargardt disease 3, 600110 Macular dystrophy, autosomal dominant, chromosome 6-linked, 600110 Ichthyosis, spastic quadriplegia, and mental retardation, 614457 |
| EMD | 84.8 | 100% | 95% | Emery-Dreifuss muscular dystrophy 1, X-linked, 310300 |
| EMG1 | 87.5 | 100% | 100% | Bowen-Conradi syndrome, 211180 |
| EMX2 | 106.1 | 100% | 100% | Schizencephaly, 269160 |
| ENAM | 130.4 | 100% | 100% | Amelogenesis imperfecta, type IB, 104500 Amelogenesis imperfecta, type IC, 204650 |
| ENG | 67.2 | 99% | 94% | Telangiectasia, hereditary hemorrhagic, type 1, 187300 |
| ENO3 | 107.7 | 99% | 96% | Glycogen storage disease XIII, 612932 |
| ENPP1 | 113.3 | 95% | 93% | Ossification of posterior longitudinal ligament of spine, 602475 {Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 {Obesity, susceptibility to}, 601665 Arterial calcification, generalized, of infancy, 1, 208000 Hypophos |
| ENTPD1 | 116.2 | 100% | 99% | Spastic paraplegia 64, 615683 |
| EOGT | 105.5 | 100% | 99% | Adams-Oliver syndrome 4, 615297 |
| EP300 | 139.2 | 99% | 98% | Rubinstein-Taybi syndrome 2, 613684 Colorectal cancer, somatic, 114500 |
| EPAS1 | 85.5 | 98% | 92% | Erythrocytosis, familial, 4, 611783 |
| EPB41 | 125.7 | 100% | 100% | Elliptocytosis-1, 611804 |
| EPB42 | 94.9 | 99% | 95% | Spherocytosis, hereditary, type 5, 612690 |
| EPCAM | 117.1 | 100% | 99% | Diarrhea 5, with tufting enteropathy, congenital, 613217 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Colorectal cancer, hereditary nonpolyposis, type 8, 613244 |
| EPG5 | 89.4 | 100% | 99% | Vici syndrome, 242840 |
| EPHA2 | 89.5 | 97% | 94% | Cataract 6, multiple types, 116600 |
| EPHB2 | 115.6 | 97% | 97% | Prostate cancer, progression and metastasis of, 603688 |
| EPHX1 | 94.0 | 95% | 91% | ?Fetal hydantoin syndrome (1) Diphenylhydantoin toxicity (1) Hypercholanemia, familial, 607748 {Preeclampsia, susceptibility to}, 189800 |
| EPM2A | 54.7 | 80% | 73% | Epilepsy, progressive myoclonic 2A (Lafora), 254780 |
| EPX | 101.2 | 100% | 97% | Eosinophil peroxidase deficiency, 261500 |
| ERBB2 | 100.5 | 98% | 98% | Adenocarcinoma of lung, somatic, 211980 Glioblastoma, somatic, 137800 Gastric cancer, somatic, 613659 Ovarian cancer, somatic, |
| ERBB3 | 112.3 | 100% | 99% | Lethal congenital contractual syndrome 2, 607598 |
| ERBB4 | 121.0 | 100% | 100% | Amyotrophic lateral sclerosis 19, 615515 |
| ERCC1 | 73.0 | 100% | 96% | Cerebrooculofacioskeletal syndrome 4, 610758 |
| ERCC2 | 88.6 | 99% | 96% | Xeroderma pigmentosum, group D, 278730 Trichothiodystrophy, 601675 Cerebrooculofacioskeletal syndrome 2, 610756 |
| ERCC3 | 123.3 | 100% | 100% | Xeroderma pigmentosum, group B, 610651 Trichothiodystrophy, 601675 |
| ERCC4 | 141.5 | 97% | 94% | Xeroderma pigmentosum, group F, 278760 XFE progeroid syndrome, 610965 Fanconi anemia, complementation group Q, 615272 Xeroderma pigmentosum, type F/Cockayne syndrome, 278760 |
| ERCC5 | 122.5 | 99% | 97% | Xeroderma pigmentosum, group G, 278780 Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 |
| ERCC6 | 153.2 | 100% | 98% | Cockayne syndrome, type B, 133540 Cerebrooculofacioskeletal syndrome 1, 214150 De Sanctis-Cacchione syndrome, 278800 {Macular degeneration, age-related, susceptibility to 5}, 613761 UV-sensitive syndrome 1, 600630 {Lung cancer, suspect} |
| ERCC6L2 | 130.4 | 100% | 100% | Bone marrow failure syndrome 2, 615715 (3) |

| | | | | |
|--------|-------|------|------|---|
| ERCC8 | 86.0 | 100% | 100% | Cockayne syndrome, type A, 216400 UV-sensitive syndrome 2, 614621 |
| ERF | 109.2 | 100% | 100% | Craniosynostosis 4, 600775 |
| ERLIN2 | 115.7 | 100% | 98% | Spastic paraplegia 18, autosomal recessive, 611225 |
| ESCO2 | 96.3 | 100% | 99% | Roberts syndrome, 268300 SC phocomelia syndrome, 269000 |
| ESPN | 42.7 | 77% | 52% | Deafness, autosomal recessive 36, 609006 Deafness, neurosensory, without vestibular involvement, autosomal dominant |
| ESR1 | 115.7 | 100% | 100% | Estrogen resistance, 615363 {HDL response to hormone replacement, augmented} {Migraine, susceptibility to}, 157300 {Atherosclerosis, susceptibility to} {Myocardial infarction, susceptibility to}, 608446 {Breast cancer}, 114480 (1) |
| ESRRB | 63.0 | 84% | 75% | Deafness, autosomal recessive 35, 608565 |
| ETFA | 115.4 | 100% | 100% | Glutaric acidemia IIA, 231680 |
| ETFB | 107.8 | 100% | 99% | Glutaric acidemia IIB, 231680 |
| ETFDH | 132.6 | 100% | 100% | Glutaric acidemia IIC, 231680 |
| ETHE1 | 61.0 | 100% | 96% | Ethylmalonic encephalopathy, 602473 |
| ETV6 | 109.8 | 100% | 98% | Leukemia, acute myeloid, somatic, 601626 |
| EVC | 81.0 | 91% | 88% | Ellis-van Creveld syndrome, 225500 Weyers acrodental dysostosis, 193530 |
| EVC2 | 102.4 | 94% | 92% | Ellis-van Creveld syndrome |
| EWSR1 | 63.3 | 91% | 73% | Ewing sarcoma, 612219 Neuroepithelioma, 612219 |
| EXOSC3 | 64.3 | 94% | 80% | Pontocerebellar hypoplasia, type 1B, 614678 |
| EXPH5 | 147.5 | 100% | 100% | Epidermolysis bullosa, nonspecific, autosomal recessive, 615028 |
| EXT1 | 104.7 | 98% | 95% | Exostoses, multiple, type 1, 133700 Chondrosarcoma, 215300 |
| EXT2 | 117.3 | 100% | 96% | Exostoses, multiple, type 2, 133701 |
| EYA1 | 113.1 | 100% | 99% | Branchiootorenal syndrome 1, with or without cataracts, 113650 Anterior segment anomalies with or without cataract, 113650 Branchiootic syndrome 1, 602588 Otofaciocervical syndrome, 166780 |
| EYA4 | 124.0 | 100% | 100% | Deafness, autosomal dominant 10, 601316 Cardiomyopathy, dilated, 1J, 605362 |

| | | | | |
|---------|-------|------|------|---|
| EYS | 127.6 | 100% | 99% | Retinitis pigmentosa 25, 602772 |
| EZH2 | 89.2 | 99% | 93% | Weaver syndrome, 277590 |
| F10 | 98.8 | 100% | 100% | Factor X deficiency, 227600 |
| F11 | 107.6 | 96% | 91% | Factor XI deficiency, autosomal recessive, 612416 Factor XI deficiency, autosomal dominant, 612416 |
| F12 | 94.8 | 100% | 96% | Factor XII deficiency, 234000 Angioedema, hereditary, type III, 610618 |
| F13A1 | 101.2 | 99% | 97% | Factor XIII A deficiency, 613225 {Myocardial infarction, protection against}, 608446 {Venous thrombosis, protection against}, 188050 |
| F13B | 91.1 | 100% | 98% | Factor XIII B deficiency, 613235 |
| F2 | 87.8 | 96% | 91% | Hypoprothrombinemia, 613679 Dysprothrombinemia, 613679 Thrombophilia due to thrombin defect, 188050 {Stroke, ischemic, susceptibility to}, 601367 {Pregnancy loss, recurrent, susceptibility to, 2}, 614390 |
| F5 | 134.3 | 100% | 99% | Factor V deficiency, 227400 {Thrombophilia, susceptibility to, due to factor V Leiden}, 188055 {Stroke, ischemic, susceptibility to}, 601367 {Budd-Chiari syndrome}, 600880 Thrombophilia due to activated protein C resistance, 188055 {Pr} |
| F7 | 87.1 | 100% | 100% | Factor VII deficiency, 227500 {Myocardial infarction, decreased susceptibility to}, 608446 |
| F8 | 68.5 | 99% | 95% | Hemophilia A, 306700 |
| F9 | 82.4 | 100% | 100% | Hemophilia B, 306900 {Warfarin sensitivity}, 122700 Thrombophilia, X-linked, due to factor IX defect, 300807 {Deep venous thrombosis, protection against}, 300807 |
| FA2H | 77.3 | 98% | 94% | Spastic paraparesis 35 autosomal recessive |
| FADD | 110.3 | 100% | 100% | Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascuclar malformations, 613759 |
| FAH | 108.6 | 100% | 98% | Tyrosinemia, type I, 276700 |
| FAM111A | 175.3 | 100% | 100% | Kenny-Caffey syndrome, type 2, 127000 Gracile bone dysplasia, 602361 |
| FAM111B | 187.0 | 100% | 99% | Poikiloderma, hereditary fibrosis, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 (3) |

| | | | | |
|---------|-------|------|------|--|
| FAM126A | 143.6 | 100% | 100% | Leukodystrophy, hypomyelinating, 5, 610532 |
| FAM134B | 89.2 | 100% | 99% | Neuropathy, hereditary sensory and autonomic, type IIB, 613115 |
| FAM161A | 148.2 | 100% | 100% | Retinitis pigmentosa 28, 606068 |
| FAM20A | 70.9 | 99% | 94% | Amelogenesis imperfecta and gingival fibromatosis syndrome, 614253 |
| FAM20C | 78.4 | 90% | 84% | Raine syndrome, 259775 |
| FAM58A | 20.3 | 48% | 45% | STAR syndrome, 300707 |
| FAM83H | 81.0 | 100% | 99% | Amelogenesis imperfecta, type 3, 130900 |
| FAN1 | 111.6 | 100% | 99% | Interstitial nephritis, karyomegalic, 614817 |
| FANCA | 86.0 | 100% | 96% | Fanconi anemia, complementation group A, 227650 |
| FANCB | 65.5 | 96% | 88% | Fanconi anemia complementation group B |
| FANCC | 78.9 | 99% | 96% | Fanconi anemia, complementation group C, 227645 |
| FANCD2 | 98.9 | 87% | 85% | Fanconi anemia, complementation group D2, 227646 |
| FANCE | 84.3 | 90% | 87% | Fanconi anemia, complementation group E, 600901 |
| FANCF | 152.2 | 100% | 100% | Fanconi anemia, complementation group F, 603467 |
| FANCG | 118.1 | 100% | 96% | Fanconi anemia complementation group G |
| FANCI | 126.2 | 100% | 99% | Fanconi anemia, complementation group I, 609053 |
| FANCL | 95.2 | 100% | 99% | Fanconi anemia complementation group L |
| FANCM | 122.3 | 100% | 99% | Fanconi anemia, complementation group M, 614087 |
| FARS2 | 97.6 | 98% | 94% | Combined oxidative phosphorylation deficiency 14, 614946 |
| FAS | 181.5 | 100% | 100% | Autoimmune lymphoproliferative syndrome type IA |
| FASLG | 83.8 | 97% | 92% | Autoimmune lymphoproliferative syndrome type IB |
| FAT4 | 160.3 | 100% | 100% | Hennekam lymphangiectasia-lymphedema syndrome 2, 616006 Van Maldergem syndrome 2, 615546 |
| FBLN1 | 104.1 | 98% | 95% | Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 |
| FBLN5 | 81.8 | 100% | 99% | Cutis laxa, autosomal recessive, type IA, 219100 Cutis laxa, autosomal dominant 2, 614434 Macular degeneration, age-related, 3, 608895 |
| FBN1 | 98.5 | 100% | 99% | Marfan syndrome, 154700 Ectopia lentis, familial, 129600 MASS syndrome, 604308 Weill-Marchesani syndrome 2, dominant, 608328 Aortic aneurysm, ascending, and dissection Stiff skin syndrome, 184900 Acromicric dysplasia, 102370 Ge |

| | | | | |
|--------|-------|------|------|--|
| FBN2 | 104.7 | 99% | 98% | Contractural arachnodactyly, congenital, 121050 |
| FBP1 | 90.3 | 100% | 96% | Fructose-1,6-bidphosphatase deficiency, 229700 |
| FBXL4 | 154.9 | 100% | 100% | Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 |
| FBXO38 | 120.7 | 100% | 96% | Neuronopathy, distal hereditary motor, type IID, 65575 |
| FBXO7 | 159.5 | 100% | 100% | Parkinson disease 15, autosomal recessive, 260300 |
| FCGR3A | 50.6 | 50% | 49% | {Viral infections, recurrent} |
| FCGR3B | 57.7 | 57% | 53% | Neutropenia, alloimmune neonatal |
| FCN3 | 105.6 | 99% | 95% | Immunodeficiency due to ficolin 3 deficiency, 613860 |
| FECH | 106.9 | 100% | 98% | Protoporphyrina, erythropoietic, autosomal recessive, 177000 |
| FERMT1 | 99.0 | 100% | 97% | Kindler syndrome |
| FERMT3 | 104.3 | 100% | 97% | Leukocyte adhesion deficiency type III |
| FGA | 169.8 | 100% | 99% | Dysfibrinogenemia, alpha type, causing bleeding diathesis Dysfibrinogenemia, alpha type, causing recurrent thrombosis Amyloidosis, hereditary renal, 105200 Afibrinogenemia, congenital, 202400 |
| FGB | 116.1 | 99% | 97% | Dysfibrinogenemia, beta type Afibrinogenemia, congenital, 202400 Thrombophilia, dysfibrinogenemic |
| FGD1 | 47.0 | 94% | 88% | Aarskog-Scott syndrome, 305400 Mental retardation, X-linked syndromic 16, 305400 |
| FGD4 | 124.3 | 100% | 100% | Charcot-Marie-Tooth disease, type 4H, 609311 |
| FGF10 | 124.1 | 100% | 100% | Aplasia of lacrimal and salivary glands, 180920 LADD syndrome, 149730 |
| FGF14 | 113.5 | 100% | 100% | Spinocerebellar ataxia 27, 609307 |
| FGF16 | 66.8 | 100% | 98% | Metacarpal 4-5 fusion, 609630 |
| FGF17 | 93.2 | 100% | 100% | Hypogonadotropic hypogonadism 20 with or without anosmia, 615270 |
| FGF23 | 75.3 | 96% | 92% | Hypophosphatemic rickets, autosomal dominant, 193100 Osteomalacia, tumor-induced (1) Tumoral calcinosis, hyperphosphatemic, familial, 211900 |
| FGF3 | 72.2 | 100% | 93% | Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 |
| FGF8 | 42.8 | 83% | 61% | Hypogonadotropic hypogonadism 6 with or without anosmia, 612702 |
| FGF9 | 150.9 | 100% | 100% | Multiple synostoses syndrome 3, 612961 |

| | | | | |
|--------|-------|------|------|---|
| FGFR1 | 123.9 | 100% | 100% | Pfeiffer syndrome, 101600 Jackson-Weiss syndrome, 123150 Hypogonadotropic hypogonadism 2 with or without anosmia, 147950 Osteoglophonic dysplasia, 166250 Trigonocephaly 1, 190440 Hartsfield syndrome, 615465 |
| FGFR2 | 122.8 | 100% | 98% | Crouzon syndrome, 123500 Jackson-Weiss syndrome, 123150 Beare-Stevenson cutis gyrata syndrome, 123790 Pfeiffer syndrome, 101600 Apert syndrome, 101200 Saethre-Chotzen syndrome, 101400 Craniosynostosis, nonspecific Gastric cancer |
| FGFR3 | 72.8 | 94% | 91% | Achondroplasia, 100800 Hypochondroplasia, 146000 Thanatophoric dysplasia, type I, 187600 Crouzon syndrome with acanthosis nigricans, 612247 Muenke syndrome, 602849 Bladder cancer, somatic, 109800 Colorectal cancer, somatic, 114500 |
| FGG | 119.4 | 100% | 97% | Dysfibrinogenemia, gamma type Hypofibrinogenemia, gamma type Thrombophilia, dysfibrinogenemic |
| FH | 85.7 | 98% | 89% | Fumarase deficiency, 606812 Leiomyomatosis and renal cell cancer, 150800 |
| FHL1 | 45.6 | 96% | 81% | Hemophagocytic lymphohistiocytosis, familial, 1 (2) |
| FIG4 | 132.9 | 100% | 99% | Charcot-Marie-Tooth disease, type 4J, 611228 Amyotrophic lateral sclerosis 11, 612577 Yunis-Varon syndrome, 216340 |
| FIGLA | 82.1 | 97% | 91% | Premature ovarian failure 6, 612310 |
| FKBP10 | 85.2 | 100% | 99% | Osteogenesis imperfecta, type XI, 610968 |
| FKBP14 | 141.6 | 100% | 100% | Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss, 614557 |

| | | | | |
|--------|-------|------|------|--|
| FKRP | 80.2 | 100% | 98% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612 Muscular dystrophy-dystroglycanopathy (limb) |
| FKTN | 108.3 | 100% | 99% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 Cardiomyopathy, dilated, 1X, 611615 Muscular dy |
| FLCN | 119.1 | 100% | 98% | Birt-Hogg-Dube syndrome, 135150 Pneumothorax, primary spontaneous, 173600 Renal carcinoma, chromophobe, somatic, 144700 Colorectal cancer, somatic, 114500 |
| FLG | 49.9 | 99% | 82% | Ichthyosis vulgaris, 146700 {Dermatitis, atopic, susceptibility to, 2}, 605803 |
| FLNA | 60.2 | 98% | 90% | Heterotopia, periventricular, 300049 Otopalatodigital syndrome, type I, 311300 Otopalatodigital syndrome, type II, 304120 Intestinal pseudoobstruction, neuronal, 300048 Melnick-Needles syndrome, 309350 Frontometaphyseal dysplasia, 3056 |
| FLNB | 88.2 | 100% | 98% | Spondylocarpotarsal synostosis syndrome, 272460 Larsen syndrome, 150250 Atelosteogenesis, type I, 108720 Atelosteogenesis, type III, 108721 Boomerang dysplasia, 112310 |
| FLNC | 93.2 | 96% | 94% | Myopathy, myofibrillar, 5, 609524 Myopathy, distal, 4, 614065 -3 |
| FLRT3 | 217.0 | 100% | 100% | Hypogonadotropic hypogonadism 21 with anosmia, 615271 |
| FLT3 | 105.7 | 99% | 96% | Leukemia, acute myeloid, reduced survival in Leukemia, acute myeloid, 601626 Leukemia, acute lymphoblastic |
| FLT4 | 98.2 | 99% | 99% | Lymphedema, hereditary I, 153100 Hemangioma, capillary infantile, somatic, 602089 |
| FLVCR1 | 95.8 | 100% | 100% | Ataxia, posterior column, with retinitis pigmentosa, 609033 |

| | | | | |
|---------|-------|------|------|---|
| FLVCR2 | 134.9 | 100% | 100% | Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome, 225790 |
| FMO3 | 107.4 | 100% | 100% | Trimethylaminuria, 602079 |
| FMR1 | 56.6 | 98% | 95% | Fragile X syndrome, 300624 Fragile X tremor/ataxia syndrome, 300623 Premature ovarian failure 1, 311360 |
| FN1 | 88.7 | 99% | 96% | Glomerulopathy with fibronectin deposits 2, 601894 Plasma fibronectin deficiency, 614101 (1) |
| FOLR1 | 78.4 | 100% | 97% | Neurodegeneration due to cerebral folate transport deficiency, 613068 |
| FOXC1 | 51.1 | 100% | 92% | Iridogoniodygenesis, type 1, 601631 Rieger or Axenfeld anomalies, 602482 Axenfeld-Rieger syndrome, type 3, 602482 Iris hypoplasia and glaucoma, 601631 |
| FOXC2 | 80.3 | 100% | 90% | Lymphedema-distichiasis syndrome, 153400 Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 |
| FOXE1 | 111.5 | 100% | 100% | Bamforth-Lazarus syndrome |
| FOXE3 | 14.2 | 70% | 38% | Anterior segment mesenchymal dysgenesis, 107250 Aphakia, congenital primary, 610256 |
| FOXF1 | 107.1 | 100% | 100% | Alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 |
| FOXG1 | 91.1 | 93% | 80% | Rett syndrome, congenital variant, 613454 |
| FOXI1 | 100.5 | 100% | 100% | Enlarged vestibular aqueduct, 600791 |
| FOXL2 | 86.1 | 100% | 100% | Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 Premature ovarian failure 3, 608996 |
| FOXN1 | 108.5 | 100% | 99% | T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 |
| FOXO1 | 123.7 | 100% | 88% | Rhabdomyosarcoma alveolar |
| FOXP1 | 102.1 | 99% | 97% | Mental retardation with language impairment and autistic features, 613670 |
| FOXP2 | 113.9 | 100% | 100% | Speech-language disorder-1, 602081 |
| FOXP3 | 31.8 | 89% | 69% | Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 {Diabetes mellitus, type I, susceptibility to}, 222100 |
| FOXRED1 | 95.2 | 100% | 97% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 Mitochondrial complex I deficiency, 252010 |
| FRAS1 | 99.0 | 98% | 95% | Fraser syndrome, 219000 |

| | | | | |
|-------|-------|------|------|--|
| FREM1 | 108.6 | 100% | 98% | Bifid nose with or without anorectal and renal anomalies, 608980 Manitoba oculotrichoanal syndrome, 248450 Trigonocephaly 2, 614485 |
| FREM2 | 127.7 | 100% | 99% | Fraser syndrome, 219000 |
| FRMD7 | 64.4 | 100% | 95% | Nystagmus 1, congenital, X-linked, 310700 Nystagmus, infantile periodic alternating, X-linked, 310700 |
| FSCN2 | 82.2 | 100% | 100% | Retinitis pigmentosa 30, 607921 |
| FSHB | 81.4 | 100% | 100% | Follicle-stimulating hormone deficiency, isolated, 229070 |
| FSHR | 92.8 | 100% | 99% | Ovarian dysgenesis 1, 233300 Ovarian response to FSH stimulation, 276400 Ovarian hyperstimulation syndrome, 608115 |
| FTCD | 58.1 | 92% | 81% | Glutamate formiminotransferase deficiency, 229100 |
| FTL | 95.3 | 100% | 95% | Hyperferritinemia-cataract syndrome, 600886 Neurodegeneration with brain iron accumulation 3, 606159 |
| FTO | 126.9 | 97% | 97% | Growth retardation, developmental delay, coarse facies, and early death, 612938 |
| FTSJ1 | 53.2 | 92% | 77% | Mental retardation, X-linked 9, 309549 |
| FUCA1 | 74.3 | 100% | 96% | Fucosidosis, 230000 |
| FUS | 79.5 | 100% | 95% | Amyotrophic lateral sclerosis 6, autosomal recessive, with or without frontotemporal dementia, 608030 Tremor, hereditary essential, 4, 614782 |
| FUT6 | 77.0 | 81% | 73% | Fucosyltransferase 6 deficiency, 613852 |
| FUZ | 79.4 | 100% | 100% | Neural tube defects, 182940 |
| FXN | 87.0 | 93% | 87% | Friedreich ataxia, 229300 Friedreich ataxia with retained reflexes, 229300 |
| FXYD2 | 64.3 | 99% | 80% | Hypomagnesemia-2, renal, 154020 |
| FYCO1 | 86.2 | 99% | 98% | Cataract 18, autosomal recessive, 610019 |
| FZD4 | 142.2 | 100% | 100% | Exudative vitreoretinopathy, 133780 Retinopathy of prematurity, 133780 |
| FZD6 | 154.0 | 100% | 100% | Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails), 614157 |
| G6PC | 140.5 | 100% | 100% | Glycogen storage disease Ia, 232200 |
| G6PC3 | 116.3 | 100% | 100% | Neutropenia, severe congenital 4, autosomal recessive, 612541 Dursun syndrome, 612541 |
| G6PD | 57.0 | 95% | 92% | Hemolytic anemia due to G6PD deficiency Favism, 134700 {Resistance to malaria due to G6PD deficiency}, 611162 |
| GAA | 96.6 | 100% | 98% | Glycogen storage disease II, 232300 |

| | | | | |
|--------|-------|------|------|--|
| GABRA1 | 135.1 | 100% | 96% | {Epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 {Epilepsy, childhood absence, susceptibility to, 4}, 611136 |
| GABRB3 | 113.7 | 100% | 97% | Insomnia {Epilepsy, childhood absence, susceptibility to, 5}, 612269 |
| GABRG2 | 135.7 | 98% | 94% | Epilepsy, generalized, with febrile seizures plus, type 3, 611277 {Epilepsy, childhood absence, susceptibility to, 2}, 607681 Febrile seizures, familial, 8, 611277 |
| GAD1 | 96.2 | 100% | 98% | Cerebral palsy, spastic quadriplegic, 1, 603513 |
| GALC | 96.4 | 100% | 96% | Krabbe disease, 245200 |
| GALE | 115.6 | 100% | 100% | Galactose epimerase deficiency, 230350 |
| GALK1 | 96.4 | 100% | 100% | Galactokinase deficiency with cataracts, 230200 |
| GALNS | 67.4 | 92% | 92% | Mucopolysaccharidosis IVA, 253000 |
| GALNT3 | 108.3 | 100% | 100% | Tumoral calcinosis, hyperphosphatemic, familial, 211900 |
| GALT | 113.2 | 100% | 100% | Galactosemia, 230400 |
| GAMT | 91.8 | 98% | 92% | Cerebral creatine deficiency syndrome 2, 612736 |
| GAN | 147.9 | 100% | 99% | Giant axonal neuropathy-1, 256850 |
| GARS | 135.8 | 100% | 100% | Charcot-Marie-Tooth disease type 2D |
| GATA1 | 53.3 | 96% | 87% | Thrombocytopenia, X-linked, with or without dyserythropoietic anemia, 300367 Leukemia, megakaryoblastic, with or without Down syndrome, somatic, 190685 Thrombocytopenia with beta-thalassemia, X-linked, 314050 Anemia, X-linked, with/without neu |
| GATA2 | 95.5 | 99% | 93% | Dendritic cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency, 614172 Emberger syndrome, 614038 {Myelodysplastic syndrome, susceptibility to}, 614286 {Leukemia, acute myeloid, susceptibility to}, 601626 |
| GATA3 | 126.7 | 100% | 98% | Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 |
| GATA4 | 58.6 | 78% | 64% | Atrial septal defect 2, 607941 Ventricular septal defect 1, 614429 Atrioventricular septal defect 4, 614430 |
| GATA6 | 49.9 | 92% | 71% | Atrioventricular septal defect 5, 614474 Atrial septal defect 9, 614475 Pancreatic agenesis and congenital heart defects, 600001 Persistent truncus arteriosus, 217095 Tetralogy of Fallot, 187500 |

| | | | | |
|---------|-------|------|------|---|
| GATAD1 | 81.4 | 93% | 89% | Cardiomyopathy, dilated, 2B, 614672 |
| GATAD2B | 112.9 | 100% | 98% | Mental retardation, autosomal dominant 18, 615074 |
| GATM | 88.8 | 100% | 94% | Cerebral creatine deficiency syndrome 3, 612718 |
| GBA | 62.1 | 63% | 58% | Gaucher disease, type I, 230800 Gaucher disease, type II, 230900 Gaucher disease, type III, 231000 Gaucher disease, type IIIC, 231005 Gaucher disease, perinatal lethal, 608013 {Parkinson disease, late-onset, susceptibility to}, 168600 |
| GBA2 | 122.9 | 100% | 100% | Spastic paraparesis 46, autosomal recessive, 614409 |
| GBE1 | 104.3 | 98% | 94% | Glycogen storage disease IV, 232500 Polyglucosan body disease, adult form, 263570 |
| GCDH | 80.6 | 92% | 91% | Glutaric aciduria, type I, 231670 |
| GCH1 | 99.7 | 100% | 100% | Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 Hyperphenylalaninemia, BH4-deficient, B, 233910 |
| GCK | 82.5 | 100% | 97% | MODY, type II, 125851 Diabetes mellitus, noninsulin-dependent, late onset, 125853 Diabetes mellitus, gestational, 125851 Hyperinsulinemic hypoglycemia, familial, 3, 602485 Diabetes mellitus, permanent neonatal, 606176 |
| GCLC | 137.3 | 100% | 100% | Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 {Myocardial infarction, susceptibility to}, 608446 |
| GCM2 | 118.7 | 100% | 100% | Hypoparathyroidism familial isolated |
| GCNT2 | 161.3 | 100% | 100% | [Blood group, li], 110800 Cataract 13 with adult i phenotype, 110800 Adult i phenotype without cataract, 110800 |
| GCSH | 14.8 | 52% | 39% | Glycine encephalopathy, 605899 |
| GDAP1 | 106.2 | 100% | 100% | Charcot-Marie-Tooth disease, type 4A, 214400 Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 Charcot-Marie-Tooth disease, axonal, type 2K, 607831 Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 |
| GDF1 | 25.4 | 95% | 71% | Double-outlet right ventricle, 217095 Tetralogy of Fallot, 187500 Transposition of great arteries, dextro-looped 3, 613854 Right atrial isomerism, 208530 |

| | | | | |
|-------|-------|------|------|---|
| GDF2 | 143.9 | 100% | 100% | Telangiectasia, hereditary hemorrhagic, type 5, 615506 |
| GDF3 | 127.8 | 100% | 100% | Klippel-Feil syndrome 3, autosomal dominant, 613702 Microphthalmia with coloboma 6, 613703 Microphthalmia, isolated 7, 613704 |
| GDF5 | 99.5 | 100% | 100% | Acromesomelic dysplasia, Hunter-Thompson type, 201250 Brachydactyly, type C, 113100 Chondrodysplasia, Grebe type, 200700 Du Pan syndrome, 228900 Brachydactyly, type A2, 112600 Symphalangism, proximal, 1B, 615298 Multiple synostoses |
| GDF6 | 135.5 | 100% | 100% | Klippel-Feil syndrome 1, autosomal dominant, 118100 Microphthalmia, isolated 4, 613094 Microphthalmia with coloboma 6, digenic, 613703 Leber congenital amaurosis 17, 615360 |
| GDI1 | 70.5 | 99% | 96% | Mental retardation, X-linked 41, 300849 |
| GDNF | 164.3 | 100% | 99% | Central hypoventilation syndrome, 209880 {Pheochromocytoma, modifier of}, 171300 {Hirschsprung disease, susceptibility to, 3}, 613711 |
| GFAP | 83.0 | 100% | 98% | Alexander disease, 203450 |
| GFER | 63.9 | 99% | 94% | Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay, 613076 |
| GFI1 | 61.8 | 100% | 93% | Neutropenia, severe congenital 2, autosomal dominant, 613107 Neutropenia, nonimmune chronic idiopathic, of adults, 607847 |
| GFI1B | 96.5 | 100% | 100% | Bleeding disorder, platelet-type, 17, 187900 |
| GFM1 | 121.8 | 100% | 100% | Combined oxidative phosphorylation deficiency 1, 609060 |
| GFPT1 | 105.6 | 100% | 96% | Myasthenia, congenital, with tubular aggregates 1, 610542 |
| GGCX | 92.4 | 99% | 99% | Vitamin K-dependent coagulation defect, 277450 Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 |
| GH1 | 66.9 | 69% | 67% | Growth hormone deficiency, isolated, type IA, 262400 Growth hormone deficiency, isolated, type IB, 612781 Growth hormone deficiency, isolated, type II, 173100 Kowarski syndrome, 262650 |

| | | | | |
|--------|-------|------|------|--|
| GHR | 132.4 | 99% | 99% | Laron dwarfism, 262500 Short stature, 604271 {Hypercholesterolemia, familial, modification of}, 143890 Increased responsiveness to growth hormone |
| GHRHR | 104.0 | 100% | 98% | Growth hormone deficiency, isolated, type IB, 612781 |
| GHSR | 128.8 | 100% | 100% | Short stature, 604271 |
| GIF | 108.9 | 100% | 100% | Intrinsic factor deficiency, 261000 |
| GIGYF2 | 106.4 | 99% | 97% | Parkinson disease 11, 607688 |
| GIPC3 | 107.2 | 95% | 92% | Deafness, autosomal recessive 15, 601869 |
| GJA1 | 63.1 | 91% | 79% | Oculodentodigital dysplasia, 164200 Syndactyly, type III, 186100 Hypoplastic left heart syndrome 1, 241550 Atrioventricular septal defect 3, 600309 Oculodentodigital dysplasia, autosomal recessive, 257850 Craniometaphyseal dysplasia, a |
| GJA3 | 100.0 | 100% | 99% | Cataract 14, multiple types, 601885 |
| GJA5 | 124.4 | 100% | 100% | Atrial fibrillation, familial, 11, 614049 Atrial standstill, digenic, 108770 |
| GJA8 | 135.9 | 100% | 99% | Cataract 1, multiple types, 116200 |
| GJB1 | 85.4 | 100% | 100% | Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 |
| GJB2 | 172.7 | 100% | 100% | Deafness, autosomal recessive 1A, 220290 Deafness, autosomal dominant 3A, 601544 Vohwinkel syndrome, 124500 Keratoderma, palmoplantar, with deafness, 148350 Keratitis-ichthyosis-deafness syndrome, 148210 Hystrix-like ichthyosis with de |
| GJB3 | 149.1 | 100% | 100% | Erythrokeratoderma variabilis et progressiva, 133200 Deafness, autosomal dominant 2B, 612644 Deafness, autosomal recessive Deafness, autosomal dominant, with peripheral neuropathy Deafness, digenic, GJB2/GJB3, 220290 |
| GJB4 | 136.7 | 100% | 100% | Erythrokeratoderma variabilis with erythema gyratum repens, 133200 |
| GJB6 | 157.2 | 100% | 100% | Deafness, autosomal dominant 3B, 612643 Deafness, autosomal recessive 1B, 612645 Deafness, digenic GJB2/GJB6, 220290 Ectodermal dysplasia 2, Clouston type, 129500 |

| | | | | |
|--------|-------|------|------|---|
| GJC2 | 57.0 | 99% | 83% | Leukodystrophy, hypomyelinating, 2, 608804 Spastic paraplegia 44, autosomal recessive, 613206 Lymphedema, hereditary, IC, 613480 |
| GK | 24.5 | 77% | 56% | Glycerol kinase deficiency, 307030 |
| GLA | 47.2 | 95% | 86% | Fabry disease, 301500 Fabry disease, cardiac variant, 301500 |
| GLB1 | 76.5 | 99% | 94% | GM1-gangliosidosis, type I, 230500 GM1-gangliosidosis, type II, 230600 GM1-gangliosidosis, type III, 230650 Mucopolysaccharidosis type IVB (Morquio), 253010 |
| GLDC | 60.1 | 98% | 85% | Glycine encephalopathy, 605899 |
| GLE1 | 103.8 | 98% | 94% | Lethal congenital contracture syndrome 1, 253310 Arthrogryposis, lethal, with anterior horn cell disease, 611890 |
| GLI2 | 107.0 | 100% | 97% | Holoprosencephaly-9, 610829 |
| GLI3 | 121.7 | 100% | 99% | Greig cephalopolysyndactyly syndrome, 175700 Pallister-Hall syndrome, 146510 Polydactyly, preaxial, type IV, 174700 Polydactyly, postaxial, types A1 and B, 174200 {Hypothalamic hamartomas, somatic}, 241800 |
| GLIS2 | 88.9 | 100% | 98% | Nephronophthisis 7, 611498 |
| GLIS3 | 95.7 | 100% | 98% | Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 -3 |
| GLMN | 99.6 | 100% | 100% | Glomuvenous malformations |
| GLRA1 | 113.9 | 100% | 98% | Hyperekplexia, hereditary 1, autosomal dominant or recessive, 149400 |
| GLRB | 135.0 | 100% | 99% | Hyperekplexia 2, autosomal recessive, 614619 |
| GLRX5 | 29.9 | 72% | 46% | Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 |
| GLUD1 | 111.8 | 88% | 88% | Hyperinsulinism-hyperammonemia syndrome, 606762 |
| GLUL | 28.1 | 60% | 49% | Glutamine deficiency, congenital, 610015 |
| GLYCTK | 83.8 | 99% | 98% | D-glyceric aciduria, 220120 |
| GM2A | 127.8 | 100% | 100% | GM2-gangliosidosis, AB variant, 272750 |
| GMPPA | 115.1 | 100% | 99% | Alacrima, achalasia, and mental retardation syndrome, 615510 (3) |
| GMPPB | 118.5 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), |
| GMPS | 116.3 | 100% | 100% | Leukemia, acute myelogenous, 601626 |

| | | | | |
|--------|-------|------|------|--|
| GNA11 | 95.5 | 100% | 99% | Hypocalciuric hypercalcemia, type II, 145981 Hypocalcemia, autosomal dominant 2, 615361 |
| GNAI2 | 76.6 | 100% | 99% | GNAI2L Pituitary ACTH-secreting adenoma Ventricular tachycardia, idiopathic, 192605 |
| GNAI3 | 125.5 | 100% | 100% | Auriculocondylar syndrome 1, 602483 |
| GNAL | 91.1 | 100% | 97% | Dystonia 25, 615073 |
| GNAO1 | 109.4 | 100% | 99% | Epileptic encephalopathy, early infantile, 17, 615473 |
| GNAQ | 69.0 | 99% | 93% | Sturge-Weber syndrome, somatic, mosaic, 185300 Capillary malformations, congenital, 1, somatic, mosaic, 163000 |
| GNAS | 125.3 | 100% | 99% | Pseudohypoparathyroidism Ia, 103580 McCune-Albright syndrome, 174800 Pseudohypoparathyroidism Ic, 612462 Osseous heteroplasia, progressive, 166350 Pseudohypoparathyroidism Ib, 603233 Prolonged bleeding time, brachydactyly and mental re |
| GNAT1 | 81.7 | 100% | 95% | Night blindness, congenital stationary, autosomal dominant 3, 610444 |
| GNAT2 | 125.7 | 100% | 100% | Achromatopsia-4, 613856 |
| GNB4 | 144.4 | 100% | 100% | Charcot-Marie-Tooth disease, dominant intermediate F, 615185 |
| GNE | 99.5 | 100% | 99% | Sialuria, 269921 Inclusion body myopathy, autosomal recessive, 600737 Nonaka myopathy, 605820 |
| GNMT | 85.8 | 100% | 99% | Glycine N-methyltransferase deficiency, 606664 |
| GNPAT | 115.9 | 100% | 100% | Chondrodyplasia punctata, rhizomelic, type 2, 222765 |
| GNPTAB | 135.6 | 100% | 100% | Mucolipidosis III alpha/beta, 252600 Mucolipidosis II alpha/beta, 252500 |
| GNPTG | 89.9 | 86% | 80% | Mucolipidosis III gamma |
| GNRH1 | 34.0 | 100% | 91% | Hypogonadotropic hypogonadism 12 with or without anosmia, 614841 |
| GNRHR | 169.5 | 100% | 100% | Hypogonadotropic hypogonadism 7 with or without anosmia, 146110 Fertile eunuch syndrome, 228300 |
| GNS | 80.0 | 94% | 85% | Mucopolysaccharidosis type IIID, 252940 |
| GOLGA5 | 124.3 | 100% | 100% | Thyroid carcinoma, papillary, 188550 |
| GORAB | 150.9 | 100% | 98% | Geroderma osteodysplasticum, 231070 |
| GOSR2 | 111.9 | 100% | 100% | Epilepsy, progressive myoclonic 6, 614018 |
| GOT1 | 100.1 | 100% | 100% | Aspartate aminotransferase, serum level of, QTL1, 614419 |

| | | | | |
|--------|-------|------|------|--|
| GP1BA | 117.2 | 96% | 95% | Bernard-Soulier syndrome, type A1 (recessive), 231200 {Nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 Bernard-Soulier syndrome, type A2 (dominant), 153670 von Willebrand disease, platelet-type, 177820 |
| GP1BB | 27.3 | 92% | 61% | Bernard-Soulier syndrome, type B, 231200 Giant platelet disorder, isolated, 231200 |
| GP6 | 100.4 | 100% | 97% | Bleeding disorder, platelet-type, 11, 614201 |
| GP9 | 56.9 | 95% | 89% | Bernard-Soulier syndrome, type C, 231200 |
| GPC3 | 51.4 | 100% | 97% | Simpson-Golabi-Behmel syndrome, type 1, 312870 Wilms tumor, somatic, 194070 |
| GPC6 | 110.0 | 100% | 100% | Omodyplasia 1, 258315 |
| GPD1 | 72.9 | 100% | 99% | Hypertriglyceridemia, transient infantile, 614480 |
| GPD1L | 105.6 | 100% | 100% | Brugada syndrome 2, 611777 |
| GPHN | 119.4 | 100% | 100% | Molybdenum cofactor deficiency, type C, 252150 |
| GPI | 91.9 | 100% | 97% | Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 |
| GPR143 | 26.6 | 83% | 62% | Ocular albinism, type I, Nettleship-Falls type, 300500 Nystagmus 6, congenital, X-linked, 300814 |
| GPR179 | 144.9 | 100% | 99% | Night blindness, congenital stationary (complete), 1E, autosomal recessive, 614565 |
| GPR56 | 94.4 | 100% | 99% | Polymicrogyria, bilateral frontoparietal, 606854 |
| GPR98 | 115.4 | 99% | 98% | Febrile seizures, familial, 4, 604352 Usher syndrome, type 2C, 605472 Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 |
| GPSM2 | 146.5 | 100% | 100% | Chudley-McCullough syndrome, 604213 |
| GRHL2 | 100.4 | 100% | 98% | Deafness, autosomal dominant 28, 608641 |
| GRHL3 | 106.2 | 100% | 98% | Van der Woude syndrome 2, 606713 (3) |
| GRHPR | 88.2 | 97% | 78% | Hyperoxaluria, primary, type II, 260000 |
| GRIA3 | 54.6 | 92% | 84% | Mental retardation, X-linked 94, 300699 |
| GRIK2 | 121.1 | 100% | 99% | Mental retardation, autosomal recessive, 6, 611092 |
| GRIN1 | 84.1 | 99% | 93% | Mental retardation, autosomal dominant 8, 614254 |
| GRIN2A | 130.9 | 99% | 98% | Epilepsy with neurodevelopmental defects, 613971 |
| GRIN2B | 140.6 | 99% | 98% | Mental retardation, autosomal dominant 6, 613970 |
| GRIP1 | 95.9 | 99% | 95% | Fraser syndrome, 219000 |
| GRK1 | 95.1 | 100% | 99% | Oguchi disease-2, 613411 |
| GRM1 | 152.4 | 100% | 99% | Spinocerebellar ataxia, autosomal recessive 13, 614831 |

| | | | | |
|---------|-------|------|------|---|
| GRM6 | 96.1 | 95% | 92% | Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 |
| GRN | 115.7 | 100% | 99% | Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 Aphasia, primary progressive, 607485 Ceroid lipofuscinoses, neuronal, 11, 614706 |
| GRXCR1 | 189.0 | 100% | 100% | Deafness, autosomal recessive 25, 613285 |
| GSC | 48.7 | 99% | 81% | Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 |
| GSN | 70.7 | 93% | 85% | Amyloidosis, Finnish type, 105120 |
| GSS | 80.0 | 98% | 94% | Hemolytic anemia due to glutathione synthetase deficiency, 231900 Glutathione synthetase deficiency, 266130 |
| GTF2H5 | 97.0 | 100% | 100% | Trichothiodystrophy, complementation group A, 601675 |
| GUCA1A | 67.7 | 65% | 52% | Cone dystrophy-3, 602093 Cone-rod dystrophy 14, 602093 |
| GUCA1B | 118.6 | 100% | 100% | Retinitis pigmentosa 48, 613827 |
| GUCY1A3 | 149.8 | 100% | 100% | Moyamoya 6 with achalasia, 615750 |
| GUCY2C | 96.2 | 100% | 99% | Diarrhea 6, 614616 Meconium ileus, 614665 |
| GUCY2D | 82.5 | 99% | 96% | Leber congenital amaurosis 1, 204000 Cone-rod dystrophy 6, 601777 |
| GUSB | 61.9 | 89% | 81% | Mucopolysaccharidosis VII, 253220 |
| GYG1 | 45.5 | 83% | 60% | Glycogen storage disease XV, 613507 |
| GYS1 | 66.9 | 95% | 82% | Glycogen storage disease 0, muscle, 611556 |
| GYS2 | 92.1 | 100% | 100% | Glycogen storage disease, type 0, 240600 |
| H6PD | 125.6 | 100% | 100% | Cortisone reductase deficiency 1, 604931 |
| HADH | 91.5 | 100% | 100% | 3-hydroxyacyl-CoA dehydrogenase deficiency |
| HADHA | 93.0 | 96% | 87% | LCHAD deficiency, 609016 Trifunctional protein deficiency, 609015 HELLP syndrome, maternal, of pregnancy, 609016 Fatty liver, acute, of pregnancy, 609016 |
| HADHB | 94.9 | 100% | 99% | Trifunctional protein deficiency, 609015 |
| HAMP | 95.8 | 100% | 99% | Hemochromatosis, type 2B, 613313 |
| HARS | 119.1 | 100% | 100% | Usher syndrome type 3B, 614504 |
| HARS2 | 135.4 | 100% | 100% | Perrault syndrome 2, 614926 |
| HAX1 | 140.7 | 100% | 100% | Neutropenia, severe congenital 3, autosomal recessive, 610738 |

| | | | | |
|---------|-------|------|------|---|
| HBA1 | 49.2 | 56% | 49% | 5'-zeta-pseudozeta-pseudoalpha-alpha-2-alpha-1-3' Thalassemias, alpha-, 604131 Methemoglobinemias, alpha- Erythremias, alpha- Heinz body anemias, alpha-, 140700 Hemoglobin H disease, nondeletional, 613978 |
| HBA2 | 54.9 | 62% | 49% | Thalassemia, alpha-, 604131 Heinz body anemia, 140700 Erythrocytosis Hypochromic microcytic anemia Hemoglobin H disease, nondeletional, 613978 |
| HBB | 151.6 | 100% | 100% | Sickle cell anemia, 603903 Thalassemias, beta-, 613985 Erythremias, beta- Methemoglobinemias, beta- Heinz body anemias, beta-, 140700 Thalassemia-beta, dominant inclusion-body, 603902 Hereditary persistence of fetal hemoglobin, 141 |
| HBD | 208.3 | 100% | 100% | Thalassemia, delta- Thalassemia due to Hb Lepore |
| HBG1 | 14.2 | 41% | 21% | Fetal hemoglobin quantitative trait locus 1, 141749 |
| HBG2 | 36.7 | 78% | 65% | Fetal hemoglobin quantitative trait locus 1, 141749 Cyanosis, transient neonatal, 613977 |
| HCCS | 63.9 | 100% | 96% | Microphthalmia, syndromic 7, 309801 |
| HCFC1 | 35.7 | 93% | 78% | Mental retardation, X-linked 3, 309541 |
| HCN4 | 66.1 | 100% | 95% | Sick sinus syndrome 2, 163800 Brugada syndrome 8, 613123 |
| HCRT | 55.8 | 93% | 81% | Narcolepsy 1, 161400 |
| HDAC4 | 70.2 | 95% | 88% | Brachydactyly-mental retardation syndrome, 600430 |
| HDAC6 | 58.0 | 92% | 84% | Chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 |
| HDAC8 | 47.9 | 99% | 82% | Wilson-Turner syndrome, 309585 Cornelia de Lange syndrome 5, 300882 |
| HEATR2 | 66.8 | 83% | 78% | Ciliary dyskinesia, primary, 18, 614874 |
| HEPACAM | 70.4 | 89% | 84% | Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926 |

| | | | | |
|--------|-------|------|------|--|
| HERC2 | 62.9 | 63% | 60% | [Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 [Skin/hair/eye pigmentation 1, blond/brown hair], 227220 |
| HES7 | 36.2 | 89% | 76% | Spondylocostal dysostosis 4, autosomal recessive, 613686 |
| HESX1 | 99.0 | 100% | 99% | Septooptic dysplasia, 182230 Pituitary hormone deficiency, combined, 5, 182230 Growth hormone deficiency with pituitary anomalies, 182230 |
| HEXA | 90.7 | 100% | 100% | Tay-Sachs disease, 272800 GM2-gangliosidosis, several forms, 272800 [Hex A pseudodeficiency], 272800 |
| HEXB | 114.8 | 100% | 100% | Sandhoff disease, infantile, juvenile, and adult forms, 268800 |
| HFE | 101.2 | 100% | 98% | Hemochromatosis, 235200 {Microvascular complications of diabetes 7}, 612635 {Porphyria variegata, susceptibility to}, 176200 {Porphyria cutanea tarda, susceptibility to}, 176100 {Alzheimer disease, susceptibility to}, 104300 [Transferr |
| HFE2 | 113.5 | 97% | 96% | Hemochromatosis type 2A |
| HFM1 | 109.5 | 98% | 98% | Split hand/foot malformation 1 (4) |
| HGD | 89.4 | 100% | 100% | Alkaptonuria, 203500 |
| HGF | 116.0 | 100% | 100% | Deafness, autosomal recessive 39, 608265 |
| HGSNAT | 105.4 | 93% | 93% | Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 |
| HIBCH | 67.3 | 100% | 99% | 3-hydroxyisobutyryl-CoA hydrolase deficiency, 250620 |
| HINT1 | 80.6 | 96% | 85% | Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 |
| HK1 | 116.1 | 100% | 100% | Hemolytic anemia due to hexokinase deficiency, 235700 Neuropathy, hereditary motor and sensory, Russe type, 605285 |
| HLCS | 141.8 | 100% | 100% | Holocarboxylase synthetase deficiency, 253270 |
| HMBS | 99.6 | 99% | 98% | Porphyria, acute intermittent, 176000 Porphyria, acute intermittent, nonerythroid variant, 176000 |
| HMGCL | 103.5 | 100% | 99% | HMG-CoA lyase deficiency, 246450 |
| HMGCS2 | 114.9 | 100% | 99% | HMG-CoA synthase-2 deficiency, 605911 |
| HMOX1 | 65.9 | 100% | 95% | Heme oxygenase-1 deficiency, 614034 {Pulmonary disease, chronic obstructive, susceptibility to}, 606963 |
| HMX1 | 37.6 | 99% | 78% | Oculoauricular syndrome, 612109 |

| | | | | |
|---------|-------|------|------|---|
| HNF1A | 81.4 | 98% | 95% | MODY, type III, 600496 {Diabetes mellitus, noninsulin-dependent, 2}, 125853 {Diabetes mellitus, insulin-dependent}, 222100 Hepatic adenoma, somatic, 142330 Renal cell carcinoma, 144700 Diabetes mellitus, insulin-dependent, 20, 612520 |
| HNF1B | 78.7 | 98% | 96% | Renal cysts and diabetes syndrome, 137920 Diabetes mellitus, noninsulin-dependent, 125853 {Renal cell carcinoma}, 144700 |
| HNF4A | 69.2 | 100% | 93% | MODY, type I, 125850 {Diabetes mellitus, noninsulin-dependent}, 125853 |
| HNRNPA1 | 46.4 | 92% | 86% | ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3, 615424 Amyotrophic lateral sclerosis 19, 615426 |
| HOGA1 | 72.6 | 100% | 94% | Hyperoxaluria, primary, type III, 613616 |
| HOXA1 | 142.1 | 100% | 100% | Bosley-Salih-Alorainy syndrome, 601536 Athabaskan brainstem dysgenesis syndrome, 601536 |
| HOXA11 | 113.8 | 100% | 100% | Radioulnar synostosis with megakaryocytic thrombocytopenia, 605432 -3 |
| HOXA13 | 62.9 | 97% | 69% | Hand-foot-uterus syndrome, 140000 Guttmacher syndrome, 176305 -3 |
| HOXB1 | 100.4 | 100% | 100% | Facial paresis, hereditary congenital, 3 |
| HOXC13 | 86.5 | 99% | 96% | Ectodermal dysplasia 9, hair/nail type, 614931 |
| HOXD10 | 151.6 | 100% | 100% | Vertical talus, congenital, 192950 Charcot-Marie-Tooth disease, foot deformity of, 192950 |
| HOXD13 | 117.0 | 100% | 98% | Synpolydactyly, type II, 186000 Brachydactyly, type E, 113300 Brachydactyly, type D, 113200 Synpolydactyly with foot anomalies, 186000 Syndactyly, type V, 186300 Brachydactyly-syndactyly syndrome, 610713 VACTERL association, 192350 |
| HPD | 98.3 | 100% | 100% | Tyrosinemia, type III, 276710 Hawkinsuria, 140350 |
| HPGD | 68.5 | 92% | 76% | Cranioosteopathia, 259100 Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 Digital clubbing, isolated congenital, 119900 |

| | | | | |
|----------|-------|------|------|---|
| HPRT1 | 50.8 | 100% | 78% | Lesch-Nyhan syndrome, 300322 HPRT-related gout, 300323 |
| HPS1 | 75.8 | 96% | 92% | Hermansky-Pudlak syndrome 1, 203300 |
| HPS3 | 119.5 | 100% | 100% | Hermansky-Pudlak syndrome 3, 614072 |
| HPS4 | 107.2 | 98% | 97% | Hermansky-Pudlak syndrome 4, 614073 |
| HPS5 | 102.3 | 100% | 100% | Hermansky-Pudlak syndrome 5, 614074 |
| HPS6 | 85.2 | 100% | 93% | Hermansky-Pudlak syndrome 6, 614075 |
| HPSE2 | 77.2 | 100% | 97% | Urofacial syndrome 1, 236730 |
| HR | 84.8 | 98% | 93% | Alopecia universalis, 203655 Atrichia with papular lesions, 209500 Hypotrichosis, hereditary, Marie Unna type, 1, 146550 |
| HRAS | 87.1 | 100% | 99% | {Bladder cancer, somatic}, 109800 Costello syndrome, 218040 {Thyroid carcinoma, follicular, somatic}, 188470 Congenital myopathy with excess of muscle spindles, 218040 {Nevus sebaceous, somatic}, 162900 Schimmelpenning-Feuerstein-Mims s |
| HRG | 141.4 | 94% | 94% | Thrombophilia due to HRG deficiency, 613116 Thrombophilia due to elevated HRG, 613116 (1) |
| HSD11B1 | 109.1 | 100% | 100% | Cortisone reductase deficiency 2, 614662 |
| HSD11B2 | 113.2 | 78% | 78% | Apparent mineralocorticoid excess, 218030 |
| HSD17B10 | 54.1 | 95% | 91% | 17-beta-hydroxysteroid dehydrogenase X deficiency, 300438 Mental retardation, X-linked syndromic 10, 300220 Mental retardation, X-linked 17/31, microduplication, 300705 |
| HSD17B3 | 105.0 | 99% | 96% | Pseudohermaphroditism, male, with gynecomastia, 264300 |
| HSD17B4 | 98.2 | 100% | 99% | D-bifunctional protein deficiency, 261515 Perrault syndrome 1, 233400 |
| HSD3B2 | 44.0 | 93% | 78% | 3-beta-hydroxysteroid dehydrogenase, type II, deficiency, 201810 |
| HSD3B7 | 72.7 | 92% | 82% | Bile acid synthesis defect, congenital, 1, 607765 |
| HSF4 | 100.0 | 100% | 98% | Cataract 5, multiple types, 116800 |
| HSPB1 | 50.1 | 98% | 80% | Neuropathy, distal hereditary motor, type IIB, 608634 Charcot-Marie-Tooth disease, axonal, type 2F, 606595 |
| HSPB3 | 208.7 | 100% | 100% | Neuronopathy, distal hereditary motor, type IIC, 613376 |
| HSPB8 | 98.5 | 100% | 100% | Neuropathy, distal hereditary motor, type IIA, 158590 Charcot-Marie-Tooth disease, axonal, type 2L, 608673 |
| HSPD1 | 14.8 | 61% | 36% | Spastic paraplegia 13, autosomal dominant, 605280 |

| | | | | |
|---------|-------|------|------|--|
| | | | | Leukodystrophy, hypomyelinating, 4, 612233 |
| HSPG2 | 73.3 | 98% | 93% | Schwartz-Jampel syndrome, type 1, 255800 Dyssegmental dysplasia, Silverman-Handmaker type, 224410 |
| HTR1A | 121.1 | 100% | 100% | Periodic fever, menstrual cycle dependent, 614674 |
| HTRA1 | 69.0 | 84% | 78% | {Macular degeneration, age-related, 7}, 610149 {Macular degeneration, age-related, neovascular type}, 610149 CARASIL syndrome, 600142 |
| HTRA2 | 141.2 | 100% | 99% | Parkinson disease 13, 610297 |
| HTT | 99.8 | 99% | 97% | Huntington disease, 143100 |
| HUWE1 | 48.2 | 96% | 86% | Mental retardation, X-linked syndromic, Turner type, 300706 |
| HYAL1 | 97.4 | 99% | 96% | Mucopolysaccharidosis type IX, 601492 |
| HYDIN | 93.5 | 88% | 85% | Ciliary dyskinesia, primary, 5, 608647 |
| HYLS1 | 154.2 | 100% | 100% | Hydrocephalus syndrome, 236680 |
| ICK | 103.8 | 100% | 100% | Endocrine-cerebroosteodysplasia, 612651 |
| ICOS | 133.8 | 100% | 100% | Immunodeficiency, common variable, 1, 607594 |
| IDH2 | 106.8 | 100% | 94% | D-2-hydroxyglutaric aciduria 2, 613657 |
| IDH3B | 116.8 | 95% | 95% | Retinitis pigmentosa 46, 612572 |
| IDS | 55.1 | 84% | 77% | Mucopolysaccharidosis II, 309900 |
| IDUA | 86.0 | 95% | 84% | Mucopolysaccharidosis Iih, 607014 Mucopolysaccharidosis Is, 607016 Mucopolysaccharidosis Ih/s, 607015 |
| IER3IP1 | 67.1 | 100% | 99% | Microcephaly, epilepsy, and diabetes syndrome, 614231 |
| IFITM5 | 95.2 | 100% | 86% | Osteogenesis imperfecta, type V, 610967 |
| IFNGR1 | 145.7 | 100% | 100% | Mycobacterial infection, atypical, familial disseminated, 209950 BCG infection, generalized familial, 209950 {H. pylori infection, susceptibility to}, 600263 {Tuberculosis, susceptibility to}, 607948 {Mycobacterium tuberculosis infection, |
| IFT122 | 79.1 | 96% | 95% | Cranioectodermal dysplasia 1, 218330 |
| IFT140 | 83.3 | 99% | 95% | Mainzer-Saldino syndrome, 266920 |
| IFT172 | 97.6 | 100% | 97% | Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 Mainzer-Saldino syndrome (Halbritter (2013) Am J Hum Genet 93, 915) Asphyxiating thoracic dystrophy with or without Joubert Syndrome (Halbritter (2013) Am J Hum Genet 93, 915) |
| IFT43 | 84.7 | 100% | 100% | Cranioectodermal dysplasia 3, 614099 |
| IFT80 | 84.4 | 100% | 93% | Asphyxiating thoracic dystrophy 2, 611263 |

| | | | | |
|----------|-------|------|------|--|
| IGBP1 | 49.0 | 84% | 74% | Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 |
| IGF1 | 132.1 | 100% | 100% | Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 |
| IGF1R | 104.7 | 100% | 99% | Insulin-like growth factor I, resistance to, 270450 |
| IGF2R | 93.7 | 98% | 95% | Hepatocellular carcinoma |
| IGFALS | 68.9 | 100% | 98% | Acid-labile subunit, deficiency of |
| IGFBP7 | 36.0 | 61% | 32% | Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 |
| IGHMBP2 | 70.4 | 97% | 88% | Neuronopathy, distal hereditary motor, type VI, 604320 |
| IGLL1 | 22.0 | 72% | 39% | Agammaglobulinemia 2, 613500 |
| IGSF1 | 59.9 | 98% | 92% | Hypothyroidism, central, and testicular enlargement, 300888 |
| IHH | 104.4 | 100% | 100% | Acrocapitofemoral dysplasia, 607778 Brachydactyly, type A1, 112500 |
| IKBKAP | 106.1 | 100% | 99% | Dysautonomia, familial, 223900 |
| IKBKB | 91.0 | 98% | 94% | Immunodeficiency 15, 615592 (3) |
| IKBKG | 11.4 | 23% | 22% | Incontinentia pigmenti, type II, 308300 Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 Immunodeficiency, isolated, 300584 {Atypical mycobacterio} |
| IKZF1 | 101.4 | 100% | 99% | Leukemia, acute lymphoblastic |
| IL10RA | 99.1 | 100% | 100% | Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 |
| IL10RB | 111.2 | 98% | 94% | Inflammatory bowel disease 25 early onset autosomal recessive |
| IL11RA | 84.6 | 100% | 96% | Craniosynostosis and dental anomalies, 614188 |
| IL17F | 90.0 | 97% | 93% | Candidiasis, familial, 6, autosomal dominant, 613956 |
| IL17RA | 90.8 | 100% | 92% | Candidiasis, familial, 5, autosomal recessive, 613953 |
| IL17RD | 99.5 | 98% | 96% | Hypogonadotropic hypogonadism 18 with or without anosmia, 615267 |
| IL1RAPL1 | 68.7 | 100% | 99% | Mental retardation, X-linked 21/34, 300143 |
| IL1RN | 106.9 | 100% | 100% | {Gastric cancer risk after H. pylori infection}, 137215 {Microvascular complications of diabetes 4}, 612628 Interleukin 1 receptor antagonist deficiency, 612852 |
| IL21R | 122.5 | 100% | 99% | [IgE, elevated level of], 147050 Immunodeficiency, primary, autosomal recessive, IL21R-related, 615207 |
| IL2RA | 101.4 | 100% | 99% | Interleukin-2 receptor, alpha chain, deficiency of, 606367 {Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 |

| | | | | |
|--------|-------|------|------|---|
| IL2RG | 46.6 | 98% | 87% | Severe combined immunodeficiency, X-linked, 300400 Combined immunodeficiency, X-linked, moderate, 312863 |
| IL31RA | 120.5 | 100% | 96% | Amyloidosis, primary localized cutaneous, 2, 613955 |
| IL36RN | 98.7 | 100% | 100% | Psoriasis, generalized pustular, 614204 |
| IL7R | 99.3 | 100% | 100% | Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 |
| ILDR1 | 57.4 | 100% | 99% | Deafness, autosomal recessive 42, 609646 |
| IMPAD1 | 130.4 | 100% | 100% | Chondrodyplasia with joint dislocations, GRAPP type, 614078 |
| IMPDH1 | 35.8 | 83% | 60% | Retinitis pigmentosa 10, 180105 Leber congenital amaurosis 11, 613837 |
| IMPG2 | 125.8 | 99% | 97% | Retinitis pigmentosa 56, 613581 Maculopathy, IMPG2-related, 613581 |
| INF2 | 67.9 | 93% | 85% | Glomerulosclerosis, focal segmental, 5, 613237 Charcot-Marie-Tooth disease, dominant intermediate E, 614455 |
| ING1 | 126.1 | 100% | 98% | Squamous cell carcinoma, head and neck, somatic, 275355 |
| INPP5E | 74.2 | 100% | 99% | Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 Joubert syndrome 1, 213300 |
| INPPL1 | 94.9 | 98% | 95% | Opsismodysplasia, 258480 |
| INS | 42.2 | 100% | 85% | Hyperproinsulinemia, familial, with or without diabetes Maturity-onset diabetes of the young, type 10, 613370 Diabetes mellitus, permanent neonatal, 606176 Diabetes mellitus, type 1, 125852 Diabetes mellitus, insulin-dependent, 2, 125852 |
| INSL3 | 43.2 | 88% | 85% | Cryptorchidism, 219050 |
| INSR | 120.8 | 96% | 93% | Leprechaunism, 246200 Rabson-Mendenhall syndrome, 262190 Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 Hyperinsulinemic hypoglycemia, familial, 5, 609968 |
| INVS | 124.2 | 100% | 99% | Nephronophthisis 2, infantile, 602088 |
| IQCB1 | 95.1 | 99% | 94% | Senior-Loken syndrome 5, 609254 |
| IQSEC2 | 40.8 | 84% | 67% | Mental retardation, X-linked 1, 309530 |
| IRAK4 | 103.5 | 100% | 100% | IRAK4 deficiency, 607676 Invasive pneumococcal disease, recurrent isolated, 1, 610799 |

| | | | | |
|--------|-------|------|------|--|
| IRF1 | 103.3 | 100% | 100% | Myelodysplastic syndrome, preleukemic Myelogenous leukemia, acute Gastric cancer, somatic, 613659 Non-small cell lung cancer, somatic, 211980 |
| IRF4 | 110.2 | 100% | 100% | Multiple myeloma, 254500 |
| IRF6 | 101.5 | 99% | 94% | van der Woude syndrome, 119300 Popliteal pterygium syndrome 1, 119500 Orofacial cleft 6, 608864 |
| IRF8 | 69.1 | 100% | 98% | Monocyte and dendritic cell deficiency, recessive, 614894 CD11C+/CD1C+ dendritic cell deficiency, dominant, 614893 |
| IRGM | 162.7 | 100% | 100% | {Mycobacterium tuberculosis, protection against}, 607948 Inflammatory bowel disease 19, 612278 |
| IRX5 | 56.3 | 97% | 88% | Hamamy syndrome, 611174 |
| ISCU | 85.5 | 100% | 96% | Myopathy with lactic acidosis, hereditary, 255125 |
| ISPD | 79.5 | 93% | 90% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 |
| ITCH | 98.4 | 95% | 95% | Autoimmune disease, syndromic multisystem, 613385 |
| ITGA2B | 71.7 | 97% | 91% | BAK platelet antigen Glanzmann thrombasthenia, 273800 Thrombocytopenia, neonatal alloimmune, BAK antigen related Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 |
| ITGA3 | 107.4 | 100% | 94% | Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital, 614748 |
| ITGA6 | 133.2 | 100% | 98% | Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 -3 |
| ITGA7 | 86.0 | 98% | 93% | Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 |
| ITGA8 | 93.6 | 99% | 98% | Renal hypodysplasia/aplasia 1, 191830 (3) |
| ITGB2 | 84.1 | 100% | 98% | Leukocyte adhesion deficiency, 116920 |
| ITGB3 | 91.8 | 99% | 98% | PL(A) platelet antigen Glanzmann thrombasthenia, 273800 Thrombocytopenia, neonatal alloimmune {Myocardial infarction, susceptibility to}, 608446 Purpura, posttransfusion Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 |
| ITGB4 | 82.1 | 97% | 92% | Epidermolysis bullosa, junctional, with pyloric atresia, 226730 Epidermolysis bullosa, junctional, non-Herlitz type, 226650 Epidermolysis bullosa of hands and feet, 131800 |
| ITK | 100.2 | 100% | 100% | Lymphoproliferative syndrome 1, 613011 |
| ITM2B | 99.6 | 100% | 100% | Dementia, familial British, 176500 Dementia, familial Danish, 117300 |

| | | | | |
|---------|-------|------|------|--|
| ITPR1 | 107.1 | 99% | 98% | Spinocerebellar ataxia 15, 606658 Spinocerebellar ataxia 29, congenital nonprogressive, 117360 |
| IVD | 96.0 | 100% | 96% | Isovaleric acidemia, 243500 |
| IYD | 78.4 | 100% | 99% | Thyroid dyshormonogenesis 4, 274800 |
| JAG1 | 110.2 | 99% | 96% | Alagille syndrome, 118450 Tetralogy of Fallot, 187500 Deafness, congenital heart defects, and posterior embryotoxon |
| JAK2 | 115.9 | 99% | 98% | Polycythemia vera, 263300 Thrombocythemia 3, 614521 Myelofibrosis, somatic, 254450 {Budd-Chiari syndrome}, 600880 Leukemia, acute myelogenous, 601626 Erythrocytosis, somatic, 133100 |
| JAK3 | 89.3 | 99% | 96% | SCID, autosomal recessive, T-negative/B-positive type, 600802 |
| JAM3 | 69.8 | 94% | 89% | Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 |
| JPH2 | 67.6 | 100% | 94% | Cardiomyopathy, familial hypertrophic 17, 613873 |
| JPH3 | 109.9 | 97% | 97% | Huntington disease-like 2, 606438 |
| JUP | 78.6 | 99% | 95% | Naxos disease, 601214 Arrhythmogenic right ventricular dysplasia 12, 611528 |
| KAL1 | 47.6 | 93% | 81% | hypogonadism 1 with or without anosmia (Kallmann syndrome 1), 308700 |
| KANK1 | 137.4 | 100% | 99% | Cerebral palsy, spastic quadriplegic, 2, 612900 |
| KANSL1 | 49.7 | 78% | 65% | Koolen-De Vries syndrome, 610443 |
| KARS | 116.2 | 100% | 100% | Charcot-Marie-Tooth disease, recessive intermediate, B, 613641 Deafness, autosomal recessive 89, 613916 |
| KAT6B | 148.4 | 100% | 100% | SBBYSS syndrome, 603736 Genitopatellar syndrome, 606170 |
| KBTBD13 | 54.0 | 100% | 96% | Nemaline myopathy 6, autosomal dominant, 609273 |
| KCNA1 | 112.2 | 100% | 100% | Episodic ataxia/myokymia syndrome, 160120 |
| KCNA5 | 152.0 | 99% | 98% | Atrial fibrillation, familial, 7, 612240 |
| KCNC3 | 78.5 | 76% | 68% | Spinocerebellar ataxia 13, 605259 |
| KCND3 | 128.2 | 99% | 97% | Spinocerebellar ataxia 19, 607346 |
| KCNE1 | 206.9 | 100% | 100% | Jervell and Lange-Nielsen syndrome 2, 612347 Long QT syndrome-5, 613695 |
| KCNE2 | 132.4 | 100% | 100% | Long QT syndrome-6, 613693 Atrial fibrillation, familial, 4, 611493 |

| | | | | |
|--------|-------|------|------|---|
| KCNE3 | 90.8 | 100% | 100% | Brugada syndrome 6, 613119 |
| KCNH2 | 64.4 | 94% | 85% | Long QT syndrome-2, 613688 {Long QT syndrome-2, acquired, susceptibility to}, 613688 Short QT syndrome-1, 609620 |
| KCNJ1 | 146.1 | 97% | 97% | Bartter syndrome, type 2, 241200 |
| KCNJ10 | 151.4 | 100% | 100% | SESAME syndrome, 612780 Enlarged vestibular aqueduct, digenic, 600791 |
| KCNJ11 | 144.0 | 100% | 100% | Hyperinsulinemic hypoglycemia, familial, 2, 601820 Diabetes, permanent neonatal, 606176 Diabetes mellitus, permanent neonatal, with neurologic features, 606176 {Diabetes mellitus, type 2, susceptibility to}, 125853 Diabetes mellitus, trans |
| KCNJ13 | 211.1 | 100% | 100% | Snowflake vitreoretinal degeneration, 193230 Leber congenital amaurosis 16, 614186 |
| KCNJ2 | 110.4 | 97% | 92% | Andersen syndrome, 170390 Short QT syndrome-3, 609622 Atrial fibrillation, familial, 9, 613980 |
| KCNJ5 | 175.5 | 100% | 100% | Long QT syndrome 13, 613485 Hyperaldosteronism, familial, type III, 613677 |
| KCNK3 | 105.2 | 96% | 92% | Pulmonary hypertension, primary, 4, 615344 |
| KCNMA1 | 75.8 | 94% | 89% | Generalized epilepsy and paroxysmal dyskinesia, 609446 |
| KCNQ1 | 62.5 | 93% | 81% | Long QT syndrome-1, 192500 Jervell and Lange-Nielsen syndrome, 220400 Atrial fibrillation, familial, 3, 607554 Short QT syndrome-2, 609621 {Long QT syndrome 1, acquired, susceptibility to}, 192500 |
| KCNQ2 | 76.3 | 100% | 98% | Seizures, benign neonatal, 1, 121200 Myokymia, 121200 Epileptic encephalopathy, early infantile, 7, 613720 |
| KCNQ3 | 100.3 | 100% | 98% | Seizures, benign neonatal, type 2, 121201 |
| KCNQ4 | 111.9 | 94% | 90% | Deafness, autosomal dominant 2A, 600101 |
| KCNT1 | 77.9 | 99% | 93% | Epileptic encephalopathy, early infantile, 14, 614959 Epilepsy, nocturnal frontal lobe, 5, 615005 |
| KCNV2 | 84.3 | 100% | 99% | Retinal cone dystrophy 3B, 610356 |
| KCTD1 | 121.8 | 99% | 97% | Scalp-ear-nipple syndrome, 181270 |
| KCTD7 | 106.4 | 92% | 87% | Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 |

| | | | | |
|----------|-------|------|------|--|
| KDM5C | 53.9 | 100% | 93% | Mental retardation, X-linked, syndromic, Claes-Jensen type, 300534 -3 |
| KDM6A | 64.4 | 99% | 92% | Kabuki syndrome 2, 300867 |
| KDR | 110.4 | 100% | 99% | Hemangioma, capillary infantile, somatic, 602089 {Hemangioma, capillary infantile, susceptibility to}, 602089 |
| KERA | 145.8 | 100% | 100% | Cornea plana congenita, recessive, 217300 |
| KHDC3L | 119.4 | 100% | 100% | Hydatidiform mole, recurrent, 2, 614293 |
| KIAA0196 | 102.3 | 99% | 98% | Spastic paraplegia 8, autosomal dominant, 603563 |
| KIAA1279 | 105.1 | 99% | 95% | Goldberg-Shprintzen megacolon syndrome, 609460 |
| KIAA2022 | 78.3 | 100% | 99% | ?Mental retardation, nonsyndromic, X-linked (2) |
| KIF11 | 98.6 | 99% | 96% | Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 |
| KIF1A | 71.6 | 98% | 92% | Spastic paraplegia 30, autosomal recessive, 610357 Neuropathy, hereditary sensory, type IIC, 614213 Mental retardation, autosomal dominant 9, 614255 |
| KIF1B | 128.9 | 100% | 100% | Charcot-Marie-Tooth disease, type 2A1, 118210 Pheochromocytoma, 171300 {Neuroblastoma, susceptibility to, 1}, 256700 |
| KIF1C | 115.5 | 100% | 96% | Spastic ataxia 2, autosomal recessive, 611302 |
| KIF21A | 108.2 | 100% | 98% | Fibrosis of extraocular muscles, congenital, 1, 135700 Fibrosis of extraocular muscles, congenital, 3B, 135700 |
| KIF22 | 104.9 | 100% | 97% | Spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 |
| KIF2A | 123.4 | 100% | 97% | Cortical dysplasia, complex, with other brain malformations 3, 615411 |
| KIF5A | 94.4 | 99% | 98% | Spastic paraplegia 10, autosomal dominant, 604187 |
| KIF7 | 67.0 | 93% | 86% | Hydrocephalus syndrome 2, 614120 Acrocallosal syndrome, 200990 Joubert syndrome 12, 200990 |
| KIRREL3 | 75.7 | 98% | 91% | Mental retardation, autosomal dominant 4, 612581 |
| KISS1 | 36.9 | 89% | 69% | Hypogonadotropic hypogonadism 13 with or without anosmia, 614842 |
| KISS1 | 36.9 | 89% | 69% | Hypogonadotropic hypogonadism 8 with or without anosmia, 614837 Precocious puberty, central, 1, 176400 |
| KISS1R | 37.5 | 99% | 90% | Hypogonadotropic hypogonadism 8 with or without anosmia, 614837 Precocious puberty, central, 1, 176400 |
| KIT | 110.8 | 100% | 96% | Piebaldism, 172800 Gastrointestinal stromal tumor, familial, 606764 Mast cell disease, 154800 Leukemia, acute myeloid, 601626 |

| | | | | |
|---------|-------|------|------|--|
| | | | | Germ cell tumors, 273300 |
| KITLG | 80.0 | 100% | 99% | [Skin/hair/eye pigmentation 7, blond/brown hair], 611664 Hyperpigmentation, familial progressive, 2, 145250 |
| KL | 139.6 | 97% | 96% | {Coronary artery disease, susceptibility to} Tumoral calcinosis, hyperphosphatemic, 211900 |
| KLF1 | 47.6 | 100% | 99% | Blood group--Lutheran inhibitor, 111150 [Hereditary persistence of fetal hemoglobin], 613566 Anemia, dyserythropoietic congenital, type IV, 613673 |
| KLF11 | 164.4 | 97% | 97% | Maturity-onset diabetes of the young, type VII, 610508 |
| KLF6 | 150.2 | 100% | 100% | Prostate cancer, somatic, 176807 Gastric cancer, somatic, 613659 |
| KLHDC8B | 58.3 | 97% | 72% | Hodgkin lymphoma, 236000 |
| KLHL10 | 131.3 | 100% | 100% | Spermatogenic failure 11, 615081 |
| KLHL3 | 85.5 | 99% | 91% | Pseudohypoaldosteronism, type IID, 614495 |
| KLHL40 | 73.8 | 100% | 100% | Nemaline myopathy 8, autosomal recessive, 615348 |
| KLHL41 | 147.8 | 100% | 100% | Nemaline myopathy 9, 615731 (3) |
| KLHL7 | 118.9 | 100% | 100% | Retinitis pigmentosa 42, 612943 |
| KLK4 | 146.3 | 100% | 100% | Amelogenesis imperfecta, type IIA1, 204700 |
| KLKB1 | 128.4 | 100% | 100% | Fletcher factor deficiency, 612423 |
| KLLN | 104.9 | 100% | 100% | Cowden syndrome 4, 615107 |
| KMT2A | 142.0 | 99% | 98% | Wiedemann-Steiner syndrome |
| KMT2D | 100.9 | 99% | 98% | Kabuki syndrome 1 |
| KPTN | 83.5 | 100% | 95% | Mental retardation, autosomal recessive 41, 615637 (3) |
| KRAS | 65.6 | 100% | 88% | Lung cancer, somatic, 211980 Bladder cancer, somatic, 109800 Pancreatic carcinoma, somatic, 260350 Gastric cancer, somatic, 137215 Leukemia, acute myelogenous Noonan syndrome 3, 609942 Cardiofaciocutaneous syndrome 2, 615278 Br |
| KRIT1 | 105.0 | 100% | 99% | Cavernous malformations of CNS and retina |

| | | | | |
|-------|-------|------|------|---|
| KRT1 | 100.4 | 100% | 100% | Epidermolytic hyperkeratosis, 113800 Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 Ichthyosis histrix, Curth-Macklin type, 146590 Palmoplantar keratoderma, nonepidermolytic, 600962 Palmoplantar keratoderma, epidermolytic, 1 |
| KRT10 | 96.5 | 89% | 88% | Epidermolytic hyperkeratosis, 113800 Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 Ichthyosis with confetti, 609165 |
| KRT12 | 108.2 | 98% | 95% | Meesmann corneal dystrophy, 122100 |
| KRT13 | 86.7 | 100% | 99% | White sponge nevus, 193900 |
| KRT14 | 28.2 | 74% | 44% | Epidermolysis bullosa simplex, Dowling-Meara type, 131760 Epidermolysis bullosa simplex, Koebner type, 131900 Epidermolysis bullosa simplex, recessive 1, 601001 Naegeli-Franceschetti-Jadassohn syndrome, 161000 Dermatopathia pigmentosa reti |
| KRT16 | 6.4 | 25% | 7% | Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 Palmoplantar keratoderma, nonepidermolytic, focal, 613000 |
| KRT17 | 7.4 | 30% | 5% | Pachyonychia congenita, Jackson-Lawler type, 167210 Steatocystoma multiplex, 184500 |
| KRT18 | 20.4 | 79% | 40% | Cirrhosis, cryptogenic {Cirrhosis, noncryptogenic, susceptibility to}, 215600 |
| KRT2 | 117.3 | 99% | 97% | Ichthyosis bullosa of Siemens, 146800 |
| KRT3 | 70.1 | 100% | 100% | Meesmann corneal dystrophy, 122100 |
| KRT4 | 81.4 | 100% | 95% | White sponge nevus, 193900 |
| KRT5 | 73.3 | 100% | 98% | Epidermolysis bullosa simplex, Dowling-Meara type, 131760 Epidermolysis bullosa simplex, Koebner type, 131900 Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 Epidermolysis bullosa simplex with mottled pigmentation, 131960 Dowlin |
| KRT6A | 32.5 | 64% | 44% | Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 |
| KRT6B | 33.8 | 66% | 49% | Pachyonychia congenita, Jackson-Lawler type, 167210 |
| KRT6C | 22.7 | 50% | 35% | Palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 |
| KRT74 | 86.2 | 96% | 90% | Woolly hair, autosomal dominant, 194300 Hypotrichosis simplex of the scalp 2, 613981 |
| KRT8 | 31.1 | 90% | 60% | Cirrhosis, cryptogenic {Cirrhosis, noncryptogenic, susceptibility to}, 215600 |
| KRT81 | 20.4 | 63% | 43% | Monilethrix, 158000 |

| | | | | |
|---------|-------|------|------|--|
| KRT83 | 26.1 | 75% | 42% | Monilethrix, 158000 |
| KRT85 | 37.9 | 77% | 57% | Ectodermal dysplasia 4, hair/nail type, 602032 |
| KRT86 | 24.8 | 63% | 42% | Monilethrix, 158000 |
| KRT9 | 102.4 | 96% | 90% | Palmoplantar keratoderma, epidermolytic, 144200 |
| L1CAM | 62.0 | 98% | 92% | Hydrocephalus due to aqueductal stenosis, 307000 MASA syndrome, 303350 CRASH syndrome, 303350 Hydrocephalus with Hirschsprung disease, 307000 Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000 Corpus callosum |
| L2HGDH | 81.2 | 100% | 97% | L-2-hydroxyglutaric aciduria, 236792 |
| LAMA2 | 103.3 | 100% | 98% | Muscular dystrophy, congenital merosin-deficient, 607855 Muscular dystrophy, congenital, due to partial LAMA2 deficiency, 607855 |
| LAMA4 | 101.2 | 100% | 99% | Cardiomyopathy dilated 1JJ |
| LAMB1 | 115.7 | 100% | 99% | Lissencephaly 5, 615191 |
| LAMB2 | 111.3 | 100% | 99% | Nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 Pierson syndrome, 609049 |
| LAMB3 | 79.0 | 98% | 93% | Epidermolysis bullosa, junctional, Herlitz type, 226700 Epidermolysis bullosa, junctional, non-Herlitz type, 226650 |
| LAMC2 | 100.0 | 100% | 99% | Epidermolysis bullosa, junctional, Herlitz type, 226700 Epidermolysis bullosa, junctional, non-Herlitz type, 226650 |
| LAMC3 | 95.8 | 99% | 94% | Cortical malformations, occipital, 614115 |
| LAMP2 | 61.4 | 98% | 90% | Danon disease, 300257 |
| LAMTOR2 | 80.1 | 100% | 100% | Immunodeficiency due to defect in MAPBP-interacting protein, 610798 -3 |
| LARGE | 108.7 | 99% | 96% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840 |
| LARP7 | 118.1 | 100% | 100% | Alazami syndrome, 615071 |
| LARS2 | 116.2 | 100% | 99% | Perrault syndrome 4, 615300 |
| LBR | 100.1 | 100% | 100% | Pelger-Huet anomaly, 169400 HEM skeletal dysplasia, 215140 Reynolds syndrome, 613471 |
| LCA5 | 142.1 | 100% | 98% | Leber congenital amaurosis 5, 604537 |
| LCAT | 107.1 | 93% | 88% | Norum disease, 245900 Fish-eye disease, 136120 |

| | | | | |
|---------|-------|------|------|---|
| LCT | 130.0 | 100% | 99% | Lactase deficiency, congenital, 223000 |
| LDB3 | 87.3 | 95% | 93% | Myopathy, myofibrillar, 4, 609452 Cardiomyopathy, dilated 1C, 601493 Left ventricular noncompaction 3, with or without dilated cardiomyopathy, 601493 |
| LDHA | 45.9 | 76% | 58% | Glycogen storage disease XI, 612933 |
| LDHB | 89.5 | 100% | 100% | Lactate dehydrogenase-B deficiency, 614128 |
| LDLR | 108.2 | 100% | 99% | C3 Hypercholesterolemia, familial, 143890 LDL cholesterol level QTL2, 143890 |
| LDLRAP1 | 84.7 | 100% | 96% | Hypercholesterolemia, familial, autosomal recessive, 603813 |
| LEF1 | 91.0 | 100% | 99% | Sebaceous tumors, somatic |
| LEFTY2 | 52.2 | 86% | 66% | - |
| LEMD3 | 110.4 | 100% | 100% | Osteopoikilosis, 166700 Buschke-Ollendorff syndrome, 166700 Melorheostosis with osteopoikilosis, 155950 |
| LEP | 105.3 | 100% | 100% | Obesity, morbid, due to leptin deficiency, 614962 |
| LEPR | 124.4 | 94% | 93% | Obesity, morbid, due to leptin receptor deficiency, 614963 |
| LEPRE1 | 91.5 | 100% | 99% | Osteogenesis imperfecta, type VIII, 610915 |
| LEPREL1 | 70.5 | 99% | 88% | Myopia, high, with cataract and vitreoretinal degeneration, 614292 -3 |
| LFNG | 58.5 | 84% | 79% | Spondylocostal dysostosis, autosomal recessive 3, 609813 |
| LGI1 | 136.6 | 100% | 100% | Epilepsy, familial temporal lobe, 1, 600512 |
| LHB | 16.6 | 57% | 50% | Hypogonadism, hypergonadotropic ?Male pseudohermaphroditism due to defective LH (1) |
| LHCGR | 147.6 | 99% | 94% | Precocious puberty, male, 176410 Leydig cell hypoplasia with pseudohermaphroditism, 238320 Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 Luteinizing hormone resistance, female, 238320 Leydig cell adenoma, somatic, with |
| LHFPL5 | 176.4 | 100% | 100% | Deafness, autosomal recessive 67, 610265 |
| LHX3 | 46.2 | 100% | 90% | Pituitary hormone deficiency, combined, 3, 221750 |
| LHX4 | 88.9 | 100% | 100% | Pituitary hormone deficiency, combined, 4, 262700 |
| LIAS | 100.3 | 100% | 100% | Pyruvate dehydrogenase lipoic acid synthetase deficiency, 614462 |
| LIFR | 114.5 | 98% | 97% | Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 |
| LIG1 | 77.8 | 99% | 93% | DNA ligase I deficiency |

| | | | | |
|--------|-------|------|------|--|
| LIG4 | 190.0 | 100% | 100% | LIG4 syndrome, 606593 {Multiple myeloma, resistance to}, 254500 Severe combined immunodeficiency with sensitivity to ionizing radiation, 602450 |
| LIM2 | 70.4 | 82% | 81% | Cataract 19, 615277 |
| LINS | 124.2 | 100% | 100% | Mental retardation, autosomal recessive 27, 614340 (3) |
| LIPA | 109.4 | 100% | 100% | ? Wolman disease, 278000 Cholesteryl ester storage disease, 278000 -3 |
| LIPC | 84.0 | 100% | 95% | [High density lipoprotein cholesterol level QTL 12], 612797 {Diabetes mellitus, noninsulin-dependent}, 125853 Hepatic lipase deficiency, 614025 |
| LIPH | 122.7 | 100% | 100% | Hypotrichosis, localized, autosomal recessive 2, 604379 Woolly hair, autosomal recessive 2 with or without hypotrichosis, 604379 |
| LIPN | 124.7 | 100% | 94% | Ichthyosis, congenital, autosomal recessive 8, 613943 |
| LITAF | 88.6 | 100% | 100% | Charcot-Marie-Tooth disease, type 1C, 601098 |
| LMAN1 | 125.5 | 100% | 100% | Combined factor V and VIII deficiency, 227300 |
| LMBR1 | 100.8 | 100% | 98% | Acheiropody, 200500 Polydactyly, preaxial type II, 174500 Triphalangeal thumb, type I, 174500 Triphalangeal thumb-polysyndactyly syndrome, 174500 Syndactyly, type IV, 186200 |
| LMBRD1 | 108.9 | 100% | 100% | Methylmalonic aciduria and homocystinuria, cblF type, 277380 |
| LMF1 | 94.1 | 100% | 98% | Lipase deficiency, combined, 246650 |
| LMNA | 71.1 | 97% | 89% | Emery-Dreifuss muscular dystrophy 2, AD, 181350 Cardiomyopathy, dilated, 1A, 115200 Lipodystrophy, familial partial, 2, 151660 Emery-Dreifuss muscular dystrophy 3, AR, 181350 Charcot-Marie-Tooth disease, type 2B1, 605588 Muscular dystr |
| LMNB1 | 78.8 | 96% | 85% | Leukodystrophy, adult-onset, autosomal dominant, 169500 |
| LMX1B | 86.7 | 100% | 98% | Nail-patella syndrome, 161200 |
| LOR | 48.0 | 100% | 95% | Vohwinkel syndrome with ichthyosis, 604117 |
| LOXHD1 | 103.8 | 100% | 99% | Deafness, autosomal recessive 77, 613079 |
| LPAR6 | 131.1 | 100% | 100% | Hypotrichosis 8, 278150 Woolly hair, autosomal recessive 1, with or without hypotrichosis, 278150 |
| LPIN1 | 100.3 | 100% | 99% | Myoglobinuria, acute recurrent, autosomal recessive, 268200 |
| LPIN2 | 75.5 | 100% | 97% | Majeed syndrome, 609628 |

| | | | | |
|--------|-------|------|------|---|
| LPL | 109.4 | 100% | 100% | Lipoprotein lipase deficiency, 238600 Combined hyperlipidemia, familial, 144250 [High density lipoprotein cholesterol level QTL 11] |
| LPP | 133.5 | 100% | 99% | Leukemia, acute myeloid, 601626 |
| LRAT | 196.5 | 100% | 100% | Retinal dystrophy, early-onset severe, 613341 Leber congenital amaurosis 14, 613341 Retinitis pigmentosa, juvenile, 613341 |
| LRBA | 111.3 | 99% | 98% | Immunodeficiency, common variable, 8, with autoimmunity, 614700 |
| LRIG2 | 124.0 | 100% | 98% | Urofacial syndrome 2, 615112 |
| LRIT3 | 140.3 | 94% | 94% | Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 |
| LRP2 | 107.4 | 100% | 99% | Donnai-Barrow syndrome, 222448 |
| LRP4 | 93.9 | 99% | 96% | Cenani-Lenz syndactyly syndrome, 212780 Sclerosteosis 2, 614305 |
| LRP5 | 89.4 | 98% | 94% | Osteoporosis-pseudoglioma syndrome, 259770 [Bone mineral density variability 1], 601884 Hyperostosis, endosteal, 144750 van Buchem disease, type 2, 607636 Osteosclerosis, 144750 {Osteoporosis}, 166710 Exudative vitreoretinopathy 4, |
| LRPAP1 | 85.4 | 100% | 96% | Myopia 23, autosomal recessive, 615431 |
| LRPPRC | 100.6 | 98% | 96% | Leigh syndrome, French-Canadian type, 220111 |
| LRRC6 | 112.2 | 100% | 100% | Ciliary dyskinesia, primary, 19, 614935 |
| LRRC8A | 121.1 | 100% | 100% | Agammaglobulinemia 5, 613506 |
| LRRK2 | 112.8 | 99% | 99% | Parkinson disease 8, 607060 |
| LRSAM1 | 81.9 | 100% | 97% | Charcot-Marie-Tooth disease, axonal, type 2P, 614436 |
| LRTOMT | 92.6 | 93% | 90% | Deafness, autosomal recessive 63, 611451 |
| LTBP2 | 71.1 | 98% | 94% | Glaucoma 3, primary congenital, D, 613086 Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 Weill-Marchesani syndrome 3, recessive, 614819 |
| LTBP3 | 72.8 | 99% | 95% | Tooth agenesis, selective, 6, 613097 |
| LTBP4 | 89.2 | 97% | 90% | Cutis laxa, autosomal recessive, type IC, 613177 |
| LYST | 120.5 | 99% | 96% | Chediak-Higashi syndrome |
| LYZ | 108.4 | 100% | 100% | Amyloidosis, renal, 105200 |
| LZTFL1 | 90.2 | 100% | 100% | Bardet-Biedl syndrome 17, 615994 |

| | | | | |
|----------|-------|------|------|--|
| LZTS1 | 142.2 | 100% | 97% | Esophageal squamous cell carcinoma |
| MAD1L1 | 69.4 | 96% | 92% | Lymphoma, somatic Prostate cancer, somatic, 176807 |
| MAF | 79.8 | 81% | 75% | Cataract, pulverulent or cerulean, with or without microcornea, 610202 |
| MAFB | 87.4 | 100% | 100% | Multicentric carpotarsal osteolysis syndrome, 166300 |
| MAGEL2 | 84.1 | 95% | 91% | Prader-Willi-like syndrome, 615547 |
| MAGT1 | 54.0 | 100% | 100% | Mental retardation, X-linked 95, 300716 Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, 300853 |
| MAK | 85.9 | 96% | 95% | REtinitis pigmentosa 62, 614181 |
| MAML2 | 110.0 | 100% | 100% | Mucoepidermoid salivary gland carcinoma |
| MAMLD1 | 63.9 | 100% | 100% | Hypospadias 2, X-linked, 300758 |
| MAN1B1 | 96.6 | 100% | 99% | Mental retardation, autosomal recessive 15, 614202 |
| MAN2B1 | 80.2 | 97% | 92% | Mannosidosis, alpha-, types I and II, 248500 |
| MANBA | 92.3 | 100% | 99% | Mannosidosis, beta, 248510 |
| MAOA | 53.7 | 100% | 95% | Brunner syndrome, 300615 |
| MAP2K1 | 103.7 | 95% | 88% | Cardiofaciocutaneous syndrome 3, 615279 |
| MAP2K2 | 101.9 | 100% | 98% | Cardiofaciocutaneous syndrome 4, 615280 |
| MAP3K1 | 114.5 | 97% | 95% | 46XY sex reversal 6, 613762 |
| MAP3K8 | 127.6 | 100% | 99% | Lung cancer, somatic, 211980 |
| MAPT | 21.1 | 57% | 37% | Dementia, frontotemporal, with or without parkinsonism, 600274 Pick disease, 172700 Supranuclear palsy, progressive, 601104 Supranuclear palsy, progressive atypical, 260540 {Parkinson disease, susceptibility to}, 168600 Tauopathy and r |
| MARS2 | 156.2 | 100% | 100% | Spastic ataxia 3, autosomal recessive, 611390 |
| MARVELD2 | 146.7 | 98% | 95% | Deafness, autosomal recessive 49, 610153 |
| MASP1 | 112.0 | 100% | 99% | 3MC syndrome 1, 257920 |
| MASP2 | 111.7 | 98% | 92% | MASP2 deficiency, 613791 |
| MASTL | 127.7 | 100% | 100% | Thrombocytopenia-2, 188000 |
| MAT1A | 94.5 | 100% | 99% | Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 Methionine adenosyltransferase deficiency, autosomal recessive, 250850 |

| | | | | |
|--------|-------|------|------|---|
| MATN3 | 96.9 | 93% | 84% | Epiphyseal dysplasia, multiple, 5, 607078 {Osteoarthritis susceptibility 2}, 140600 Spondyloepimetaphyseal dysplasia, 608728 |
| MATR3 | 115.3 | 95% | 93% | Myopathy, distal 2, 606070 |
| MBD5 | 140.8 | 100% | 99% | Mental retardation, autosomal dominant 1, 156200 |
| MBTPS2 | 71.3 | 100% | 98% | IFAP syndrome with or without BRESHECK syndrome, 308205 Keratosis follicularis spinulosa decalvans, X-linked, 308800 |
| MC2R | 149.2 | 100% | 100% | Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 |
| MC4R | 173.9 | 100% | 100% | Obesity, autosomal dominant, 601665 |
| MCC | 88.2 | 99% | 97% | Colorectal cancer |
| MCCC1 | 97.0 | 99% | 98% | 3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 |
| MCCC2 | 113.1 | 98% | 92% | 3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 |
| MCEE | 79.6 | 100% | 100% | Methylmalonyl-CoA epimerase deficiency, 251120 |
| MCFD2 | 59.5 | 100% | 96% | Factor V and factor VIII, combined deficiency of, 613625 |
| MCM4 | 105.2 | 99% | 97% | Natural killer cell and glucocorticoid deficiency with DNA repair defect, 609981 |
| MCM6 | 108.7 | 100% | 97% | Lactase persistance/nonpersistance, 223100 |
| MCOLN1 | 96.7 | 97% | 92% | Mucolipidosis IV, 252650 |
| MCPH1 | 122.8 | 100% | 100% | Microcephaly 1, primary, autosomal recessive, 251200 |
| MECOM | 123.7 | 100% | 98% | Myelodysplasia syndrome-1 |
| MECP2 | 89.1 | 97% | 90% | Rett syndrome, 312750 Mental retardation, X-linked, syndromic 13, 300055 Rett syndrome, preserved speech variant, 312750 Encephalopathy, neonatal severe, 300673 {Autism susceptibility, X-linked 3}, 300496 Angelman syndrome, 105830 |
| MED12 | 62.1 | 94% | 85% | Opitz-Kaveggia syndrome, 305450 Lujan-Fryns syndrome, 309520 Ohdo syndrome, X-linked, 300895 |
| MED13L | 116.1 | 100% | 99% | Transposition of the great arteries, dextro-looped 1, 608808 |
| MED17 | 149.7 | 100% | 97% | Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 |
| MED23 | 113.6 | 100% | 100% | Mental retardation, autosomal recessive 18, 614249 |
| MED25 | 98.4 | 99% | 87% | Charcot-Marie-Tooth disease, type 2B2, 605589 |
| MEF2C | 117.4 | 100% | 100% | Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443 Chromosome 5q14.3 deletion syndrome, 613443 (4) |

| | | | | |
|--------|-------|------|------|---|
| MEFV | 116.1 | 100% | 100% | Familial Mediterranean fever, AR, 249100 Familial Mediterranean fever, AD, 134610 |
| MEGF10 | 107.7 | 100% | 99% | Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, 614399 Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant, 614399 |
| MEGF8 | 90.5 | 99% | 93% | Carpenter syndrome 2, 614976 |
| MEN1 | 111.0 | 99% | 96% | Multiple endocrine neoplasia 1, 131100 Carcinoid tumor of lung Parathyroid adenoma, somatic Lipoma, somatic Angiofibroma, somatic Adrenal adenoma, somatic |
| MEOX1 | 74.6 | 100% | 99% | Klippel-Feil syndrome 2, 214300 |
| MERTK | 114.9 | 100% | 99% | Retinitis pigmentosa 38, 613862 |
| MESP2 | 72.8 | 100% | 100% | Spondylocostal dysostosis, autosomal recessive 2, 608681 |
| MET | 124.5 | 100% | 100% | Renal cell carcinoma, papillary, familial and somatic, 605074 Hepatocellular carcinoma, childhood type, 114550 {Autism susceptibility 9}, 611015 |
| MFN2 | 102.2 | 100% | 97% | Charcot-Marie-Tooth disease, type 2A2, 609260 Hereditary motor and sensory neuropathy VI, 601152 |
| MFRP | 87.8 | 100% | 99% | Microphthalmia, isolated 5, 611040 Nanophthalmos 2, 609549 |
| MFSD8 | 120.0 | 100% | 100% | Ceroid lipofuscinosis, neuronal, 7, 610951 |
| MGAT2 | 217.2 | 100% | 100% | Congenital disorder of glycosylation, type IIa, 212066 |
| MGME1 | 159.2 | 100% | 100% | Mitochondrial DNA depletion syndrome 11, 615084 |
| MGP | 72.8 | 100% | 98% | Keutel syndrome, 245150 {Natural teeth remaining intact} (2) |
| MIB1 | 107.6 | 100% | 100% | Left ventricular noncompaction 7, 615092 |
| MICU1 | 94.9 | 100% | 98% | Myopathy with extrapyramidal signs, 615673 (3) |
| MID1 | 93.3 | 99% | 96% | Opitz GBBB syndrome, type I, 300000 |
| MINPP1 | 165.5 | 100% | 100% | Thyroid carcinoma, follicular, 188470 |
| MIP | 76.1 | 100% | 97% | Cataract 15, multiple types, 615274 |
| MITF | 131.8 | 100% | 100% | Waardenburg syndrome, type 2A, 193510 Waardenburg syndrome/ocular albinism, digenic, 103470 Tietz albinism-deafness syndrome, 103500 {Melanoma, cutaneous malignant, susceptibility to, 8}, 614456 |

| | | | | |
|--------|-------|------|------|--|
| MKKS | 148.8 | 100% | 100% | McKusick-Kaufman syndrome, 236700 Bardet-Biedl syndrome 6, 209900 |
| MKL1 | 70.5 | 97% | 91% | Megakaryoblastic leukemia, acute |
| MKRN3 | 119.1 | 100% | 100% | Precocious puberty, central, 2, 615346 |
| MKS1 | 110.6 | 100% | 99% | Meckel syndrome 1, 249000 Bardet-Biedl syndrome 13, 209900 |
| MLC1 | 95.0 | 100% | 100% | Megalencephalic leukoencephalopathy with subcortical cysts, 604004 -3 |
| MLH1 | 101.0 | 100% | 99% | Colorectal cancer, hereditary nonpolyposis, type 2, 609310 Mismatch repair cancer syndrome, 276300 Muir-Torre syndrome, 158320 |
| MLH3 | 169.3 | 100% | 99% | Colorectal cancer, somatic, 114500 Colorectal cancer, hereditary nonpolyposis, type 7, 614385 Endometrial cancer, 608089 |
| MLLT10 | 114.1 | 96% | 95% | Leukemia acute myeloid |
| MLLT11 | 150.0 | 100% | 100% | Leukemia, acute myelomonocytic |
| MLPH | 83.9 | 99% | 95% | Griselli syndrome, type 3, 609227 |
| MLYCD | 78.3 | 94% | 81% | Malonyl-CoA decarboxylase deficiency, 248360 |
| MMAA | 174.5 | 100% | 100% | Methylmalonic aciduria, vitamin B12-responsive, 251100 |
| MMAB | 79.8 | 100% | 92% | Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 |
| MMACHC | 177.9 | 100% | 100% | Methylmalonic aciduria and homocystinuria, cblC type, 277400 |
| MMADHC | 79.5 | 100% | 100% | Homocystinuria cblD type variant 1 |
| MMP1 | 119.6 | 100% | 100% | COPD, rate of decline of lung function in, 606963 {Epidermolysis bullosa dystrophica, autosomal recessive, modifier of}, 226600 |
| MMP13 | 148.0 | 100% | 100% | Spondyloepimetaphyseal dysplasia, Missouri type, 602111 Metaphyseal anadysplasia 1, 602111 |
| MMP2 | 102.8 | 100% | 100% | Torg-Winchester syndrome, 259600 |
| MMP20 | 100.2 | 100% | 98% | Amelogenesis imperfecta, type IIA2, 612529 |
| MMP9 | 91.8 | 95% | 91% | Metaphyseal anadysplasia 2, 613073 |
| MN1 | 76.0 | 100% | 100% | Meningioma, 607174 |
| MNX1 | 52.1 | 76% | 65% | Currarino syndrome, 176450 |
| MOCS1 | 68.9 | 98% | 92% | Molybdenum cofactor deficiency, type A, 252150 |
| MOCS2 | 116.2 | 100% | 100% | Molybdenum cofactor deficiency, type B, 252150 |
| MOG | 19.1 | 70% | 42% | Narcolepsy 7, 614250 |
| MOGS | 125.1 | 100% | 100% | Congenital disorder of glycosylation type IIb |

| | | | | |
|--------|-------|------|------|--|
| MPC1 | 89.7 | 100% | 100% | Mitochondrial pyruvate carrier deficiency |
| MPDU1 | 113.2 | 100% | 99% | Congenital disorder of glycosylation, type If, 609180 |
| MPDZ | 103.8 | 98% | 97% | Hydrocephalus, nonsyndromic, autosomal recessive 2, 615219 |
| MPI | 92.1 | 100% | 97% | Congenital disorder of glycosylation, type Ib, 602579 |
| MPL | 119.3 | 99% | 94% | Thrombocytopenia, congenital amegakaryocytic, 604498 Thrombocythemia 2, 601977 Myelofibrosis with myeloid metaplasia, somatic, 254450 |
| MPLKIP | 91.9 | 100% | 100% | Trichothiodystrophy, nonphotosensitive 1, 234050 |
| MPO | 89.2 | 100% | 97% | Myeloperoxidase deficiency, 254600 {Alzheimer disease, susceptibility to}, 104300 {Lung cancer, protection against, in smokers} |
| MPV17 | 114.3 | 100% | 100% | Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 -3 |
| MPZ | 103.2 | 100% | 95% | Charcot-Marie-Tooth disease, type 1B, 118200 Dejerine-Sottas disease, 145900 Neuropathy, congenital hypomyelinating, 605253 Charcot-Marie-Tooth disease, type 2J, 607736 Roussy-Levy syndrome, 180800 Charcot-Marie-Tooth disease, type 2I, |
| MRAP | 75.0 | 99% | 95% | Glucocorticoid deficiency 2 |
| MRE11A | 97.1 | 100% | 100% | Ataxia-telangiectasia-like disorder, 604391 |
| MRPL3 | 74.9 | 96% | 92% | Combined oxidative phosphorylation deficiency 9, 614582 |
| MRPS16 | 141.6 | 100% | 100% | Combined oxidative phosphorylation deficiency 2, 610498 |
| MRPS22 | 90.7 | 100% | 100% | Combined oxidative phosphorylation deficiency 5, 611719 |
| MS4A1 | 152.1 | 100% | 100% | Immunodeficiency, common variable, 5, 613495 |
| MSH2 | 99.7 | 99% | 96% | Colorectal cancer, hereditary nonpolyposis, type 1, 120435 Muir-Torre syndrome, 158320 Mismatch repair cancer syndrome, 276300 |
| MSH3 | 109.4 | 99% | 98% | Endometrial carcinoma |
| MSH6 | 148.5 | 100% | 100% | Colorectal cancer, hereditary nonpolyposis, type 5, 614350 Endometrial cancer, familial, 608089 Mismatch repair cancer syndrome, 276300 |
| MSR1 | 115.3 | 99% | 98% | Prostate cancer, hereditary, 176807 Barrett esophagus/esophageal adenocarcinoma, 614266 |
| MSRB3 | 115.5 | 100% | 98% | Deafness, autosomal recessive 74, 613718 |
| MSTN | 196.3 | 100% | 100% | Muscle hypertrophy |

| | | | | |
|-------|-------|------|------|---|
| MSX1 | 60.2 | 100% | 89% | Tooth agenesis, selective, 1, with or without orofacial cleft, 106600 Orofacial cleft 5, 608874 Ectodermal dysplasia 3, Witkop type, 189500 |
| MSX2 | 38.8 | 82% | 62% | Craniosynostosis, type 2, 604757 Parietal foramina 1, 168500 Parietal foramina with cleidocranial dysplasia, 168550 |
| MTAP | 84.1 | 100% | 100% | Diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 |
| MTFMT | 100.3 | 100% | 100% | Combined oxidative phosphorylation deficiency 15, 614947 |
| MTHFR | 93.8 | 100% | 98% | Homocystinuria due to MTHFR deficiency, 236250 {Schizophrenia, susceptibility to}, 181500 {Vascular disease, susceptibility to} {Neural tube defects, susceptibility to}, 601634 {Thromboembolism, susceptibility to}, 188050 |
| MTM1 | 55.5 | 100% | 98% | Myotubular myopathy, X-linked, 310400 |
| MTMR2 | 106.9 | 100% | 100% | Charcot-Marie-Tooth disease, type 4B1, 601382 |
| MTO1 | 129.0 | 100% | 98% | Combined oxidative phosphorylation deficiency 10, 614702 |
| MTPAP | 119.0 | 91% | 91% | Ataxia, spastic, 4, 613672 |
| MTR | 104.3 | 100% | 99% | Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 {Neural tube defects, folate-sensitive, susceptibility to}, 601634 |
| MTRR | 105.2 | 100% | 98% | Homocystinuria-megaloblastic anemia, cbl E type, 236270 {Neural tube defects, folate-sensitive, susceptibility to}, 601634 |
| MTTP | 102.2 | 100% | 98% | Abetalipoproteinemia |
| MUC1 | 84.2 | 93% | 87% | Medullary cystic kidney disease 1, 174000 |
| MUSK | 130.9 | 100% | 98% | Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 |
| MUT | 124.8 | 100% | 100% | Methylmalonic aciduria, mut(0) type, 251000 |
| MUTYH | 112.8 | 100% | 100% | Adenomas, multiple colorectal, 608456 Gastric cancer, somatic, 613659 Colorectal adenomatous polyposis, autosomal recessive, with pilomatrixomas, 132600 |
| MVK | 88.3 | 100% | 97% | Mevalonic aciduria, 610377 Hyper-IgD syndrome, 260920 Porokeratosis 3, disseminated superficial actinic, 175900 |
| MXI1 | 108.4 | 100% | 94% | Neurofibrosarcoma {Prostate cancer, susceptibility to}, 176807 |

| | | | | |
|--------|-------|------|------|--|
| MYBPC1 | 96.3 | 100% | 98% | Arthrogryposis, distal, type 1B, 614335 Lethal congenital contracture syndrome 4, 614915 |
| MYBPC3 | 90.7 | 95% | 94% | Cardiomyopathy, familial hypertrophic, 4, 115197 Cardiomyopathy, dilated, 1MM, 615396 Left ventricular noncompaction 10, 615396 |
| MYCN | 107.3 | 97% | 94% | Feingold syndrome, 164280 |
| MYD88 | 165.8 | 100% | 96% | Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 Macroglobulinemia, Waldenstrom, somatic, 153600 |
| MYF6 | 145.5 | 100% | 100% | Myopathy, centronuclear, 3, 614408 |
| MYH11 | 118.8 | 100% | 97% | Aortic aneurysm, familial thoracic 4, 132900 |
| MYH14 | 62.4 | 96% | 85% | Deafness, autosomal dominant 4A, 600652 Peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 |
| MYH2 | 100.8 | 97% | 93% | Inclusion body myopathy-3, 605637 |
| MYH3 | 111.2 | 97% | 95% | Arthrogryposis, distal, type 2A, 193700 Arthrogryposis, distal, type 2B, 601680 |
| MYH6 | 97.4 | 95% | 89% | Cardiomyopathy, familial hypertrophic, 14, 613251 Atrial septal defect 3, 614089 Cardiomyopathy, dilated, 1EE, 613252 {Sick sinus syndrome 3}, 614090 |
| MYH7 | 89.3 | 95% | 88% | Cardiomyopathy, familial hypertrophic, 1, 192600 Cardiomyopathy, dilated, 1S, 613426 Myopathy, myosin storage, 608358 Laing distal myopathy, 160500 Scapuloperoneal syndrome, myopathic type, 181430 Left ventricular noncompaction 5, 6134 |
| MYH8 | 104.4 | 95% | 86% | Carney complex variant, 608837 Trismus-pseudocamptodactyly syndrome, 158300 |
| MYH9 | 96.5 | 100% | 98% | May-Hegglin anomaly, 155100 Fechtner syndrome, 153640 Sebastian syndrome, 605249 Deafness, autosomal dominant 17, 603622 Epstein syndrome, 153650 Macrothrombocytopenia and progressive sensorineural deafness, 600208 |
| MYL2 | 101.4 | 100% | 100% | Cardiomyopathy, familial hypertrophic, 10, 608758 |
| MYL3 | 86.1 | 100% | 99% | Cardiomyopathy, familial hypertrophic, 8, 608751 |
| MYLK | 111.5 | 99% | 96% | Aortic aneurysm, familial thoracic 7, 613780 |
| MYLK2 | 89.2 | 98% | 97% | Cardiomyopathy, hypertrophic, midventricular, digenic, 192600 |

| | | | | |
|--------|-------|------|------|--|
| MYO15A | 89.7 | 98% | 92% | Deafness, autosomal recessive 3, 600316 |
| MYO1A | 102.3 | 100% | 97% | Deafness, autosomal dominant 48, 607841 |
| MYO1E | 82.6 | 97% | 93% | Glomerulosclerosis focal segmental 6 |
| MYO3A | 109.8 | 99% | 97% | Deafness, autosomal recessive 30, 607101 |
| MYO5A | 95.6 | 99% | 97% | Griselli syndrome, type 1, 214450 |
| MYO5B | 83.5 | 95% | 92% | Microvillus inclusion disease, 251850 |
| MYO6 | 108.0 | 100% | 99% | Deafness, autosomal dominant 22, 606346 Deafness, autosomal recessive 37, 607821 Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 |
| MYO7A | 77.0 | 95% | 91% | Usher syndrome, type 1B, 276900 Deafness, autosomal recessive 2, 600060 Deafness, autosomal dominant 11, 601317 |
| MYOC | 182.9 | 100% | 100% | Glaucoma 1A, primary open angle, 137750 |
| MYOT | 140.1 | 100% | 100% | Muscular dystrophy, limb-girdle, type 1A, 159000 Myopathy, myofibrillar, 3, 609200 Myopathy, spheroid body, 182920 |
| MYOZ2 | 105.2 | 100% | 100% | Cardiomyopathy, familial hypertrophic, 16, 613838 |
| MYPN | 109.9 | 100% | 96% | Cardiomyopathy, dilated, 1KK, 615248 Cardiomyopathy, familial hypertrophic, 22, 615248 Cardiomyopathy, familial restrictive 4, 615248 |
| NAA10 | 50.5 | 94% | 86% | N-terminal acetyltransferase deficiency, 300855 |
| NAGA | 78.6 | 100% | 99% | Schindler disease, type I, 609241 Kanzaki disease, 609242 Schindler disease, type III, 609241 |
| NAGLU | 67.1 | 94% | 89% | Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 |
| NAGS | 52.2 | 85% | 75% | N-acetylglutamate synthase deficiency, 237310 |
| NALCN | 109.7 | 99% | 97% | ?Neuroaxonal neurodegeneration, infantile, with facial dysmorphism, 615419 |
| NANOS1 | 39.1 | 94% | 80% | Spermatogenic failure 12, 615413 |
| NBAS | 103.6 | 100% | 99% | Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 |
| NBEAL2 | 109.7 | 99% | 98% | Gray platelet syndrome, 139090 |
| NBN | 121.4 | 98% | 97% | Leukemia |
| NCF1 | .9 | % | % | Chronic granulomatous disease due to deficiency of NCF-1, 233700 |
| NCF2 | 101.4 | 100% | 98% | Chronic granulomatous disease due to deficiency of NCF-2, 233710 |
| NCF4 | 79.4 | 97% | 96% | Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III, 613960 |

| | | | | |
|---------|-------|------|------|--|
| NCOA4 | 36.4 | 72% | 62% | Thyroid carcinoma, papillary, 188550 |
| NCSTN | 80.1 | 97% | 90% | Acne inversa, familial, 1, 142690 |
| NDE1 | 97.3 | 100% | 96% | Lissencephaly 4 (with microcephaly), 614019 |
| NDN | 41.1 | 100% | 100% | Prader-Willi syndrome, 176270 |
| NDP | 52.2 | 86% | 78% | Norrie disease, 310600 Exudative vitreoretinopathy, X-linked, 305390 |
| NDRG1 | 82.9 | 97% | 92% | Charcot-Marie-Tooth disease, type 4D, 601455 |
| NDUFA1 | 116.6 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFA10 | 88.8 | 100% | 97% | previous assignment to chr. 12 Leigh syndrome, 256000 |
| NDUFA11 | 102.0 | 99% | 84% | Mitochondrial complex I deficiency, 252010 |
| NDUFA12 | 105.7 | 100% | 100% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFA2 | 160.5 | 100% | 100% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFA9 | 99.3 | 100% | 100% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 -3 |
| NDUFAF1 | 116.9 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF2 | 55.3 | 100% | 98% | Mitochondrial complex I deficiency, 252010 Leigh syndrome, 256000 |
| NDUFAF3 | 131.2 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF4 | 81.2 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF5 | 136.0 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF6 | 101.9 | 100% | 97% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFB3 | 1.5 | % | % | Mitochondrial complex I deficiency, 252010 |
| NDUFS1 | 80.4 | 100% | 98% | Mitochondrial complex I deficiency, 252010 |
| NDUFS2 | 122.5 | 100% | 97% | Mitochondrial complex I deficiency, 252010 |
| NDUFS3 | 153.9 | 100% | 100% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 Mitochondrial complex I deficiency, 252010 |
| NDUFS4 | 127.6 | 100% | 100% | Leigh syndrome, 256000 Mitochondrial complex I deficiency, 252010 |
| NDUFS6 | 118.7 | 90% | 77% | Complex I, mitochondrial respiratory chain, deficiency of, 252010 |
| NDUFS7 | 100.0 | 100% | 100% | Leigh syndrome, 256000 |
| NDUFS8 | 107.7 | 100% | 96% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFV1 | 63.4 | 100% | 92% | Mitochondrial complex I deficiency, 252010 |
| NDUFV2 | 124.6 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NEB | 89.1 | 82% | 80% | Nemaline myopathy 2, autosomal recessive, 256030 |
| NEFL | 133.8 | 100% | 100% | Charcot-Marie-Tooth disease, type 2E, 607684 Charcot-Marie-Tooth disease, type 1F, 607734 |
| NEK1 | 129.4 | 100% | 99% | Short rib-polydactyly syndrome, type IIA, 263520 |

| | | | | |
|---------|-------|------|------|---|
| NEU1 | 13.5 | 64% | 20% | Sialidosis, type I, 256550 Sialidosis, type II, 256550 |
| NEUROD1 | 130.4 | 100% | 100% | {Diabetes mellitus, noninsulin-dependent}, 125853 Maturity-onset diabetes of the young 6, 606394 |
| NEUROG3 | 105.6 | 100% | 100% | Diarrhea 4, malabsorptive, congenital, 610370 |
| NEXN | 136.1 | 100% | 100% | Cardiomyopathy, dilated, 1CC, 613122 Cardiomyopathy, familial hypertrophic, 20, 613876 |
| NF1 | 82.4 | 84% | 81% | Neurofibromatosis, type 1, 162200 Leukemia, juvenile myelomonocytic, 607785 Melanoma, desmoplastic neurotrophic (2) Neurofibromatosis, familial spinal, 162210 Neurofibromatosis-Noonan syndrome, 601321 Watson syndrome, 193520 |
| NF2 | 82.2 | 100% | 98% | loss of heterozygosity Neurofibromatosis, type 2, 101000 Meningioma, NF2-related, somatic, 607174 Schwannomatosis, 162091 |
| NFIX | 129.0 | 98% | 97% | Sotos syndrome 2, 614753 Marshall-Smith syndrome, 602535 |
| NFKB2 | 87.4 | 100% | 98% | Immunodeficiency, common variable, 10, 615577 |
| NFKBIA | 100.8 | 100% | 100% | Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency, 612132 |
| NFU1 | 86.0 | 98% | 91% | Multiple mitochondrial dysfunctions syndrome 1, 605711 |
| NGF | 180.0 | 100% | 100% | Neuropathy hereditary sensory and autonomic type V |
| NHEJ1 | 74.6 | 100% | 99% | Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 |
| NHLRC1 | 109.3 | 100% | 100% | Epilepsy, progressive myoclonic 2B (Lafora), 254780 |
| NHP2 | 52.5 | 100% | 97% | Dyskeratosis congenita autosomal recessive 2 |
| NHS | 67.6 | 93% | 89% | Nance-Horan syndrome, 302350 Cataract 40, X-linked, 302200 |
| NIN | 132.5 | 100% | 99% | Seckel syndrome 7, 614851 |
| NIPA1 | 98.4 | 91% | 82% | Spastic paraparesis 6, autosomal dominant, 600363 |
| NIPAL4 | 131.8 | 100% | 98% | Ichthyosis, congenital, autosomal recessive 6, 612281 |
| NIPBL | 122.1 | 98% | 98% | Cornelia de Lange syndrome 1, 122470 |
| NKX2-1 | 89.6 | 100% | 100% | Goiter, familial, due to TTF-1 defect (1) Chorea, hereditary benign, 118700 Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 |

| | | | | |
|--------|-------|------|------|--|
| NKX2-5 | 113.0 | 100% | 99% | Atrial septal defect 7, with or without AV conduction defects, 108900 Tetrology of Fallot, 187500 Hypothyroidism, congenital nongoitrous, 5, 225250 Ventricular septal defect 3, 614432 Hypoplastic left heart syndrome 2, 614435 Conotrunc |
| NKX2-6 | 82.4 | 100% | 93% | Persistent truncus arteriosus, 217095 |
| NKX3-2 | 71.0 | 100% | 98% | Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 |
| NLGN4X | 34.1 | 66% | 56% | Mental retardation X-linked |
| NLRP12 | 99.6 | 100% | 98% | Familial cold autoinflammatory syndrome 2, 611762 |
| NLRP3 | 124.2 | 100% | 99% | Cold-induced autoinflammatory syndrome, familial, 120100 Muckle-Wells syndrome, 191900 CINCA syndrome, 607115 |
| NLRP7 | 134.0 | 100% | 100% | Hydatidiform mole |
| NME8 | 102.2 | 100% | 100% | Ciliary dyskinesia, primary, 6, 610852 |
| NMNAT1 | 96.0 | 100% | 100% | Leber congenital amaurosis 9, 608553 |
| NNT | 96.8 | 100% | 100% | Glucocorticoid deficiency 4, 614736 |
| NOBOX | 84.4 | 96% | 93% | Premature ovarian failure 5, 611548 |
| NOD2 | 96.2 | 100% | 98% | {Inflammatory bowel disease 1}, 266600 Blau syndrome, 186580 {Psoriatic arthritis, susceptibility to}, 607507 Sarcoidosis, early-onset, 609464 |
| NODAL | 126.5 | 94% | 83% | Heterotaxy, visceral, 5, 270100 |
| NOG | 110.9 | 100% | 100% | Symphalangism, proximal, 185800 Multiple synostosis syndrome 1, 186500 Tarsal-carpal coalition syndrome, 186570 Stapes ankylosis with broad thumb and toes, 184460 Brachydactyly, type B2, 611377 |
| NOL3 | 173.8 | 100% | 100% | Myoclonus familial cortical |
| NOP10 | 193.8 | 100% | 100% | Dyskeratosis congenita autosomal recessive 1 |
| NOP56 | 95.7 | 99% | 96% | Spinocerebellar ataxia 36, 614153 |
| NOTCH1 | 71.3 | 97% | 89% | Aortic valve disease, 109730 Leukemia, T-cell acute lymphoblastic (2) |
| NOTCH2 | 89.5 | 91% | 89% | Alagille syndrome 2, 610205 Hajdu-Cheney syndrome, 102500 |

| | | | | |
|--------|-------|------|------|--|
| NOTCH3 | 69.6 | 93% | 84% | Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, 125310 ?Myofibromatosis, infantile 2, 615293 |
| NPC1 | 90.2 | 99% | 98% | Niemann-Pick disease, type C1, 257220 Niemann-Pick disease, type D, 257220 |
| NPC2 | 74.4 | 100% | 100% | Niemann-pick disease, type C2, 607625 |
| NPHP1 | 167.1 | 100% | 100% | Nephronophthisis 1, juvenile, 256100 Senior-Loken syndrome-1, 266900 Joubert syndrome 4, 609583 |
| NPHP3 | 110.4 | 100% | 99% | Nephronophthisis 3, 604387 Renal-hepatic-pancreatic dysplasia 1, 208540 Meckel syndrome 7, 267010 |
| NPHP4 | 89.5 | 98% | 93% | Nephronophthisis 4, 606966 Senior-Loken syndrome 4, 606996 |
| NPHS1 | 87.3 | 100% | 96% | Nephrotic syndrome, type 1, 256300 |
| NPHS2 | 128.4 | 100% | 100% | Nephrotic syndrome type 2 |
| NPM1 | 45.0 | 82% | 79% | Leukemia, acute promyelocytic, NPM/RARA type Leukemia, acute myeloid, 601626 |
| NPPA | 154.3 | 100% | 98% | Atrial fibrillation, familial, 6, 612201 |
| NPR2 | 152.7 | 100% | 100% | Acromesomelic dysplasia, Maroteaux type, 602875 |
| NR0B1 | 61.6 | 100% | 100% | 46XY sex reversal 2 dosage-sensitive |
| NR0B2 | 69.5 | 100% | 100% | Obesity, mild, early-onset, 601665 |
| NR2E3 | 82.8 | 98% | 93% | Enhanced S-cone syndrome, 268100 Retinitis pigmentosa 37, 611131 |
| NR2F1 | 164.8 | 100% | 100% | Bosch-Boonstra-Schaaf optic atrophy syndrome, 615722 |
| NR3C1 | 108.1 | 98% | 85% | Cortisol resistance |
| NR3C2 | 140.9 | 100% | 98% | Pseudohypoaldosteronism type I, autosomal dominant, 177735 Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 |
| NR4A3 | 97.2 | 100% | 96% | Chondrosarcoma extraskeletal myxoid |
| NR5A1 | 69.4 | 92% | 85% | 46XY sex reversal 3 |
| NRAS | 129.6 | 100% | 100% | Autoimmune lymphoproliferative syndrome type IV, 614470 Noonan syndrome 6, 613224 Epidermal nevus, somatic, 162900 Thyroid carcinoma, follicular, somatic, 188470 Colorectal cancer, somatic, 114500 |

| | | | | |
|--------|-------|------|------|--|
| NRL | 47.6 | 100% | 98% | Retinitis pigmentosa 27, 613750 Retinal degeneration, autosomal recessive, clumped pigment type |
| NRXN1 | 117.0 | 99% | 98% | Pitt-Hopkins-like syndrome 2, 614325 {Schizophrenia, susceptibility to, 17}, 614332 |
| NSD1 | 124.8 | 100% | 100% | Sotos syndrome 1, 117550 Leukemia, acute myeloid, 601626 (1) Beckwith-Wiedemann syndrome, 130650 |
| NSDHL | 52.1 | 97% | 94% | CHILD syndrome, 308050 CK syndrome, 300831 |
| NSMF | 84.3 | 93% | 93% | Hypogonadotropic hypogonadism 9 with or without anosmia, 614838 |
| NSUN2 | 124.4 | 99% | 90% | Mental retardation, autosomal recessive 5, 611091 |
| NT5C2 | 122.9 | 100% | 100% | Spastic paraplegia 45, 613162 |
| NT5C3A | 73.3 | 96% | 88% | Anemia hemolytic due to UMPH1 deficiency |
| NT5E | 111.7 | 100% | 100% | Calcification of joints and arteries, 211800 |
| NTF4 | 43.9 | 99% | 92% | Glaucoma 1, open angle, 1O, 613100 |
| NTRK1 | 67.5 | 99% | 94% | Insensitivity to pain, congenital, with anhidrosis, 256800 Medullary thyroid carcinoma, familial, 155240 |
| NTRK2 | 99.9 | 98% | 97% | Obesity, hyperphagia, and developmental delay, 613886 |
| NUBPL | 86.1 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NUMA1 | 90.2 | 97% | 96% | Leukemia, acute promyelocytic, NUMA/RARA type |
| NUP214 | 129.1 | 100% | 99% | Leukemia, acute myeloid, 601626 Leukemia, T-cell acute lymphoblastic |
| NUP62 | 86.1 | 100% | 97% | Striatonigral degeneration, infantile, 271930 |
| NYX | 47.7 | 97% | 94% | Night blindness, congenital stationary (complete), 1A, X-linked, 310500 |
| OAT | 44.9 | 83% | 71% | Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 |
| OBSL1 | 83.1 | 99% | 94% | 3-M syndrome 2, 612921 |
| OCA2 | 96.0 | 100% | 99% | ?hypopigmentation in PWS and AS Albinism, oculocutaneous, type II, 203200 Albinism, brown oculocutaneous, 203200 [Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 [Skin/hair/eye pigmentation 1, blond/brown hair], 227220 |
| OCLN | 92.4 | 74% | 73% | Band-like calcification with simplified gyration and polymicrogyria, 251290 |
| OCRL | 59.4 | 97% | 94% | Lowe syndrome, 309000 Dent disease 2, 300555 |
| OFD1 | 37.0 | 88% | 78% | Oral-facial-digital syndrome 1, 311200 Simpson-Golabi-Behmel syndrome, type 2, 300209 Joubert syndrome 10, 300804 |

| | | | | |
|--------|-------|------|------|---|
| OGG1 | 94.0 | 100% | 98% | Renal cell carcinoma, clear cell, somatic, 144700 |
| OPA1 | 129.7 | 99% | 99% | Optic atrophy 1, 165500 {Glaucoma, normal tension, susceptibility to}, 606657 Optic atrophy plus syndrome, 125250 |
| OPA3 | 108.0 | 100% | 100% | 3-methylglutaconic aciduria, type III, 258501 Optic atrophy 3 with cataract, 165300 |
| OPHN1 | 48.4 | 99% | 88% | Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance, 300486 |
| OPLAH | 97.3 | 99% | 96% | 5-oxoprolinase deficiency, 260005 |
| OPN1LW | .4 | % | % | Colorblindness, protan, 303900 Blue cone monochromacy, 303700 -3 |
| OPN1MW | .5 | % | % | Colorblindness, deutan, 303800 Blue cone monochromacy, 303700 -3 |
| OPN1SW | 91.8 | 96% | 92% | Colorblindness, tritan, 190900 |
| OPTN | 95.9 | 100% | 100% | Glaucoma 1, open angle, E, 137760 {Glaucoma, normal tension, susceptibility to}, 606657 Amyotrophic lateral sclerosis 12, 613435 |
| ORAI1 | 79.1 | 99% | 87% | Immunodeficiency 9, 612782 |
| ORC1 | 103.4 | 100% | 99% | Meier-Gorlin syndrome 1, 224690 |
| ORC4 | 104.9 | 100% | 100% | Meier-Gorlin syndrome 2, 613800 |
| ORC6 | 88.7 | 100% | 98% | Meier-Gorlin syndrome 3, 613803 |
| OSMR | 134.3 | 100% | 100% | Amyloidosis, primary localized cutaneous, 1, 105250 |
| OSTM1 | 106.3 | 100% | 100% | Osteopetrosis, autosomal recessive 5, 259720 |
| OTC | 54.5 | 100% | 94% | Ornithine transcarbamylase deficiency, 311250 |
| OTOA | 65.3 | 67% | 66% | Deafness, autosomal recessive 22, 607039 |
| OTOF | 92.6 | 99% | 96% | Deafness, autosomal recessive 9, 601071 Auditory neuropathy, autosomal recessive, 1, 601071 |
| OTOG | 89.0 | 99% | 94% | Deafness, autosomal recessive 18B, 614945 |
| OTOGL | 119.0 | 100% | 99% | Deafness, autosomal recessive 84B, 614944 |
| OTX2 | 153.3 | 100% | 100% | Microphthalmia, syndromic 5, 610125 Pituitary hormone deficiency, combined, 6, 613986 Retinal dystrophy, early-onset, and pituitary dysfunction, 610125 |
| OXCT1 | 96.3 | 100% | 98% | Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 |
| P2RX1 | 76.4 | 100% | 98% | Bleeding disorder due to P2RX1 defect |
| P2RX2 | 96.6 | 100% | 99% | Deafness, autosomal dominant 41, 608224 |
| P2RY12 | 183.0 | 100% | 100% | Bleeding disorder, platelet-type, 8, 609821 |

| | | | | |
|----------|-------|------|------|---|
| PABPN1 | 55.9 | 67% | 54% | Oculopharyngeal muscular dystrophy, 164300 |
| PACS1 | 104.1 | 98% | 97% | Mental retardation, autosomal dominant 17, 615009 |
| PAFAH1B1 | 71.2 | 89% | 80% | Lissencephaly 1, 607432 Subcortical laminar heterotopia, 607432 -3 |
| PAH | 86.5 | 100% | 98% | Phenylketonuria, 261600 [Hyperphenylalaninemia, non-PKU mild], 261600 |
| PAK3 | 51.4 | 100% | 97% | Mental retardation, X-linked 30/47, 300558 |
| PALB2 | 136.6 | 100% | 97% | Fanconi anemia, complementation group N, 610832 {Breast cancer, susceptibility to}, 114480 {Pancreatic cancer, susceptibility to, 3}, 613348 |
| PANK2 | 112.1 | 90% | 86% | Neurodegeneration with brain iron accumulation 1, 234200 HARP syndrome, 607236 |
| PAPSS2 | 93.4 | 100% | 99% | Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 -3 |
| PARK2 | 66.8 | 98% | 95% | Adenocarcinoma of lung somatic |
| PARK7 | 101.0 | 100% | 100% | Parkinson disease 7 autosomal recessive early-onset |
| PAX2 | 88.9 | 93% | 85% | Papillorenal syndrome, 120330 Renal hypoplasia, isolated, 191830 -3 |
| PAX3 | 111.9 | 99% | 96% | Waardenburg syndrome, type 1, 193500 Waardenburg syndrome, type 3, 148820 Craniofacial-deafness-hand syndrome, 122880 Rhabdomyosarcoma 2, alveolar, 268220 |
| PAX4 | 64.4 | 100% | 93% | Maturity-onset diabetes of the young, type IX, 612225 Diabetes mellitus, type 2, 125853 Diabetes mellitus, ketosis-prone, 612227 |
| PAX6 | 83.7 | 100% | 100% | Aniridia, 106210 Peters anomaly, 604229 Cataract with late-onset corneal dystrophy, 106210 Keratitis, 148190 Foveal hyperplasia, 136520 Morning glory disc anomaly, 120430 Optic nerve hypoplasia, 165550 Coloboma, ocular, 120200 |
| PAX8 | 67.5 | 100% | 86% | Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 |
| PAX9 | 206.0 | 99% | 99% | Tooth agenesis, selective, 3, 604625 |
| PC | 96.7 | 95% | 92% | Pyruvate carboxylase deficiency, 266150 |
| PCBD1 | 60.2 | 100% | 98% | Hyperphenylalaninemia BH4-deficient D |

| | | | | |
|--------|-------|------|------|--|
| PCCA | 96.2 | 96% | 94% | Propionicacidemia, 606054 |
| PCCB | 114.2 | 100% | 100% | Propionicacidemia, 606054 |
| PCDH15 | 134.8 | 100% | 100% | Usher syndrome, type 1F, 602083 Deafness, autosomal recessive 23, 609533 Usher syndrome, type 1D/F digenic, 601067 |
| PCDH19 | 72.6 | 100% | 98% | Epileptic encephalopathy, early infantile, 9, 300088 |
| PCM1 | 123.2 | 100% | 99% | Thyroid carcinoma, papillary, 188550 |
| PCNT | 94.7 | 98% | 94% | Microcephalic osteodysplastic primordial dwarfism, type II, 210720 -3 |
| PCSK1 | 110.5 | 100% | 98% | Obesity with impaired prohormone processing, 600955 {Obesity, susceptibility to, BMIQ12}, 612362 |
| PCSK9 | 68.4 | 97% | 93% | Hypercholesterolemia, familial, 3, 603776 {Low density lipoprotein cholesterol level QTL 1}, 603776 |
| PCYT1A | 90.8 | 100% | 98% | Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 |
| PDCD10 | 85.0 | 97% | 79% | Cerebral cavernous malformations 3, 603285 |
| PDE11A | 120.4 | 99% | 97% | Pigmented nodular adrenocortical disease, primary, 2, 610475 |
| PDE4D | 109.4 | 97% | 91% | {Stroke, susceptibility to, 1}, 606799 Acrody sostosis 2, with or without hormone resistance, 614613 |
| PDE6A | 100.7 | 99% | 95% | Retinitis pigmentosa 43, 613810 |
| PDE6B | 101.0 | 100% | 99% | Night blindness, congenital stationary, autosomal dominant 2, 163500 Retinitis pigmentosa-40, 613801 |
| PDE6C | 109.6 | 100% | 99% | Cone dystrophy 4, 613093 |
| PDE6G | 99.1 | 100% | 100% | Retinitis pigmentosa 57, 613582 |
| PDE6H | 40.0 | 87% | 75% | Retinal cone dystrophy 3, 610024 Achromatopsia 6, 610024 |
| PDE8B | 96.6 | 100% | 100% | Pigmented nodular adrenocortical disease, primary, 3, 614190 Striatal degeneration, autosomal dominant, 609161 |
| PDGFB | 66.7 | 100% | 100% | Meningioma, SIS-related, 607174 Dermatofibrosarcoma protuberans, 607907 |
| PDGFRA | 126.1 | 100% | 99% | Gastrointestinal stromal tumor, somatic, 606764 Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 |
| PDGFRB | 86.9 | 100% | 98% | Myeloproliferative disorder with eosinophilia, 131440 (4) Basal ganglia calcification, idiopathic, 4, 615007 Myofibromatosis, infantile, 1, 228550 |
| PDGFRL | 108.6 | 99% | 96% | Hepatocellular cancer, somatic, 114550 Colorectal cancer, somatic, 114500 |
| PDHA1 | 60.8 | 98% | 90% | Pyruvate dehydrogenase E1-alpha deficiency, 312170 |

| | | | | |
|--------|-------|------|------|--|
| | | | | Leigh syndrome, X-linked, 308930 |
| PDHB | 97.2 | 100% | 100% | Pyruvate dehydrogenase E1-beta deficiency, 614111 |
| PDP1 | 155.3 | 100% | 100% | Pyruvate dehydrogenase phosphatase deficiency, 608782 |
| PDSS1 | 94.4 | 90% | 86% | Coenzyme Q10 deficiency, primary, 2, 614651 |
| PDSS2 | 90.7 | 100% | 99% | Coenzyme Q10 deficiency, primary, 3, 614652 |
| PDX1 | 46.2 | 100% | 98% | Lacticacidemia due to PDX1 deficiency, 245349 |
| PDX1 | 46.2 | 100% | 98% | MODY type IV |
| PDYN | 136.3 | 100% | 100% | Spinocerebellar ataxia 23, 610245 |
| PDZD7 | 74.0 | 96% | 86% | {Retinal disease in Usher syndrome type IIA, modifier of}, 276901 Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 |
| PEPD | 66.4 | 97% | 89% | Prolidase deficiency, 170100 |
| PER2 | 80.1 | 100% | 99% | Advanced sleep phase syndrome, familial, 1, 604348 |
| PET100 | 70.5 | 100% | 99% | Mitochondrial complex IV deficiency, 220110 |
| PEX1 | 124.5 | 100% | 100% | Peroxisome biogenesis disorder 1A (Zellweger), 214100 Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 |
| PEX10 | 73.0 | 95% | 86% | Peroxisome biogenesis disorder 6A (Zellweger), 614870 Peroxisome biogenesis disorder 6B, 614871 |
| PEX11B | 157.2 | 100% | 100% | Peroxisome biogenesis disorder 14B, 614920 |
| PEX12 | 133.0 | 100% | 100% | Peroxisome biogenesis disorder 3A (Zellweger), 614859 Peroxisome biogenesis disorder 3B, 266510 |
| PEX13 | 134.6 | 100% | 95% | Peroxisome biogenesis disorder 11A (Zellweger), 614883 Peroxisome biogenesis disorder 11B, 614885 |
| PEX14 | 92.3 | 100% | 100% | Peroxisome biogenesis disorder 13A (Zellweger), 614887 |
| PEX16 | 91.8 | 94% | 84% | Peroxisome biogenesis disorder 8A, (Zellweger), 614876 Peroxisome biogenesis disorder 8B, 614877 |
| PEX19 | 104.7 | 100% | 99% | Peroxisome biogenesis disorder 12A (Zellweger), 614886 |
| PEX2 | 159.1 | 100% | 100% | Peroxisome biogenesis disorder 5A (Zellweger) |
| PEX26 | 113.0 | 100% | 100% | Peroxisome biogenesis disorder 7A (Zellweger), 614872 Peroxisome biogenesis disorder 7B, 614873 |
| PEX3 | 141.1 | 100% | 100% | Peroxisome biogenesis disorder 10A (Zellweger), 614882 |
| PEX5 | 88.7 | 97% | 96% | Peroxisome biogenesis disorder 2A (Zellweger), 214110 Peroxisome biogenesis disorder 2B, 202370 |
| PEX6 | 91.3 | 94% | 85% | Peroxisome biogenesis disorder 4A (Zellweger), 614862 Peroxisome biogenesis disorder 4B, 614863 |
| PEX7 | 102.2 | 99% | 93% | Rhizomelic chondrodysplasia punctata, type 1, 215100 |

| | | | | |
|--------|-------|------|------|---|
| | | | | Peroxisome biogenesis disorder 9B, 614879 |
| PFKM | 102.2 | 100% | 100% | Glycogen storage disease VII, 232800 |
| PFN1 | 51.6 | 100% | 79% | Amyotrophic lateral sclerosis 18, 614808 |
| PGAM2 | 96.8 | 100% | 100% | Glycogen storage disease X, 261670 |
| PGAP2 | 117.1 | 100% | 99% | Hyperphosphatasia with mental retardation syndrome 3, 614207 |
| PGAP3 | 61.6 | 98% | 92% | Hyperphosphatasia with mental retardation syndrome 4, 615716 (3) |
| PGK1 | 42.7 | 75% | 67% | Phosphoglycerate kinase 1 deficiency, 300653 |
| PGM1 | 109.2 | 100% | 99% | Glycogen storage disease XIV, 612934 Congenital disorder of glycosylation, type Ia, 614921 |
| PHEX | 63.1 | 100% | 98% | Hypophosphatemic rickets, X-linked dominant, 307800 |
| PHF6 | 78.0 | 100% | 98% | Borjeson-Forssman-Lehmann syndrome, 301900 |
| PHF8 | 51.1 | 97% | 85% | Mental retardation syndrome, X-linked, Siderius type, 300263 |
| PHGDH | 84.6 | 100% | 97% | Phosphoglycerate dehydrogenase deficiency, 601815 |
| PHKA1 | 47.3 | 94% | 88% | Muscle glycogenosis, 300559 |
| PHKA2 | 49.6 | 97% | 85% | Glycogen storage disease, type IXa1, 306000 Glycogen storage disease, type IXa2, 306000 |
| PHKB | 119.0 | 97% | 97% | Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 |
| PHKG2 | 143.0 | 100% | 100% | Glycogen storage disease IXc, 613027 Cirrhosis due to liver phosphorylase kinase deficiency |
| PHOX2A | 30.2 | 81% | 64% | Fibrosis of extraocular muscles, congenital, 2, 602078 |
| PHOX2B | 58.6 | 100% | 96% | Central hypoventilation syndrome congenital with or without Hirschsprung disease |
| PHYH | 88.8 | 100% | 99% | Refsum disease, 266500 |
| PICALM | 105.1 | 100% | 98% | Leukemia, acute myeloid, 601626 Leukemia, acute T-cell lymphoblastic |
| PIEZ01 | 85.0 | 98% | 91% | Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 |
| PIEZ02 | 101.1 | 99% | 98% | ?Marden-Walker syndrome, 248700 Arthrogryposis, distal, type 3, 114300 Arthrogryposis, distal, type 5, 108145 |
| PIGA | 66.6 | 99% | 98% | Paroxysmal nocturnal hemoglobinuria, somatic, 300818 Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 |
| PIGL | 95.7 | 100% | 100% | CHIME syndrome, 280000 |
| PIGM | 105.4 | 100% | 100% | Glycosylphosphatidylinositol deficiency, 610293 |
| PIGN | 107.0 | 100% | 100% | Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 |

| | | | | |
|---------|-------|------|------|--|
| PIGO | 104.6 | 100% | 99% | Hyperphosphatasia with mental retardation syndrome 2, 614749 |
| PIGV | 182.7 | 100% | 100% | Hyperphosphatasia with mental retardation syndrome 1, 239300 |
| PIK3CA | 126.7 | 93% | 90% | Ovarian cancer, somatic, 167000 Breast cancer, somatic, 114480 Colorectal cancer, somatic, 114500 Gastric cancer, somatic, 613659 Hepatocellular carcinoma, somatic, 114550 Non-small cell lung cancer, somatic, 211980 Keratosis, sebor |
| PIK3CD | 90.4 | 98% | 90% | Immunodeficiency 14, 615513 |
| PIK3R1 | 144.1 | 100% | 100% | Agammaglobulinemia 7, autosomal recessive, 615214 SHORT syndrome, 269880 |
| PIK3R2 | 80.8 | 96% | 87% | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome, 603387 |
| PIK3R5 | 72.9 | 100% | 98% | Ataxia-oculomotor apraxia 3, 615217 |
| PIKFYVE | 138.0 | 100% | 100% | Corneal fleck dystrophy, 121850 |
| PINK1 | 78.0 | 93% | 87% | Parkinson disease 6, early onset, 605909 |
| PIP5K1C | 58.1 | 87% | 83% | Lethal congenital contractural syndrome 3, 611369 |
| PITPNM3 | 77.8 | 99% | 93% | Cone-rod dystrophy 5, 600977 |
| PITX1 | 69.5 | 99% | 92% | Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 Liebenberg syndrome, 186550 (4) |
| PITX2 | 109.7 | 95% | 83% | Axenfeld-Rieger syndrome, type 1, 180500 Iridogoniodysgenesis, type 2, 137600 Ring dermoid of cornea, 180550 Peters anomaly, 604229 |
| PITX3 | 37.2 | 99% | 84% | Anterior segment mesenchymal dysgenesis, 107250 Cataract 11, multiple types, 610623 Cataract 11, syndromic, 610623 |
| PKD1 | 13.9 | 19% | 18% | Polycystic kidney disease, adult type I, 173900 |
| PKD2 | 101.4 | 98% | 92% | Polycystic kidney disease 2, 613095 |
| PKHD1 | 103.8 | 98% | 96% | Polycystic kidney and hepatic disease |
| PKLR | 123.2 | 100% | 97% | Pyruvate kinase deficiency, 266200 Adenosine triphosphate, elevated, of erythrocytes, 102900 |
| PKP1 | 82.7 | 96% | 86% | Ectodermal dysplasia/skin fragility syndrome, 604536 |
| PKP2 | 62.9 | 87% | 73% | Arrhythmogenic right ventricular dysplasia 9, 609040 |
| PLA2G4A | 133.0 | 100% | 98% | Phospholipase A2, group IV A, deficiency of |

| | | | | |
|---------|-------|------|------|--|
| PLA2G5 | 108.2 | 100% | 100% | Fleck retina, familial benign, 228980 |
| PLA2G6 | 77.6 | 99% | 93% | Infantile neuroaxonal dystrophy 1, 256600 Neurodegeneration with brain iron accumulation 2B, 610217 Parkinson disease 14, 612953 |
| PLA2G7 | 122.6 | 100% | 100% | Platelet-activating factor acetylhydrolase deficiency, 614278 {Asthma, susceptibility to}, 600807 {Atopy, susceptibility to}, 147050 |
| PLAG1 | 153.3 | 100% | 99% | Adenomas, salivary gland pleomorphic, 181030 |
| PLAU | 92.1 | 100% | 91% | {Alzheimer disease, late-onset, susceptibility to}, 104300 Quebec platelet disorder, 601709 |
| PLCB1 | 113.0 | 100% | 98% | Epileptic encephalopathy, early infantile, 12, 613722 |
| PLCB4 | 93.3 | 100% | 98% | Auriculocondylar syndrome 2, 614669 |
| PLCD1 | 95.1 | 97% | 92% | Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 |
| PLCE1 | 123.8 | 99% | 97% | Nephrotic syndrome, type 3, 610725 |
| PLCG2 | 107.3 | 99% | 98% | Familial cold autoinflammatory syndrome 3, 614468 Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 |
| PLEC | 97.5 | 99% | 96% | Epidermolysis bullosa simplex with pyloric atresia |
| PLEKHG5 | 80.3 | 96% | 93% | Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 Charcot-Marie-Tooth disease, recessive intermediate C, 615376 |
| PLEKHM1 | 6.7 | 25% | 15% | Osteopetrosis, autosomal recessive 6, 611497 |
| PLG | 65.3 | 74% | 70% | Plasminogen Tochigi disease Thrombophilia, dysplasminogenemic (1) Plasminogen deficiency, types I and II (1) Conjunctivitis, ligneous, 217090 |
| PLIN1 | 54.5 | 90% | 78% | Lipodystrophy, familial partial, type 4, 613877 |
| PLN | 156.1 | 100% | 100% | Cardiomyopathy, dilated, 1P, 609909 Cardiomyopathy, familial hypertrophic, 18, 613874 |
| PLOD1 | 78.4 | 100% | 96% | Ehlers-Danlos syndrome, type VI, 225400 |
| PLOD2 | 111.0 | 100% | 100% | Bruck syndrome 2, 609220 |
| PLOD3 | 79.6 | 95% | 85% | Lysyl hydroxylase 3 deficiency, 612394 |
| PLP1 | 48.9 | 100% | 95% | Pelizaeus-Merzbacher disease, 312080 Spastic paraparesis 2, X-linked, 312920 |
| PLS3 | 66.7 | 100% | 100% | Bone mineral density QTL18, osteoporosis, 300910 |
| PML | 103.1 | 99% | 97% | Leukemia, acute promyelocytic, PML/RARA type |
| PMM2 | 92.4 | 100% | 100% | Congenital disorder of glycosylation, type Ia, 212065 |

| | | | | |
|---------|-------|------|------|--|
| PMP22 | 94.8 | 100% | 100% | Charcot-Marie-Tooth disease, type 1A, 118220 Dejerine-Sottas disease, 145900 Neuropathy, recurrent, with pressure palsies, 162500 Charcot-Marie-Tooth disease, type 1E, 118300 Roussy-Levy syndrome, 180800 Neuropathy, inflammatory demyel |
| PMS2 | 62.1 | 56% | 55% | Mismatch repair cancer syndrome, 276300 Colorectal cancer, hereditary nonpolyposis, type 4, 614337 |
| PNKP | 70.4 | 100% | 99% | Epileptic encephalopathy, early infantile, 10, 613402 |
| PNP | 124.9 | 100% | 100% | Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 |
| PNPLA1 | 122.3 | 100% | 100% | Ichthyosis, congenital, autosomal recessive 10, 615024 |
| PNPLA2 | 78.5 | 100% | 91% | Neutral lipid storage disease with myopathy, 610717 |
| PNPLA6 | 81.5 | 100% | 96% | Spastic paraparesis 39, autosomal recessive, 612020 |
| PNPO | 71.8 | 100% | 97% | Pyridoxamine 5'-phosphate oxidase deficiency, 610090 |
| PNPT1 | 103.6 | 100% | 100% | Combined oxidative phosphorylation deficiency 13, 614932 Deafness, autosomal recessive 70, 614934 |
| POC1A | 102.0 | 96% | 87% | Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 |
| POF1B | 62.4 | 98% | 90% | Premature ovarian failure 2B |
| POFUT1 | 118.3 | 100% | 100% | Dowling-Degos disease 2, 615327 |
| POGLUT1 | 107.5 | 100% | 98% | Dowling-Degos disease 4, 615696 (3) |
| POLD1 | 78.7 | 94% | 86% | {Colorectal cancer, susceptibility to, 10}, 612591 Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 |
| POLE | 104.0 | 100% | 98% | FILS syndrome |
| POLG | 90.5 | 98% | 92% | Progressive external ophthalmoplegia, autosomal recessive, 258450 Progressive external ophthalmoplegia, autosomal dominant, 157640 Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 Mitochondrial DNA depletion syndrome 4A (Alpers typ |
| POLG2 | 129.6 | 100% | 100% | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4, 610131 |
| POLH | 138.3 | 99% | 96% | Xeroderma pigmentosum, variant type, 278750 |
| POLR1C | 122.6 | 100% | 96% | Treacher Collins syndrome 3, 248390 |
| POLR1D | 190.6 | 100% | 100% | Treacher Collins syndrome 2, 613717 |
| POLR3A | 90.6 | 99% | 96% | Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 |

| | | | | |
|---------|-------|------|------|---|
| POLR3B | 104.2 | 100% | 99% | Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 |
| POMC | 58.2 | 80% | 63% | Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 {Obesity, early-onset, susceptibility to}, 601665 |
| POMGNT1 | 96.7 | 100% | 99% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 Muscular dystrophy-dystroglycanopathy (limb-girdle), t |
| POMGNT2 | 135.3 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies type A 8 |
| POMP | 176.3 | 100% | 100% | Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 |
| POMT1 | 99.9 | 100% | 98% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 Muscular dystrophy-dystroglycanopathy (limb-girdle), t |
| POMT2 | 74.5 | 100% | 93% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 Muscular dystrophy-dystroglycanopathy (limb-girdle), t |
| POR | 101.0 | 100% | 100% | Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 |
| PORCN | 55.0 | 85% | 76% | Focal dermal hypoplasia, 305600 |
| POU1F1 | 105.7 | 100% | 100% | Pituitary hormone deficiency, combined, 1, 613038 |
| POU3F4 | 68.1 | 100% | 100% | Deafness, X-linked 2, 304400 |
| POU4F3 | 173.5 | 100% | 100% | Deafness, autosomal dominant 15, 602459 |
| PPARG | 113.8 | 99% | 96% | Obesity, severe, 601665 [Obesity, resistance to] Insulin resistance, severe, digenic, 604367 Lipodystrophy, familial partial, type 3, 604367 Carotid intimal medial thickness 1, 609338 |

| | | | | |
|----------|-------|------|------|--|
| | | | | {Diabetes, type 2}, 125853 |
| PPIB | 90.7 | 100% | 100% | Osteogenesis imperfecta, type IX, 259440 |
| PPM1D | 147.2 | 100% | 99% | Breast cancer, 114480 |
| PPM1K | 99.8 | 100% | 94% | Maple syrup urine disease, mild variant, 615135 |
| PPOX | 90.4 | 100% | 97% | Porphyria variegata, 176200 |
| PPP1R3A | 191.6 | 100% | 100% | Insulin resistance, severe, digenic, 604367 |
| PPP2R1B | 116.8 | 100% | 100% | Lung cancer, 211980 |
| PPP2R2B | 98.4 | 94% | 85% | Spinocerebellar ataxia 12, 604326 |
| PPT1 | 66.2 | 100% | 93% | Ceroid lipofuscinosis, neuronal, 1, 256730 |
| PQBP1 | 66.2 | 100% | 99% | Renpenning syndrome, 309500 |
| PRCC | 92.6 | 100% | 99% | Renal cell carcinoma, papillary, 605074 |
| PRCD | 87.0 | 100% | 100% | Retinitis pigmentosa 36, 610599 |
| PRDM16 | 111.0 | 99% | 97% | Left ventricular noncompaction 8, 615373 Cardiomyopathy, dilated, 1LL, 615373 |
| PRDM5 | 108.1 | 100% | 100% | Brittle cornea syndrome 2, 614170 |
| PRF1 | 94.1 | 100% | 98% | Hemophagocytic lymphohistiocytosis, familial, 2, 603553 Lymphoma, non-Hodgkin, 605027 |
| PRG4 | 99.9 | 96% | 85% | Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 |
| PRICKLE1 | 104.2 | 99% | 98% | Epilepsy, progressive myoclonic 1B, 612437 |
| PRICKLE2 | 109.8 | 100% | 100% | Epilepsy, progressive myoclonic 5, 613832 |
| PRIMPOL | 123.2 | 100% | 97% | Myopia 22, autosomal dominant, 615420 (3) |
| PRKAG2 | 90.4 | 100% | 100% | Wolff-Parkinson-White syndrome, 194200 Cardiomyopathy, familial hypertrophic 6, 600858 Glycogen storage disease of heart, lethal congenital, 261740 |
| PRKAR1A | 104.7 | 97% | 89% | Carney complex, type 1, 160980 Myxoma, intracardiac, 255960 Thyroid carcinoma, papillary, somatic, 188550 Pigmented nodular adrenocortical disease, primary, 1, 610489 Adrenocortical tumor, somatic, Acrodysostosis 1, with or without hor |

| | | | | |
|--------|-------|------|------|--|
| PRKCA | 107.8 | 100% | 99% | Pituitary tumor, invasive |
| PRKCG | 94.5 | 98% | 92% | Spinocerebellar ataxia 14, 605361 |
| PRKCSH | 86.2 | 100% | 96% | Polycystic liver disease, 174050 |
| PRKG1 | 94.8 | 100% | 97% | Aortic aneurysm, familial thoracic 8, 615436 |
| PRKRA | 90.3 | 91% | 76% | Dystonia 16 |
| PRLR | 91.2 | 100% | 100% | ?Hyperprolactinemia, 615555 Multiple fibroadenomas of the breast, 615554 |
| PRNP | 97.8 | 100% | 100% | Creutzfeldt-Jakob disease, 123400 Gerstmann-Straussler disease, 137440 Insomnia, fatal familial, 600072 Prion disease with protracted course, 606688 Huntington disease-like 1, 603218 {Kuru, susceptibility to}, 245300 |
| PROC | 93.7 | 99% | 94% | Thrombophilia due to protein C deficiency, autosomal dominant, 176860 Thrombophilia due to protein C deficiency, autosomal recessive, 612304 |
| PRODH | 51.5 | 84% | 66% | Hyperprolinemia, type I, 239500 {Schizophrenia, susceptibility to, 4}, 600850 |
| PROK2 | 86.2 | 100% | 98% | Hypogonadotropic hypogonadism 4 with or without anosmia, 610628 |
| PROKR2 | 177.3 | 100% | 100% | Hypogonadotropic hypogonadism 3 with or without anosmia, 244200 |
| PROM1 | 87.8 | 99% | 93% | Retinitis pigmentosa 41, 612095 Cone-rod dystrophy 12, 612657 Stargardt disease 4, 603786 Macular dystrophy, retinal, 2, 608051 |
| PROP1 | 66.3 | 100% | 70% | Pituitary hormone deficiency, combined, 2, 262600 |
| PROS1 | 58.0 | 85% | 72% | Thrombophilia due to protein S deficiency, autosomal dominant, 612336 Thrombophilia due to protein S deficiency, autosomal recessive, 614514 |
| PRPF3 | 96.8 | 100% | 100% | Retinitis pigmentosa 18 |
| PRPF31 | 82.2 | 86% | 83% | Retinitis pigmentosa 11, 600138 |
| PRPF6 | 88.8 | 100% | 99% | Retinitis pigmentosa 60, 613983 |
| PRPF8 | 120.7 | 99% | 98% | Retinitis pigmentosa 13, 600059 |
| PRPH2 | 147.4 | 100% | 100% | Retinitis pigmentosa 7, 608133 Retinitis punctata albescens, 136880 Macular dystrophy, patterned, 169150 Macular dystrophy, vitelliform, 608161 Foveomacular dystrophy, adult-onset, with choroidal neovascularization, 608161 Macular dyst |

| | | | | |
|---------|-------|------|------|---|
| PRPS1 | 63.6 | 99% | 97% | Gout, PRPS-related, 300661 Phosphoribosylpyrophosphate synthetase superactivity, 300661 Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 Arts syndrome, 301835 Deafness, X-linked 1, 304500 |
| PRRT2 | 77.9 | 100% | 100% | Episodic kinesigenic dyskinesia 1, 128200 Seizures, benign familial infantile, 2, 605751 Convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 |
| PRRX1 | 76.7 | 99% | 94% | Agnathia-otocephaly complex, 202650 |
| PRSS1 | 99.7 | 78% | 78% | Preeclampsia/eclampsia 5, 614595 |
| PRSS1 | 99.7 | 78% | 78% | Pancreatitis, hereditary, 167800 Trypsinogen deficiency, 614044 (1) |
| PRSS12 | 99.7 | 98% | 96% | Mental retardation, autosomal recessive 1, 249500 |
| PRSS56 | 60.5 | 97% | 85% | Microphthalmia, isolated 6, 613517 |
| PRX | 113.1 | 99% | 98% | Dejerine-Sottas disease, autosomal recessive, 145900 Charcot-Marie-Tooth disease, type 4F, 614895 |
| PSAP | 80.2 | 100% | 98% | Metachromatic leukodystrophy due to SAP-b deficiency, 249900 Gaucher disease, atypical, 610539 Combined SAP deficiency, 611721 Krabbe disease, atypical, 611722 |
| PSAT1 | 41.1 | 67% | 54% | Phosphoserine aminotransferase deficiency, 610992 |
| PSEN1 | 96.5 | 100% | 93% | Alzheimer disease, type 3, 607822 Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 Dementia, frontotemporal, 600274 Pick disease, 172700 |
| PSEN2 | 86.9 | 100% | 99% | Alzheimer disease-4, 606889 Cardiomyopathy, dilated, 1V, 613697 -3 |
| PSENEN | 130.5 | 100% | 100% | Acne inversa, familial, 2, 613736 |
| PSMB8 | 9.8 | 35% | 11% | Autoinflammation, lipodystrophy, and dermatosis syndrome, 256040 |
| PSMC3IP | 142.5 | 100% | 94% | Ovarian dysgenesis 3, 614324 |
| PSTPIP1 | 61.6 | 99% | 85% | Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 -3 |
| PTCH1 | 87.7 | 99% | 96% | Basal cell nevus syndrome, 109400 Basal cell carcinoma, somatic, 605462 Holoprosencephaly-7, 610828 |

| | | | | |
|--------|-------|------|------|--|
| PTCH2 | 77.8 | 98% | 94% | Medulloblastoma, 155255 Basal cell carcinoma, somatic, 605462 -3 |
| PTDSS1 | 120.9 | 100% | 100% | Lenz-Majewski hyperostotic dwarfism, 151050 |
| PTEN | 137.7 | 100% | 97% | Cowden syndrome 1, 158350 Lhermitte-Duclos syndrome, 158350 Bannayan-Riley-Ruvalcaba syndrome, 153480 {Meningioma}, 607174 {Glioma susceptibility 2}, 613028 Macrocephaly/autism syndrome, 605309 PTEN hamartoma tumor syndrome VAT |
| PTF1A | 36.0 | 87% | 58% | Diabetes mellitus, permanent neonatal, with cerebellar agenesis, 609069 |
| PTGIS | 56.1 | 100% | 89% | Hypertension, essential, 145500 |
| PTH | 199.9 | 100% | 100% | Hypoparathyroidism, autosomal dominant, 146200 Hypoparathyroidism, autosomal recessive, 146200 |
| PTH1R | 83.8 | 97% | 95% | Chondrodysplasia Blomstrand type |
| PTHLH | 131.2 | 100% | 100% | Humoral hypercalcemia of malignancy (1) Brachydactyly, type E2, 613382 |
| PTPN11 | 46.9 | 88% | 66% | Noonan syndrome 1, 163950 LEOPARD syndrome 1, 151100 Leukemia, juvenile myelomonocytic, 607785 Metachondromatosis, 156250 |
| PTPN12 | 118.8 | 100% | 100% | Colon cancer |
| PTPN14 | 122.3 | 100% | 98% | Choanal atresia and lymphedema, 613611 |
| PTPRC | 101.1 | 98% | 94% | {Hepatitis C virus, susceptibility to}, 609532 Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 |
| PTPRJ | 112.1 | 97% | 96% | Colon cancer, somatic, 114500 |
| PTPRO | 106.4 | 98% | 97% | Nephrotic syndrome, type 6, 614196 |
| PTPRQ | 118.2 | 100% | 98% | Deafness, autosomal recessive 84A, 613391 |
| PTRF | 151.4 | 100% | 100% | Lipodystrophy, congenital generalized, type 4, 613327 |
| PTS | 118.4 | 100% | 100% | Hyperphenylalaninemia, BH4-deficient, A, 261640 |
| PUF60 | 123.9 | 97% | 94% | Verheij syndrome, 615583 (3) |
| PUS1 | 65.8 | 100% | 98% | Mitochondrial myopathy and sideroblastic anemia 1, 600462 |
| PVRL1 | 71.7 | 100% | 97% | Cleft lip/palate-ectodermal dysplasia syndrome |
| PVRL4 | 140.1 | 100% | 100% | Ectodermal dysplasia-syndactyly syndrome 1 |

| | | | | |
|----------|-------|------|------|---|
| PYCR1 | 83.6 | 100% | 96% | Cutis laxa, autosomal recessive, type IIB, 612940 Cutis laxa, autosomal recessive, type IIIB, 614438 |
| PYGL | 102.8 | 100% | 99% | Glycogen storage disease VI, 232700 |
| PYGM | 97.3 | 100% | 98% | McArdle disease, 232600 |
| QARS | 119.4 | 100% | 99% | Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 |
| QDPR | 77.2 | 100% | 98% | Hyperphenylalaninemia, BH4-deficient, C, 261630 |
| RAB18 | 105.5 | 100% | 100% | Warburg micro syndrome 3, 614222 |
| RAB23 | 134.0 | 100% | 100% | Carpenter syndrome, 201000 |
| RAB27A | 112.7 | 100% | 100% | Griselli syndrome, type 2, 607624 |
| RAB28 | 79.0 | 96% | 95% | Cone-rod dystrophy 18, 615374 |
| RAB33B | 108.1 | 100% | 99% | Smith-McCort dysplasia 2 |
| RAB39B | 86.9 | 100% | 100% | Mental retardation, X-linked 72, 300271 |
| RAB3GAP1 | 124.9 | 99% | 97% | Warburg micro syndrome 1, 600118 |
| RAB3GAP2 | 110.7 | 99% | 99% | Martsolf syndrome, 212720 Warburg micro syndrome 2, 614225 |
| RAB40AL | 16.2 | 69% | 39% | Mental retardation, X-linked, syndromic, Martin-Probst type, 300519 -3 |
| RAB7A | 78.9 | 100% | 100% | Charcot-Marie-Tooth disease type 2B |
| RAC2 | 53.0 | 100% | 94% | Neutrophil immunodeficiency syndrome, 608203 |
| RAD21 | 97.2 | 99% | 95% | Cornelia de Lange syndrome 4, 614701 |
| RAD50 | 115.0 | 100% | 99% | Nijmegen breakage syndrome-like disorder, 613078 |
| RAD51 | 88.5 | 100% | 96% | Mirror movements 2 |
| RAD51C | 105.5 | 100% | 100% | Fanconi anemia, complementation group O, 613390 {Breast-ovarian cancer, familial, susceptibility to, 3}, 613399 |
| RAD54B | 128.3 | 100% | 100% | Lymphoma, non-Hodgkin Colon adenocarcinoma |
| RAD54L | 88.6 | 99% | 96% | {Breast cancer, invasive ductal}, 114480 Lymphoma, non-Hodgkin,somatic, 605027 Adenocarcinoma, colonic, somatic |
| RAF1 | 90.7 | 100% | 100% | Noonan syndrome 5, 611553 LEOPARD syndrome 2, 611554 |
| RAG1 | 149.1 | 100% | 100% | Severe combined immunodeficiency, B cell-negative, 601457 Omenn syndrome, 603554 Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 Combined cellular and humoral immune |

| | | | | |
|----------|-------|------|------|---|
| RAG2 | 206.1 | 100% | 100% | Severe combined immunodeficiency, B cell-negative, 601457 Omenn syndrome, 603554 Combined cellular and humoral immune defects with granulomas, 233650 |
| RAI1 | 137.2 | 99% | 99% | Smith-Magenis syndrome, 182290 |
| RAP1GDS1 | 88.6 | 99% | 99% | Lymphocytic leukemia, acute T-cell |
| RAPSN | 92.2 | 92% | 86% | Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 Myasthenic syndrome, congenital, associated with facial dysmorphism and acetylcholine receptor deficiency, 608931 Fetal akinesia deformation sequence, 20815 |
| RARB | 144.6 | 98% | 98% | Microphthalmia, syndromic 12, 615524 |
| RARS2 | 83.0 | 100% | 98% | Pontocerebellar hypoplasia, type 6, 611523 |
| RASA1 | 100.0 | 100% | 99% | Parkes Weber syndrome, 608355 Capillary malformation-arteriovenous malformation, 608354 Basal cell carcinoma, somatic, 605462 |
| RAX2 | 57.2 | 100% | 99% | Cone-rod dystrophy 11 |
| RB1 | 112.4 | 98% | 98% | Retinoblastoma, 180200 Osteosarcoma, somatic, 259500 Bladder cancer, somatic, 109800 Small cell cancer of the lung, somatic, 182280 Retinoblastoma, trilateral, 180200 |
| RB1CC1 | 130.4 | 100% | 100% | Breast cancer, somatic, 114480 |
| RBBP8 | 115.5 | 100% | 100% | Pancreatic carcinoma, somatic Seckel syndrome 2, 606744 Jawad syndrome, 251255 |
| RBM10 | 49.0 | 91% | 82% | TARP syndrome, 311900 |
| RBM20 | 111.0 | 98% | 96% | Cardiomyopathy, dilated, 1DD, 613172 |
| RBM28 | 101.9 | 100% | 99% | Alopecia, neurologic defects, and endocrinopathy syndrome, 612079 |
| RBM8A | 85.9 | 100% | 100% | Thrombocytopenia-absent radius syndrome, 274000 |
| RBP4 | 80.1 | 95% | 90% | Retinol dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 |
| RBPJ | 76.2 | 99% | 95% | Adams-Oliver syndrome 3, 614814 |
| RD3 | 56.9 | 100% | 100% | Leber congenital amaurosis 12, 610612 |
| RDH12 | 63.6 | 91% | 80% | Leber congenital amaurosis 13, 612712 |
| RDH5 | 107.3 | 100% | 100% | Fundus albipunctatus, 136880 |
| RDX | 56.3 | 91% | 81% | Deafness, autosomal recessive 24, 611022 |

| | | | | |
|--------|-------|------|------|---|
| RECQL4 | 87.7 | 98% | 95% | Rothmund-Thomson syndrome, 268400 RAPADILINO syndrome, 266280 Baller-Gerold syndrome, 218600 |
| REEP1 | 96.3 | 100% | 94% | Spastic paraparesis 31, autosomal dominant, 610250 Neuronopathy, distal hereditary motor, type VB, 614751 |
| RELN | 105.7 | 99% | 98% | Lissencephaly 2 (Norman-Roberts type), 257320 |
| REN | 104.6 | 100% | 100% | [Hyperproreninemia] Renal tubular dysgenesis, 267430 Hyperuricemic nephropathy, familial juvenile 2, 613092 |
| RET | 90.8 | 98% | 94% | Multiple endocrine neoplasia IIA, 171400 Medullary thyroid carcinoma, 155240 Multiple endocrine neoplasia IIB, 162300 Central hypoventilation syndrome, congenital, 209880 Pheochromocytoma, 171300 Renal agenesis, 191830 {Hirschsprung} |
| RFT1 | 78.3 | 100% | 97% | Congenital disorder of glycosylation, type In, 612015 |
| RFX5 | 116.0 | 99% | 97% | Bare lymphocyte syndrome, type II, complementation group C, 209920 Bare lymphocyte syndrome, type II, complementation group E, 209920 |
| RFX6 | 126.4 | 100% | 100% | Martinez-Frias syndrome, 601346 |
| RFXANK | 94.4 | 97% | 95% | MHC class II deficiency, complementation group B, 209920 |
| RFXAP | 86.6 | 93% | 88% | Bare lymphocyte syndrome, type II, complementation group D, 209920 |
| RGR | 87.0 | 95% | 87% | Retinitis pigmentosa 44, 613769 |
| RGS9 | 104.9 | 98% | 93% | Bradyopsia, 608415 |
| RGS9BP | 37.4 | 100% | 94% | Bradyopsia, 608415 |
| RHAG | 85.6 | 100% | 100% | Anemia, hemolytic, Rh-null, regulator type, 268150 Rh-mod syndrome |
| RHBDF2 | 60.4 | 99% | 88% | Tylosis with esophageal cancer, 148500 |
| RHCE | 96.3 | 73% | 69% | [Blood group, Rhesus], 111690 Rh-null disease, amorph type -3 |
| RHO | 125.6 | 100% | 98% | Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 Night blindness, congenital stationary, autosomal dominant 1, 610445 Retinitis punctata albescens, 136880 |
| RIMS1 | 103.9 | 100% | 100% | Cone-rod dystrophy 7, 603649 |
| RIN2 | 126.8 | 100% | 98% | Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 |
| RIPK4 | 104.8 | 99% | 94% | Popliteal pterygium syndrome 2, lethal type, 263650 |

| | | | | |
|----------|-------|------|------|--|
| RIT1 | 162.5 | 100% | 100% | Noonan syndrome 8, 615355 |
| RLBP1 | 101.2 | 100% | 98% | Fundus albipunctatus, 136880 Retinitis punctata albescens, 136880 Newfoundland rod-cone dystrophy, 607476 Bothnia retinal dystrophy, 607475 |
| RMND1 | 86.7 | 95% | 92% | Combined oxidative phosphorylation deficiency 11, 614922 |
| RMRP | 146.5 | 100% | 100% | Anauxetic dysplasia |
| RNASEH2A | 90.2 | 100% | 88% | Aicardi-Goutieres syndrome 4, 610333 |
| RNASEH2B | 115.0 | 100% | 100% | Aicardi-Goutieres syndrome 2, 610181 |
| RNASEH2C | 161.5 | 100% | 100% | Aicardi-Goutieres syndrome 3, 610329 |
| RNASEL | 139.3 | 99% | 96% | Prostate cancer 1, 601518 |
| RNASET2 | 102.0 | 100% | 98% | Leukoencephalopathy, cystic, without megalencephaly, 612951 |
| RNF135 | 95.0 | 95% | 85% | Macrocephaly, macrosomia, facial dysmorphism syndrome, 614192 |
| RNF139 | 158.8 | 100% | 100% | Renal cell carcinoma, 144700 |
| RNF168 | 204.4 | 100% | 100% | RIDDLE syndrome, 611943 |
| RNF170 | 121.0 | 100% | 100% | Ataxia, sensory, 1, autosomal dominant, 608984 |
| RNF212 | 97.7 | 99% | 98% | Recombination rate QTL 1, 612042 |
| RNF216 | 78.8 | 95% | 91% | Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 |
| RNF6 | 155.7 | 100% | 100% | Esophageal carcinoma, somatic, 133239 |
| ROBO2 | 108.8 | 100% | 99% | Vesicoureteral reflux 2, 610878 |
| ROBO3 | 81.8 | 97% | 87% | Gaze palsy, horizontal, with progressive scoliosis, 607313 |
| ROGDI | 94.4 | 96% | 95% | Kohlschutter-Tonz syndrome, 226750 |
| ROM1 | 92.5 | 100% | 100% | Retinitis pigmentosa 7, digenic, 608133 |
| ROR2 | 109.8 | 99% | 95% | Brachydactyly, type B1, 113000 Robinow syndrome, autosomal recessive, 268310 |
| RP1 | 179.8 | 100% | 100% | Retinitis pigmentosa 1, 180100 {Hypertriglyceridemia, susceptibility to}, 145750 |
| RP1L1 | 128.3 | 100% | 100% | Occult macular dystrophy, 613587 |
| RP2 | 60.2 | 100% | 98% | Retinitis pigmentosa 2, 312600 |
| RPE65 | 114.7 | 100% | 98% | Leber congenital amaurosis 2, 204100 Retinitis pigmentosa 20, 613794 |

| | | | | |
|----------|-------|------|------|---|
| RPGR | 51.9 | 83% | 75% | Retinitis pigmentosa 3, 300029 Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness, 300455 Macular degeneration, X-linked atrophic, 300834 Cone-rod dystrophy, X-linked, 1, 304020 |
| RPGRIP1 | 118.5 | 100% | 98% | Leber congenital amaurosis 6, 613826 Cone-rod dystrophy 13, 608194 |
| RPGRIP1L | 101.4 | 98% | 96% | Joubert syndrome 7, 611560 Meckel syndrome 5, 611561 COACH syndrome, 216360 |
| RPIA | 72.0 | 100% | 95% | Ribose 5-phosphate isomerase deficiency, 608611 |
| RPL11 | 75.5 | 100% | 99% | Diamond-Blackfan anemia 7, 612562 |
| RPL35A | 30.2 | 87% | 56% | Diamond-Blackfan anemia 5, 612528 |
| RPL5 | 31.5 | 86% | 60% | Diamond-Blackfan anemia 6, 612561 |
| RPS10 | 30.7 | 89% | 77% | Diamond-Blackfan anemia 9, 613308 |
| RPS14 | 33.0 | 77% | 60% | Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 -3 |
| RPS17 | .0 | % | % | Diamond-Blackfan anemia 4, 612527 |
| RPS19 | 38.6 | 55% | 42% | Diamond-Blackfan anemia 1, 105650 |
| RPS24 | 91.1 | 100% | 94% | Diamond-blackfan anemia 3, 610629 |
| RPS26 | 35.7 | 63% | 58% | Diamond-Blackfan anemia 10, 613309 |
| RPS6KA3 | 50.9 | 98% | 91% | Coffin-Lowry syndrome, 303600 Mental retardation, X-linked 19, 300844 |
| RPS7 | 18.4 | 76% | 37% | Diamond-Blackfan anemia 8, 612563 |
| RPSA | 25.5 | 75% | 54% | Asplenia, isolated congenital |
| RRAS2 | 102.7 | 98% | 93% | Ovarian carcinoma |
| RRM2B | 111.9 | 100% | 100% | Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5, 613077 Mitochondrial DNA depletion syndrome 8B (MNGIE ty |
| RS1 | 39.8 | 92% | 82% | 25cM from XG Retinoschisis, 312700 |
| RSPH1 | 101.7 | 100% | 98% | Ciliary dyskinesia, primary, 24, 615481 |
| RSPH4A | 146.2 | 100% | 100% | Ciliary dyskinesia, primary, 11, 612649 |
| RSPH9 | 85.6 | 100% | 97% | Ciliary dyskinesia, primary, 12, 612650 |
| RSPO1 | 43.3 | 98% | 74% | Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 |

| | | | | |
|--------|-------|------|------|--|
| | | | | Palmoplantar hyperkeratosis and true hermaphroditism, 610644 |
| RSPO4 | 90.4 | 100% | 100% | Anonychia congenita, 206800 |
| RTEL1 | 86.0 | 99% | 96% | Dyskeratosis congenita, autosomal recessive 5, 615190 Dyskeratosis congenita, autosomal dominant 4, 615190 |
| RTN2 | 73.4 | 97% | 95% | Spastic paraplegia 12, autosomal dominant, 604805 |
| RTTN | 90.5 | 99% | 98% | Polymicrogyria with seizures, 614833 |
| RUNX1 | 70.5 | 100% | 91% | Leukemia, acute myeloid, 601626 Platelet disorder, familial, with associated myeloid malignancy, 601399 |
| RUNX2 | 129.2 | 100% | 100% | Cleidocranial dysplasia, 119600 Cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 Cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyl |
| RXFP2 | 128.5 | 100% | 100% | Cryptorchidism |
| RYR1 | 80.7 | 97% | 92% | {Malignant hyperthermia susceptibility 1}, 145600 Central core disease, 117000 Minicore myopathy with external ophthalmoplegia, 255320 Neuromuscular disease, congenital, with uniform type 1 fiber, 117000 King-Denborough syndrome, 145600 |
| RYR2 | 115.1 | 100% | 99% | Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 Arrhythmogenic right ventricular dysplasia 2, 600996 |
| SACS | 159.3 | 100% | 100% | Spastic ataxia, Charlevoix-Saguenay type, 270550 |
| SAG | 111.5 | 100% | 100% | Oguchi disease-1, 258100 Retinitis pigmentosa 47, 613758 |
| SALL1 | 145.0 | 100% | 98% | Townes-Brocks syndrome, 107480 Townes-Brocks branchiootorenal-like syndrome, 107480 |
| SALL4 | 97.7 | 97% | 95% | Duane-radial ray syndrome, 607323 IVIC syndrome, 147750 |
| SAMD9 | 201.0 | 100% | 100% | Tumoral calcinosis, familial, normophosphatemic, 610455 |
| SAMHD1 | 122.5 | 100% | 99% | Aicardi-Goutieres syndrome 5, 612952 Chilblain lupus 2, 614415 -3 |
| SAR1B | 100.4 | 100% | 100% | Chylomicron retention disease, 246700 |
| SARS2 | 66.5 | 98% | 91% | Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 |
| SART3 | 93.6 | 100% | 98% | Porokeratosis, disseminated superficial actinic, 1, 175900 |

| | | | | |
|--------|-------|------|------|---|
| SAT1 | 74.9 | 100% | 96% | Keratosis follicularis spinulosa decalvans, 308800 |
| SATB2 | 105.8 | 97% | 94% | Cleft palate and mental retardation, 119540 |
| SBDS | 78.8 | 100% | 97% | Shwachman-Bodian-Diamond syndrome |
| SBF2 | 104.6 | 99% | 97% | Charcot-Marie-Tooth disease, type 4B2, 604563 |
| SC5D | 175.4 | 100% | 100% | Lathosterolosis |
| SCARB2 | 88.9 | 100% | 95% | Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 |
| SCARF2 | 53.1 | 93% | 89% | Van den Ende-Gupta syndrome, 600920 |
| SCN10A | 125.2 | 99% | 98% | Episodic pain syndrome, familial, 2, 615551 |
| SCN11A | 124.9 | 99% | 98% | Episodic pain syndrome, familial, 3, 615552 Neuropathy, hereditary sensory and autonomic, type VII, 615548 |
| SCN1A | 118.3 | 99% | 98% | Epilepsy, generalized, with febrile seizures plus, type 2, 604403 Dravet syndrome, 607208 Migraine, familial hemiplegic, 3, 609634 Febrile seizures, familial, 3A, 604403 |
| SCN1B | 100.1 | 96% | 96% | Epilepsy, generalized, with febrile seizures plus, type 1, 604233 Brugada syndrome 5, 612838 Cardiac conduction defect, nonspecific, 612838 Atrial fibrillation, familial, 13, 615377 |
| SCN2A | 126.7 | 100% | 98% | Seizures, benign familial infantile, 3, 607745 Epileptic encephalopathy, early infantile, 11, 613721 |
| SCN2B | 98.2 | 100% | 99% | Atrial fibrillation, familial, 14, 615378 |
| SCN3B | 99.0 | 100% | 100% | Brugada syndrome 7, 613120 |
| SCN4A | 132.7 | 100% | 99% | Hyperkalemic periodic paralysis, type 2, 170500 Paramyotonia congenita, 168300 Myotonia congenita, atypical, acetazolamide-responsive, 608390 Myasthenic syndrome, acetazolamide-responsive, 614198 Hypokalemic periodic paralysis, type 2, 613 |
| SCN4B | 79.7 | 100% | 98% | Long QT syndrome-10, 611819 |
| SCN5A | 112.0 | 100% | 99% | Long QT syndrome-3, 603830 Brugada syndrome 1, 601144 Heart block, progressive, type IA, 113900 Heart block, nonprogressive, 113900 Ventricular fibrillation, familial, 1, 603829 Sick sinus syndrome 1, 608567 Cardiomyopathy, dilated |
| SCN8A | 142.4 | 100% | 99% | Cognitive impairment with or without cerebellar ataxia, 614306 Epileptic encephalopathy, early infantile, 13, 614558 |

| | | | | |
|---------|-------|------|------|--|
| SCN9A | 113.8 | 100% | 99% | Erythermalgia, primary, 133020 Insensitivity to pain, channelopathy-associated, 243000 Paroxysmal extreme pain disorder, 167400 Febrile seizures, familial, 3B, 613863 Epilepsy, generalized, with febrile seizures plus, type 7, 613863 Sm |
| SCNN1A | 94.5 | 97% | 93% | Pseudohypoaldosteronism, type I, 264350 Bronchiectasis with or without elevated sweat chloride 2, 613021 |
| SCNN1B | 89.4 | 98% | 96% | Liddle syndrome, 177200 Pseudohypoaldosteronism, type I, 264350 Bronchiectasis with or without elevated sweat chloride 1, 211400 |
| SCNN1G | 129.4 | 100% | 99% | Liddle syndrome, 177200 Pseudohypoaldosteronism, type I, 264350 Bronchiectasis with or without elevated sweat chloride 3, 613071 |
| SCO1 | 94.2 | 96% | 95% | Hepatic failure early onset |
| SCO2 | 85.4 | 100% | 100% | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1, 604377 Myopia 6, 608908 |
| SCP2 | 98.4 | 99% | 97% | Leukoencephalopathy with dystonia and motor neuropathy, 613724 |
| SDCCAG8 | 105.0 | 100% | 100% | Senior-Loken syndrome 7, 613615 |
| SDHA | 9.1 | 30% | 16% | Leigh syndrome, 256000 Mitochondrial respiratory chain complex II deficiency, 252011 Cardiomyopathy, dilated, 1GG, 613642 Paragangliomas 5, 614165 |
| SDHAF1 | 91.8 | 98% | 93% | Mitochondrial complex II deficiency, 252011 |
| SDHAF2 | 107.4 | 100% | 100% | Paragangliomas 2, 601650 |
| SDHB | 85.5 | 100% | 100% | Pheochromocytoma, 171300 Paraganglioma and gastric stromal sarcoma, 606864 Cowden syndrome 2, 612359 Gastrointestinal stromal tumor, 606764 |
| SDHC | 21.1 | 39% | 33% | Paragangliomas 3, 605373 Paraganglioma and gastric stromal sarcoma, 606864 Gastrointestinal stromal tumor, 606764 |

| | | | | |
|----------|-------|------|------|--|
| SDHD | 10.7 | 33% | 16% | Paragangliomas 1, with or without deafness, 168000 Pheochromocytoma, 171300 Carcinoid tumors, intestinal, 114900 Merkel cell carcinoma, somatic Paraganglioma and gastric stromal sarcoma, 606864 Cowden syndrome 3, 615106 |
| SEC23A | 114.2 | 100% | 100% | Craniolenticulosutural dysplasia, 607812 |
| SEC23B | 121.3 | 100% | 100% | Anemia, dyserythropoietic congenital, type II, 224100 |
| SEC63 | 89.3 | 93% | 91% | Polycystic liver disease, 174050 |
| SECISBP2 | 94.9 | 100% | 99% | Thyroid hormone metabolism, abnormal, 609698 |
| SEMA3E | 108.7 | 100% | 100% | CHARGE syndrome, 214800 |
| SEMA4A | 120.6 | 99% | 96% | Retinitis pigmentosa 35, 610282 Cone-rod dystrophy 10, 610283 -3 |
| SEPN1 | 74.4 | 88% | 79% | Muscular dystrophy, rigid spine, 1, 602771 Myopathy, congenital, with fiber-type disproportion, 255310 |
| SEPSECS | 89.6 | 100% | 90% | Pontocerebellar hypoplasia type 2D |
| SEPT12 | 75.7 | 100% | 98% | Spermatogenic failure 10 |
| SEPT9 | 102.9 | 88% | 88% | Amyotrophy hereditary neuralgic |
| SERAC1 | 89.8 | 100% | 100% | 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 |
| SERPINA1 | 132.6 | 100% | 100% | Emphysema due to AAT deficiency, 613490 Emphysema-cirrhosis, due to AAT deficiency, 613490 Hemorrhagic diathesis due to 'antithrombin' Pittsburgh, 613490 {Pulmonary disease, chronic obstructive, susceptibility to}, 606963 (1) |
| SERPINA3 | 157.3 | 100% | 98% | Cerebrovascular disease, occlusive |
| SERPINA6 | 118.6 | 100% | 100% | Corticosteroid-binding globulin deficiency |
| SERPINA7 | 73.5 | 100% | 99% | Thyroxine-binding globulin deficiency |
| SERPINB6 | 133.2 | 93% | 93% | Deafness, autosomal recessive 91, 613453 |
| SERPINB7 | 105.8 | 100% | 100% | Palmoplantar keratoderma, Nagashima type, 615598 |
| SERPINC1 | 130.8 | 100% | 100% | Thrombophilia due to antithrombin III deficiency, 613118 |

| | | | | |
|----------|-------|------|------|--|
| SERPIND1 | 116.4 | 100% | 97% | Thrombophilia due to heparin cofactor II deficiency |
| SERPINE1 | 94.5 | 97% | 90% | Plasminogen activator inhibitor-1 deficiency |
| SERPINF1 | 109.8 | 92% | 84% | Osteogenesis imperfecta, type VI, 613982 |
| SERPINF2 | 134.7 | 100% | 99% | Alpha-2-plasmin inhibitor deficiency |
| SERPING1 | 117.4 | 97% | 95% | Angioedema hereditary types I and II |
| SERPINH1 | 137.6 | 100% | 100% | {Preterm premature rupture of the membranes, susceptibility to}, 610504 Osteogenesis imperfecta, type X, 613848 |
| SERPINI1 | 91.5 | 97% | 90% | Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 -3 |
| SETBP1 | 147.4 | 98% | 96% | Schinzel-Giedion midface retraction syndrome, 269150 |
| SETD5 | 162.3 | 100% | 98% | Mental retardation, autosomal dominant 23, 615761 (3) |
| SETX | 152.7 | 100% | 100% | Ataxia-ocular apraxia-2, 606002 Amyotrophic lateral sclerosis 4, juvenile, 602433 |
| SF3B1 | 119.3 | 100% | 99% | Myelodysplastic syndrome, somatic, 614286 |
| SF3B4 | 73.2 | 100% | 99% | Acrofacial dysostosis 1, Nager type, 154400 |
| SFTPA2 | 30.2 | 51% | 44% | contiguous with SFTPA1 Pulmonary fibrosis, idiopathic, 178500 |
| SFTPB | 61.2 | 95% | 86% | Surfactant metabolism dysfunction, pulmonary, 1, 265120 |
| SFTPC | 67.2 | 100% | 99% | Surfactant metabolism dysfunction, pulmonary, 2, 610913 |
| SFXN4 | 92.5 | 100% | 100% | Combined oxidative phosphorylation deficiency 18, 615578 (3) |
| SGCA | 83.4 | 90% | 81% | Muscular dystrophy, limb-girdle, type 2D, 608099 |
| SGCB | 138.7 | 96% | 96% | Muscular dystrophy, limb-girdle, type 2E, 604286 |
| SGCD | 100.0 | 100% | 100% | Muscular dystrophy, limb-girdle, type 2F, 601287 Cardiomyopathy, dilated, 1L, 606685 |
| SGCE | 89.6 | 95% | 94% | Dystonia-11, myoclonic, 159900 |
| SGCG | 105.5 | 100% | 100% | Muscular dystrophy, limb-girdle, type 2C, 253700 |
| SGSH | 76.0 | 94% | 94% | Mucopolysaccharidosis type IIIA (Sanfilippo A), 252900 |
| SH2B3 | 95.5 | 96% | 94% | Myelofibrosis, somatic, 254450 Thrombocythemia, somatic, 187950 Erythrocytosis, somatic, 133100 |
| SH2D1A | 52.7 | 94% | 83% | Lymphoproliferative syndrome, X-linked, 308240 |
| SH3BP2 | 82.8 | 87% | 87% | Cherubism, 118400 |
| SH3PXD2B | 116.7 | 99% | 96% | Frank-ter Haar syndrome, 249420 |

| | | | | |
|----------|-------|------|------|--|
| SH3TC2 | 97.8 | 97% | 96% | Charcot-Marie-Tooth disease, type 4C, 601596 Mononeuropathy of the median nerve, mild, 613353 |
| SHANK3 | 66.6 | 93% | 77% | Phelan-McDermid syndrome, 606232 {Schizophrenia 15}, 613950 |
| SHH | 95.9 | 99% | 85% | Holoprosencephaly-3, 142945 Single median maxillary central incisor, 147250 Microphthalmia with coloboma 5, 611638 Schizencephaly, 269160 |
| SHOC2 | 117.3 | 100% | 99% | Noonan-like syndrome with loose anagen hair, 607721 |
| SHOX | .6 | % | % | Short stature, idiopathic familial, 300582 Leri-Weill dyschondrosteosis, 127300 Langer mesomelic dysplasia, 249700 |
| SHROOM4 | 63.7 | 98% | 94% | Stocco dos Santos X-linked mental retardation syndrome, 300434 |
| SI | 107.2 | 100% | 99% | Sucrase-isomaltase deficiency, congenital, 222900 |
| SIGMAR1 | 93.3 | 100% | 99% | Amyotrophic lateral sclerosis 16, juvenile, 614373 |
| SIL1 | 93.0 | 100% | 93% | Marinesco-Sjogren syndrome, 248800 |
| SIM1 | 120.6 | 100% | 98% | Obesity, severe, 601665 |
| SIX1 | 80.7 | 100% | 100% | Brachioototic syndrome 3, 608389 Deafness, autosomal dominant 23, 605192 |
| SIX3 | 119.8 | 100% | 100% | Holoprosencephaly-2, 157170 Schizencephaly, 269160 |
| SIX5 | 44.7 | 94% | 81% | Branchiootorenal syndrome 2, 610896 |
| SIX6 | 128.1 | 100% | 97% | Microphthalmia with cataract 2, 212550 |
| SKI | 59.7 | 82% | 79% | Shprintzen-Goldberg syndrome, 182212 |
| SKIV2L | 17.7 | 72% | 39% | Trichohepatoenteric syndrome 2, 614602 |
| SLC10A2 | 140.8 | 100% | 100% | Bile acid malabsorption, primary, 613291 |
| SLC11A2 | 88.8 | 99% | 97% | Anemia hypochromic microcytic |
| SLC12A1 | 142.0 | 100% | 100% | Bartter syndrome, type 1, 601678 |
| SLC12A3 | 85.6 | 99% | 97% | Gitelman syndrome, 263800 |
| SLC12A6 | 99.5 | 100% | 99% | Agenesis of the corpus callosum with peripheral neuropathy, 218000 -3 |
| SLC16A1 | 139.9 | 100% | 99% | Erythrocyte lactate transporter defect, 245340 Hyperinsulinemic hypoglycemia, familial, 7, 610021 |
| SLC16A12 | 110.4 | 99% | 95% | Cataract, juvenile, with microcornea and glucosuria, 612018 |
| SLC16A2 | 50.4 | 99% | 92% | Allan-Herndon-Dudley syndrome, 300523 |

| | | | | |
|----------|-------|------|------|---|
| SLC17A5 | 100.9 | 100% | 99% | Salla disease, 604369 Sialic acid storage disorder, infantile, 269920 |
| SLC17A8 | 124.0 | 100% | 100% | Deafness, autosomal dominant 25, 605583 |
| SLC19A2 | 94.7 | 100% | 100% | Thiamine-responsive megaloblastic anemia syndrome, 249270 |
| SLC19A3 | 110.7 | 100% | 100% | Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 |
| SLC1A3 | 113.7 | 100% | 100% | Episodic ataxia, type 6, 612656 |
| SLC20A2 | 88.3 | 99% | 96% | Basal ganglia calcification, idiopathic, 3, 614540 |
| SLC22A12 | 85.5 | 97% | 92% | Hypouricemia, renal, 220150 |
| SLC22A18 | 96.4 | 100% | 99% | Breast cancer somatic |
| SLC22A5 | 123.3 | 100% | 99% | Carnitine deficiency, systemic primary, 212140 |
| SLC24A1 | 143.1 | 100% | 98% | Night blindness, congenital stationary (complete), 1D, autosomal recessive, 613830 |
| SLC24A5 | 117.8 | 100% | 96% | [Skin/hair/eye pigmentation 4, fair/dark skin], 113750 Albinism, oculocutaneous, type VI, 113750 |
| SLC25A1 | 73.0 | 89% | 82% | No OMIM phenotype |
| SLC25A12 | 111.6 | 100% | 100% | Hypomyelination, global cerebral, 612949 |
| SLC25A13 | 99.0 | 100% | 99% | Citrullinemia, adult-onset type II, 603471 Citrullinemia, type II, neonatal-onset, 605814 |
| SLC25A15 | 100.6 | 88% | 83% | Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 -3 |
| SLC25A19 | 79.7 | 100% | 97% | Microcephaly, Amish type, 607196 Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 |
| SLC25A20 | 75.1 | 100% | 100% | Carnitine-acylcarnitine translocase deficiency, 212138 |
| SLC25A22 | 75.4 | 100% | 92% | Epileptic encephalopathy, early infantile, 3, 609304 |
| SLC25A3 | 95.1 | 100% | 100% | Mitochondrial phosphate carrier deficiency, 610773 |
| SLC25A38 | 74.4 | 100% | 96% | Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 |
| SLC25A4 | 117.8 | 100% | 98% | Progressive external ophthalmoplegia with mitochondrial DNA deletions 3, 609283 Mitochondrial DNA depletion syndrome 12 (cardiomyopathic type), 615418 |

| | | | | |
|----------|-------|------|------|---|
| SLC26A2 | 137.6 | 100% | 100% | Diastrophic dysplasia, 222600 Atelosteogenesis II, 256050 Achondrogenesis Ib, 600972 Epiphyseal dysplasia, multiple, 4, 226900 Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 De la Chapelle dysplasia, 256050 |
| SLC26A3 | 113.4 | 100% | 98% | ?Colon cancer (1) Chloride diarrhea, congenital, Finnish type, 214700 |
| SLC26A4 | 95.4 | 99% | 95% | Pendred syndrome, 274600 Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 |
| SLC26A5 | 93.4 | 100% | 99% | Deafness, autosomal recessive 61, 613865 |
| SLC26A8 | 106.9 | 100% | 97% | Spermatogenic failure 3, 606766 |
| SLC27A4 | 78.2 | 89% | 86% | Ichthyosis prematurity syndrome, 608649 |
| SLC29A3 | 143.7 | 100% | 99% | Histiocytosis-lymphadenopathy plus syndrome, 602782 |
| SLC2A1 | 94.3 | 100% | 100% | GLUT1 deficiency syndrome 1, 606777 GLUT1 deficiency syndrome 2, 612126 {Epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 Dystonia 9, 601042 |
| SLC2A10 | 88.5 | 99% | 98% | Arterial tortuosity syndrome, 208050 |
| SLC2A2 | 125.4 | 100% | 100% | {Diabetes mellitus, noninsulin-dependent} Fanconi-Bickel syndrome, 227810 |
| SLC2A9 | 67.1 | 100% | 94% | {Uric acid concentration, serum, QTL 2}, 612076 Hypouricemia, renal, 2, 612076 |
| SLC30A10 | 133.4 | 100% | 100% | Hypermanganesemia with dystonia, polycythemia, and cirrhosis, 613280 |
| SLC30A2 | 85.8 | 100% | 97% | Zinc deficiency, transient neonatal, 608118 |
| SLC33A1 | 107.9 | 100% | 100% | Spastic paraplegia 42, autosomal dominant, 612539 Congenital cataracts, hearing loss, and neurodegeneration, 614482 |
| SLC34A1 | 84.3 | 99% | 96% | Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 Fanconi renotubular syndrome 2, 613388 |
| SLC34A2 | 129.4 | 100% | 100% | Pulmonary alveolar microlithiasis, 265100 ?Testicular microlithiasis, 610441 |
| SLC34A3 | 74.0 | 98% | 90% | Hypophosphatemic rickets with hypercalciuria, 241530 |
| SLC35A1 | 117.6 | 100% | 100% | Congenital disorder of glycosylation, type IIf, 603585 |
| SLC35A2 | 57.1 | 97% | 96% | Congenital disorder of glycosylation, type IIm, 300896 |
| SLC35C1 | 97.8 | 100% | 100% | Congenital disorder of glycosylation, type IIc, 266265 |

| | | | | |
|----------|-------|------|------|--|
| SLC35D1 | 111.7 | 100% | 100% | Schneckenbecken dysplasia, 269250 |
| SLC36A2 | 126.6 | 100% | 100% | Iminoglycinuria, digenic, 242600 Hyperglycinuria, 138500 |
| SLC37A4 | 86.8 | 99% | 97% | Glycogen storage disease Ib, 232220 Glycogen storage disease Ic, 232240 |
| SLC38A8 | 65.5 | 98% | 86% | Foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis, 609218 (3) |
| SLC39A13 | 104.4 | 100% | 98% | Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 |
| SLC39A4 | 65.8 | 100% | 98% | Acrodermatitis enteropathica, 201100 |
| SLC3A1 | 134.0 | 100% | 100% | Cystinuria, 220100 |
| SLC40A1 | 117.9 | 99% | 97% | Hemochromatosis, type 4, 606069 |
| SLC45A2 | 99.4 | 100% | 92% | Albinism, oculocutaneous, type IV, 606574 [Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 [Skin/hair/eye pigmentation 5, dark/fair skin], 227240 [Skin/hair/eye pigmentation 5, dark/light eyes], 227240 |
| SLC46A1 | 79.2 | 100% | 98% | Folate malabsorption, hereditary, 229050 |
| SLC4A1 | 91.9 | 99% | 96% | Ovalocytosis Spherocytosis, type 4, 612653 [Malaria, resistance to], 611162 Renal tubular acidosis, distal, AD, 179800 Renal tubular acidosis, distal, AR, 611590 [Blood group, Diego], 110500 [Blood group, Waldner], 112010 [Bloo |
| SLC4A11 | 110.0 | 99% | 98% | Corneal endothelial dystrophy 2, autosomal recessive, 217700 Corneal endothelial dystrophy and perceptive deafness, 217400 Corneal dystrophy, Fuchs endothelial, 4, 613268 |
| SLC4A4 | 110.4 | 100% | 100% | Renal tubular acidosis, proximal, with ocular abnormalities, 604278 |
| SLC52A1 | 132.0 | 100% | 100% | Riboflavin deficiency, 615026 |
| SLC52A2 | 116.3 | 100% | 100% | Brown-Vialetto-Van Laere syndrome 2, 614707 |
| SLC52A3 | 69.1 | 100% | 95% | Brown-Vialetto-Van Laere syndrome 1, 211530 Fazio-Londe disease, 211500 |
| SLC5A1 | 106.2 | 100% | 99% | Glucose/galactose malabsorption, 606824 |
| SLC5A2 | 81.4 | 98% | 95% | Renal glucosuria, 233100 |
| SLC5A5 | 58.1 | 99% | 92% | Thyroid dyshormonogenesis 1, 274400 |
| SLC5A7 | 109.8 | 100% | 100% | Neuronopathy, distal hereditary motor, type VIIA, 158580 |

| | | | | |
|----------|-------|------|------|---|
| SLC6A19 | 93.4 | 98% | 95% | Hartnup disorder, 234500 Iminoglycinuria, digenic, 242600 Hyperglycinuria, 138500 |
| SLC6A2 | 174.3 | 100% | 100% | Orthostatic intolerance |
| SLC6A20 | 93.8 | 92% | 89% | Hyperglycinuria, 138500 Iminoglycinuria, digenic, 242600 |
| SLC6A3 | 77.2 | 100% | 100% | {Nicotine dependence, protection against}, 188890 Parkinsonism-dystonia, infantile, 613135 |
| SLC6A5 | 107.1 | 100% | 99% | Hyperekplexia 3, 614618 |
| SLC6A8 | 4.4 | 13% | 5% | Cerebral creatine deficiency syndrome 1, 300352 |
| SLC7A14 | 142.2 | 100% | 99% | Retinitis pigmentosa 68, 615725 (3) |
| SLC7A7 | 90.3 | 100% | 100% | Lysinuric protein intolerance, 222700 |
| SLC7A9 | 69.4 | 100% | 96% | Cystinuria, 220100 |
| SLC9A3R1 | 101.2 | 100% | 95% | Nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 |
| SLC9A6 | 62.5 | 98% | 91% | Mental retardation, X-linked syndromic, Christianson type, 300243 |
| SLCO1B1 | 113.3 | 100% | 99% | Hyperbilirubinemia, Rotor type, digenic, 237450 |
| SLCO1B3 | 121.6 | 100% | 97% | Hyperbilirubinemia, Rotor type, digenic, 237450 |
| SLCO2A1 | 70.3 | 100% | 98% | Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 |
| SLTRK1 | 133.1 | 100% | 100% | Tourette syndrome, 137580 Trichotillomania, 613229 |
| SLTRK6 | 162.2 | 100% | 100% | Deafness and myopia, 221200 |
| SLURP1 | 38.7 | 96% | 75% | Meleda disease, 248300 |
| SLX4 | 134.1 | 99% | 94% | Fanconi anemia, complementation group P, 613951 |
| SMAD3 | 76.6 | 100% | 90% | Loeys-Dietz syndrome, type 3, 613795 |
| SMAD4 | 134.5 | 100% | 99% | Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome |
| SMAD6 | 78.5 | 95% | 67% | Aortic valve disease 2, 614823 |
| SMAD9 | 116.7 | 100% | 100% | Pulmonary hypertension primary 2 |
| SMARCA2 | 89.6 | 97% | 94% | Nicolaides-Baraitser syndrome, 601358 |
| SMARCA4 | 82.7 | 97% | 92% | Rhabdoid tumor predisposition syndrome 2, 613325 Mental retardation, autosomal dominant 16, 614609 |
| SMARCAD1 | 126.6 | 100% | 100% | Adermatoglyphia, 136000 |
| SMARCAL1 | 121.3 | 99% | 96% | Schimke immunoosseous dysplasia, 242900 |

| | | | | |
|----------|-------|------|------|--|
| SMARCB1 | 126.2 | 100% | 100% | Rhabdoid tumors, somatic, 609322 Rhabdoid predisposition syndrome 1, 609322 Mental retardation, autosomal dominant 15, 614608 |
| SMC1A | 70.7 | 97% | 88% | Cornelia de Lange syndrome 2 |
| SMC3 | 116.6 | 99% | 98% | Cornelia de Lange syndrome 3 |
| SMCHD1 | 116.4 | 100% | 99% | Fascioscapulohumeral muscular dystrophy 2, digenic, 158901 |
| SMN1 | 2.2 | 10% | % | Spinal muscular atrophy-1, 253300 Spinal muscular atrophy-2, 253550 Spinal muscular atrophy-3, 253400 Spinal muscular atrophy-4, 271150 |
| SMO | 98.4 | 100% | 97% | Basal cell carcinoma |
| SMOC1 | 80.6 | 100% | 96% | Microphthalmia with limb anomalies, 206920 |
| SMOC2 | 79.2 | 99% | 86% | Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 |
| SMPD1 | 109.7 | 99% | 91% | Niemann-Pick disease, type A, 257200 Niemann-Pick disease, type B, 607616 |
| SMPX | 61.5 | 100% | 89% | Deafness, X-linked 4, 300066 |
| SMS | 12.7 | 54% | 29% | Mental retardation, X-linked, Snyder-Robinson type, 309583 |
| SNAI2 | 84.3 | 100% | 100% | Waardenburg syndrome, type 2D, 608890 Piebaldism, 172800 |
| SNAP29 | 128.5 | 100% | 100% | Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 |
| SNCA | 113.6 | 100% | 100% | Parkinson disease 4, 605543 Dementia, Lewy body, 127750 Parkinson disease 1, 168601 |
| SNCB | 65.4 | 100% | 100% | Dementia, Lewy body, 127750 |
| SNIP1 | 142.4 | 100% | 99% | Psychomotor retardation, epilepsy, and craniofacial dysmorphism, 614501 |
| SNRNP200 | 112.4 | 100% | 98% | Retinitis pigmentosa 33, 610359 |
| SNRPE | 56.2 | 79% | 77% | Hypotrichosis 11, 615059 |
| SNRPN | 80.7 | 100% | 80% | Prader-Willi syndrome, 176270 |
| SNTA1 | 57.7 | 95% | 84% | Long QT syndrome 12 |
| SNX10 | 108.0 | 100% | 100% | Osteopetrosis, autosomal recessive 8, 615085 |
| SOBP | 118.7 | 100% | 94% | Mental retardation, anterior maxillary protrusion, and strabismus, 613671 |
| SOD1 | 100.5 | 100% | 100% | Amyotrophic lateral sclerosis 1, 105400 |
| SOS1 | 122.2 | 100% | 100% | Fibromatosis, gingival, 135300 Noonan syndrome 4, 610733 |

| | | | | |
|---------|-------|------|------|---|
| SOST | 120.9 | 100% | 100% | Sclerosteosis, 269500 Van Buchem disease, 239100 Craniodiaphyseal dysplasia, autosomal dominant, 122860 |
| SOX10 | 85.0 | 100% | 100% | Waardenburg syndrome, type 4C, 613266 Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584 PCWH syndrome, 609136 |
| SOX17 | 74.3 | 100% | 100% | Vesicoureteral reflux 3, 613674 |
| SOX18 | 26.0 | 84% | 55% | Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 |
| SOX2 | 129.8 | 100% | 100% | Microphthalmia, syndromic 3, 206900 Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 |
| SOX3 | 49.4 | 91% | 84% | Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 Panhypopituitarism, X-linked, 312000 |
| SOX9 | 115.5 | 100% | 100% | Campomelic dysplasia with autosomal sex reversal, 114290 Acampomelic campomelic dysplasia, 114290 Campomelic dysplasia, 114290 |
| SP110 | 93.7 | 100% | 100% | Hepatic venoocclusive disease with immunodeficiency, 235550 {Mycobacterium tuberculosis, susceptibility to}, 607948 |
| SP7 | 75.5 | 100% | 100% | Osteogenesis imperfecta, type XII, 613849 |
| SPAG1 | 118.3 | 99% | 97% | Ciliary dyskinesia, primary, 28, 615505 |
| SPAST | 113.7 | 100% | 100% | Spastic paraplegia 4, autosomal dominant, 182601 |
| SPATA16 | 127.9 | 98% | 95% | Spermatogenic failure 6, 102530 |
| SPATA7 | 132.6 | 100% | 100% | Leber congenital amaurosis 3, 604232 Retinitis pigmentosa, juvenile, autosomal recessive, 604232 |
| SPECC1L | 120.2 | 100% | 98% | Facial clefting, oblique, 1, 600251 |
| SPG11 | 109.6 | 100% | 99% | Spastic paraplegia 11, autosomal recessive, 604360 |
| SPG20 | 111.5 | 100% | 100% | Troyer syndrome, 275900 |
| SPG21 | 110.6 | 100% | 100% | Mast syndrome |
| SPG7 | 83.8 | 97% | 87% | Spastic paraplegia 7 autosomal recessive |
| SPINK1 | 124.5 | 100% | 89% | Pancreatitis, hereditary, 167800 {Fibrocalculus pancreatic diabetes, susceptibility to}, 608189 Tropical calcific pancreatitis, 608189 |
| SPINK5 | 99.5 | 100% | 97% | Netherton syndrome, 256500 Atopy, 147050 |
| SPINT2 | 55.8 | 90% | 59% | Diarrhea 3, secretory sodium, congenital, syndromic, 270420 |

| | | | | |
|---------|-------|------|------|--|
| SPR | 67.2 | 100% | 99% | Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 |
| SPRED1 | 135.9 | 100% | 100% | Legius syndrome, 611431 |
| SPRY4 | 93.6 | 100% | 100% | Hypogonadotropic hypogonadism 17 with or without anosmia, 615266 |
| SPTA1 | 102.8 | 99% | 98% | Elliptocytosis-2, 130600 Pyropoikilocytosis, 266140 Spherocytosis, type 3, 270970 |
| SPTAN1 | 97.8 | 100% | 98% | Epileptic encephalopathy, early infantile, 5, 613477 |
| SPTB | 105.0 | 100% | 99% | Elliptocytosis-3 Spherocytosis, type 2 Anemia, neonatal hemolytic, fatal and near-fatal |
| SPTBN2 | 94.6 | 99% | 97% | Spinocerebellar ataxia 5, 600224 Spinocerebellar ataxia, autosomal recessive 14, 615386 |
| SPTLC1 | 79.2 | 95% | 90% | Neuropathy, hereditary sensory and autonomic, type IA, 162400 |
| SPTLC2 | 110.0 | 100% | 100% | Neuropathy, hereditary sensory and autonomic, type IC, 613640 |
| SQSTM1 | 93.6 | 100% | 98% | Paget disease of bone, 602080 |
| SRC | 80.1 | 94% | 85% | ?Colon cancer, advanced |
| SRCAP | 134.9 | 100% | 99% | Floating-Harbor syndrome, 136140 |
| SRD5A2 | 66.8 | 100% | 100% | Pseudovaginal perineoscrotal hypospadias, 264600 |
| SRD5A3 | 130.2 | 100% | 100% | Congenital disorder of glycosylation, type Ig, 612379 Kahrizi syndrome, 612713 |
| SRP72 | 91.6 | 99% | 97% | Bone marrow failure, familial, 614675 |
| SRPX2 | 46.7 | 97% | 82% | Rolandic epilepsy, mental retardation, and speech dyspraxia, 300643 -3 |
| SRY | 73.5 | 98% | 98% | 46XY sex reversal 1, 400044 46XX sex reversal 1, 400045 |
| SSTR5 | 98.3 | 99% | 91% | Somatostatin analog, resistance to, 102200 |
| ST14 | 89.2 | 99% | 94% | Ichthyosis with hypotrichosis, 610765 |
| ST3GAL3 | 114.0 | 100% | 100% | Mental retardation, autosomal recessive 12, 611090 Epileptic encephalopathy, early infantile, 15, 615006 |
| ST3GAL5 | 103.7 | 93% | 93% | Amish infantile epilepsy syndrome |
| STAC3 | 105.3 | 100% | 100% | Native American myopathy, 255995 (3) |
| STAMBP | 121.9 | 100% | 100% | Microcephaly-capillary malformation syndrome, 614261 |
| STAR | 100.6 | 100% | 100% | Lipoid adrenal hyperplasia, 201710 |
| STAT1 | 89.5 | 100% | 99% | Mycobacterial infection, atypical, familial disseminated, 209950 Mycobacterial and viral infections, susceptibility to, autosomal recessive, 613796 Candidiasis, familial, 7, 614162 |

| | | | | |
|--------|-------|------|------|--|
| STAT3 | 84.3 | 98% | 93% | Hyper-IgE recurrent infection syndrome, 147060 |
| STAT5B | 73.1 | 84% | 74% | Leukemia, acute promyelocytic, STAT5B/RARA type Growth hormone insensitivity with immunodeficiency, 245590 |
| STIL | 154.8 | 100% | 100% | Microcephaly 7, primary, autosomal recessive, 612703 |
| STIM1 | 80.5 | 93% | 90% | Immunodeficiency 10, 612783 Myopathy, tubular aggregate, 160565 |
| STK11 | 77.8 | 100% | 90% | Peutz-Jeghers syndrome, 175200 Melanoma, malignant, somatic Pancreatic cancer, 260350 Testicular tumor, somatic, 273300 |
| STK4 | 98.4 | 100% | 100% | T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 |
| STOX1 | 138.2 | 90% | 89% | Preeclampsia/eclampsia 4, 609404 |
| STRA6 | 73.8 | 100% | 96% | Microphthalmia, syndromic 9, 601186 Microphthalmia, isolated, with coloboma 8, 601186 |
| STRADA | 78.4 | 100% | 95% | Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 |
| STRC | 11.6 | 17% | 15% | Deafness, autosomal recessive 16, 603720 |
| STS | 69.1 | 98% | 92% | nonlyonizing Ichthyosis, X-linked, 308100 |
| STX11 | 173.6 | 100% | 100% | Hemophagocytic lymphohistiocytosis, familial, 4, 603552 |
| STX16 | 120.5 | 100% | 100% | Pseudohypoparathyroidism, type IB, 603233 |
| STXBP1 | 91.8 | 100% | 100% | Epileptic encephalopathy, early infantile, 4, 612164 (2) |
| STXBP2 | 81.3 | 100% | 96% | Hemophagocytic lymphohistiocytosis, familial, 5, 613101 |
| SUCLA2 | 81.6 | 94% | 91% | Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 |
| SUCLG1 | 94.7 | 95% | 91% | Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 |
| SUFU | 82.2 | 96% | 84% | Medulloblastoma, desmoplastic, 155255 {Meningioma, familial, susceptibility to}, 607174 |
| SUMF1 | 69.1 | 100% | 95% | Multiple sulfatase deficiency, 272200 |
| SUMO1 | 29.3 | 71% | 66% | Orofacial cleft 10, 613705 |
| SUOX | 172.0 | 100% | 100% | Sulfite oxidase deficiency, 272300 |
| SURF1 | 91.8 | 88% | 88% | Leigh syndrome, due to COX deficiency, 256000 |
| SYCP3 | 129.9 | 100% | 100% | Spermatogenic failure 4, 270960 {Pregnancy loss, susceptibility to} |
| SYN1 | 33.0 | 69% | 52% | Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 |

| | | | | |
|---------|-------|------|------|--|
| SYNE1 | 110.6 | 99% | 97% | Spinocerebellar ataxia, autosomal recessive 8, 610743 Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998 |
| SYNE2 | 108.7 | 100% | 98% | Emery-Dreifuss muscular dystrophy 5, autosomal dominant, 612999 |
| SYNE4 | 81.5 | 100% | 100% | Deafness, autosomal recessive 76, 615540 (3) |
| SYNGAP1 | 53.6 | 92% | 77% | Mental retardation, autosomal dominant 5, 612621 |
| SYNJ1 | 102.8 | 100% | 97% | Parkinson disease 20, early-onset, 615530 |
| SYP | 50.2 | 99% | 92% | Mental retardation, X-linked 96, 300802 |
| SYT14 | 135.6 | 94% | 94% | Spinocerebellar ataxia, autosomal recessive 11, 614229 |
| SZT2 | 100.9 | 99% | 95% | Epileptic encephalopathy, early infantile, 18, 615476 |
| T | 117.6 | 98% | 96% | {Neural tube defects, susceptibility to}, 182940 |
| TAB2 | 157.6 | 100% | 100% | Congenital heart defects, nonsyndromic, 2, 614980 |
| TAC3 | 74.8 | 100% | 100% | Hypogonadotropic hypogonadism 10 with or without anosmia, 614839 |
| TACR3 | 140.8 | 100% | 100% | Hypogonadotropic hypogonadism 11 with or without anosmia, 614840 |
| TACSTD2 | 182.1 | 100% | 97% | Corneal dystrophy, gelatinous drop-like, 204870 |
| TAF1 | 74.4 | 100% | 99% | SVA retrotransposon insertion Dystonia-Parkinsonism, X-linked, 314250 |
| TAF2 | 106.2 | 100% | 100% | Mental retardation, autosomal recessive 40 |
| TAL1 | 36.1 | 93% | 81% | Leukemia-1, T-cell acute lymphocytic |
| TAL2 | 168.8 | 100% | 100% | Leukemia-2, T-cell acute lymphoblastic |
| TALDO1 | 91.9 | 100% | 100% | Transaldolase deficiency, 606003 |
| TAP1 | 13.6 | 56% | 21% | Bare lymphocyte syndrome, type I, 604571 |
| TAP2 | 9.8 | 27% | 17% | Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 Wegener-like granulomatosis |
| TAPBP | 21.6 | 69% | 42% | Bare lymphocyte syndrome, type I, 604571 |
| TARDBP | 27.1 | 40% | 33% | Amyotrophic lateral sclerosis 10, with or without FTD, 612069 Frontotemporal lobar degeneration, TARDBP-related, 612069 |
| TAT | 100.6 | 100% | 100% | Tyrosinemia, type II, 276600 |
| TAZ | 50.6 | 100% | 98% | Barth syndrome, 302060 |
| TBC1D20 | 83.8 | 94% | 91% | Warburg micro syndrome 4, 615663 |
| TBC1D24 | 107.1 | 100% | 100% | Myoclonic epilepsy, infantile, familial, 605021 Epileptic encephalopathy, early infantile, 16, 615338 |
| TBCE | 118.9 | 100% | 100% | Kenny-Caffey syndrome-1, 244460 Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 |
| TBP | 97.5 | 100% | 99% | Spinocerebellar ataxia 17, 607136 {Parkinson disease, susceptibility to}, 168600 |

| | | | | |
|--------|-------|------|------|--|
| TBX1 | 64.9 | 77% | 72% | Conotruncal anomaly face syndrome, 217095 DiGeorge syndrome, 188400 Velocardiofacial syndrome, 192430 Tetralogy of Fallot, 187500 |
| TBX15 | 82.4 | 100% | 96% | Cousin syndrome, 260660 |
| TBX19 | 133.2 | 100% | 99% | Adrenocorticotrophic hormone deficiency, 201400 |
| TBX20 | 47.4 | 72% | 66% | Atrial septal defect 4, 611363 |
| TBX21 | 109.7 | 88% | 84% | {Asthma, aspirin-induced, susceptibility to}, 208550 Asthma and nasal polyps, 208550 |
| TBX22 | 83.1 | 96% | 93% | Cleft palate with ankyloglossia, 303400 ?Abruzzo-Erickson syndrome, 302905 |
| TBX3 | 78.5 | 100% | 95% | Ulnar-mammary syndrome, 181450 |
| TBX4 | 115.7 | 95% | 90% | Small patella syndrome, 147891 |
| TBX5 | 86.6 | 99% | 97% | Holt-Oram syndrome, 142900 |
| TBXAS1 | 99.9 | 100% | 99% | Ghosal hematodiaphyseal syndrome, 231095 ?Thromboxane synthase deficiency, 614158 (1) |
| TCAP | 38.8 | 68% | 48% | Muscular dystrophy, limb-girdle, type 2G, 601954 Cardiomyopathy, dilated, 1N, 607487 |
| TCF12 | 114.0 | 100% | 100% | Craniosynostosis 3, 615314 |
| TCF4 | 99.0 | 97% | 97% | Pitt-Hopkins syndrome, 610954 |
| TCIRG1 | 78.3 | 95% | 85% | Osteopetrosis, autosomal recessive 1, 259700 |
| TCN2 | 103.4 | 100% | 97% | Transcobalamin II deficiency, 275350 |
| TCOF1 | 95.5 | 99% | 96% | Treacher Collins syndrome 1, 154500 |
| TCTN1 | 103.9 | 96% | 94% | Joubert syndrome 13 |
| TCTN2 | 91.8 | 100% | 98% | Meckel syndrome 8, 613885 |
| TCTN3 | 103.8 | 100% | 99% | Orofaciodigital syndrome IV, 258860 Joubert syndrome 18, 614815 |
| TDGF1 | 79.9 | 100% | 99% | Forebrain defects |
| TDP1 | 111.6 | 100% | 100% | Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 |
| TDRD7 | 116.4 | 100% | 100% | Cataract 36, 613887 |
| TEAD1 | 88.6 | 100% | 99% | Sveinsson choreoretinal atrophy, 108985 |
| TECPR2 | 113.1 | 100% | 99% | Spastic paraplegia 49, autosomal recessive, 615031 |
| TECR | 81.1 | 100% | 89% | Mental retardation, autosomal recessive 14, 614020 |
| TECTA | 122.4 | 99% | 98% | Deafness, autosomal dominant 8/12, 601543 Deafness, autosomal recessive 21, 603629 |

| | | | | |
|--------|-------|------|------|--|
| TEK | 112.0 | 100% | 99% | Venous malformations, multiple cutaneous and mucosal, 600195 |
| TENM3 | 131.3 | 100% | 99% | Microphthalmia isolated with coloboma 9 |
| TET2 | 128.8 | 100% | 99% | Myelodysplastic syndrome, somatic, 614286 |
| TEX28 | .3 | % | % | No OMIM phenotype Mental retardation, x-linked 99 Blue cone monochromacy Achromatopsia Colorblindness |
| TF | 94.1 | 98% | 97% | Atransferrinemia, 209300 |
| TFAP2A | 72.6 | 95% | 88% | Branchiooculofacial syndrome, 113620 |
| TFAP2B | 106.2 | 100% | 100% | Char syndrome, 169100 |
| TFE3 | 36.7 | 91% | 74% | Renal cell carcinoma, papillary, 1, 300854 |
| TFG | 108.2 | 100% | 97% | Hereditary motor and sensory neuropathy, proximal type, 604484 Chondrosarcoma, extraskeletal myxoid, 612237 (1) |
| TFR2 | 75.0 | 98% | 94% | Hemochromatosis, type 3, 604250 |
| TG | 103.6 | 100% | 98% | Thyroid dyshormonogenesis 3, 274700 {Autoimmune thyroid disease, susceptibility to, 3}, 608175 |
| TGFB1 | 55.3 | 99% | 84% | Camurati-Engelmann disease, 131300 {Cystic fibrosis lung disease, modifier of}, 219700 |
| TGFB2 | 129.5 | 100% | 98% | Loeys-Dietz syndrome, type 4, 614816 |
| TGFB3 | 105.4 | 100% | 100% | Arrhythmogenic right ventricular dysplasia 1, 107970 |
| TGFBI | 106.6 | 100% | 100% | Corneal dystrophy, Groenouw type I, 121900 Corneal dystrophy, lattice type I, 122200 Corneal dystrophy, Reis-Bucklers type, 608470 Corneal dystrophy, Avellino type, 607541 Corneal dystrophy, lattice type IIIA, 608471 Corneal dystrophy, |
| TGFBR1 | 128.4 | 99% | 94% | Loeys-Dietz syndrome, type 1A, 609192 Loeys-Dietz syndrome, type 2A, 608967 {Multiple self-healing squamous epithelioma, susceptibility to}, 132800 |
| TGFBR2 | 86.4 | 100% | 100% | Colorectal cancer, hereditary nonpolyposis, type 6, 614331 Esophageal cancer, somatic, 133239 Loeys-Dietz syndrome, type 1B, 610168 Loeys-Dietz syndrome, type 2B, 610380 |
| TGIF1 | 192.6 | 99% | 99% | Holoprosencephaly-4 |
| TGM1 | 104.6 | 100% | 95% | Ichthyosis, congenital, autosomal recessive 1, 242300 |
| TGM5 | 98.5 | 100% | 100% | Peeling skin syndrome, acral type, 609796 |

| | | | | |
|----------|-------|------|------|--|
| TGM6 | 65.1 | 91% | 86% | Spinocerebellar ataxia 35, 613908 |
| TH | 77.8 | 96% | 83% | Segawa syndrome, recessive, 605407 |
| THAP1 | 127.9 | 100% | 100% | Dystonia 6, torsion, 602629 |
| THBD | 75.2 | 100% | 100% | Thrombophilia due to thrombomodulin defect, 614486 {Hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 |
| THOC6 | 155.1 | 100% | 98% | Beaulieu-Boycott-Innes syndrome, 613680 |
| THPO | 101.5 | 98% | 89% | Thrombocythemia 1, 187950 |
| THRA | 121.6 | 100% | 100% | Hypothyroidism, congenital, nongoitrous, 6, 614450 |
| THRΒ | 117.9 | 100% | 100% | Thyroid hormone resistance, 188570 Thyroid hormone resistance, autosomal recessive, 274300 Thyroid hormone resistance, selective pituitary, 145650 |
| TIA1 | 120.4 | 100% | 100% | Welander distal myopathy, 604454 |
| TIMM8A | 26.0 | 75% | 67% | Deafness, X-linked 1, progressive Mohr-Tranebjaerg syndrome, 304700 Jensen syndrome, 311150 |
| TIMP3 | 123.0 | 100% | 100% | Sorsby fundus dystrophy, 136900 |
| TINF2 | 182.1 | 100% | 100% | Dyskeratosis congenita, autosomal dominant 3, 613990 Revesz syndrome, 268130 |
| TJP2 | 86.5 | 100% | 97% | Hypercholanemia, familial, 607748 |
| TK2 | 89.7 | 100% | 100% | Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 |
| TLL1 | 113.2 | 100% | 100% | Atrial septal defect 6, 613087 |
| TLR4 | 148.4 | 100% | 99% | Endotoxin hyporesponsiveness {Macular degeneration, age-related, 10}, 611488 {Colorectal cancer, susceptibility to}, 114500 |
| TMC1 | 111.4 | 100% | 100% | Deafness, autosomal recessive 7, 600974 Deafness, autosomal dominant 36, 606705 |
| TMC6 | 58.3 | 100% | 93% | Epidermodysplasia verruciformis, 226400 |
| TMC8 | 79.4 | 100% | 98% | Epidermodysplasia verruciformis, 226400 |
| TMCO1 | 73.3 | 100% | 98% | Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 614132 |
| TMEM126A | 78.5 | 100% | 99% | Optic atrophy-7, 612989 |
| TMEM138 | 97.1 | 100% | 100% | Joubert syndrome 16, 614465 |
| TMEM165 | 92.6 | 100% | 100% | Congenital disorder of glycosylation, type IIk, 614727 |
| TMEM216 | 71.0 | 97% | 78% | Joubert syndrome 2, 608091 Meckel syndrome 2, 603194 |

| | | | | |
|-----------|-------|------|------|---|
| TMEM231 | 73.6 | 97% | 90% | Joubert syndrome 20, 614970 Meckel syndrome, type 11, 615397 -3 |
| TMEM237 | 101.8 | 100% | 94% | Joubert syndrome 14, 614424 |
| TMEM38B | 114.6 | 100% | 98% | Osteogenesis imperfecta, type XIV, 615066 |
| TMEM43 | 83.1 | 100% | 98% | Arrhythmogenic right ventricular dysplasia 5, 604400 Emery-Dreifuss muscular dystrophy 7, AD, 614302 |
| TMEM5 | 168.4 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 |
| TMEM67 | 115.6 | 100% | 99% | Meckel syndrome 3, 607361 Joubert syndrome 6, 610688 {Bardet-Biedl syndrome 14, modifier of}, 209900 COACH syndrome, 216360 Nephronophthisis 11, 613550 |
| TMEM70 | 210.6 | 100% | 100% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 |
| TMIE | 57.4 | 99% | 87% | Deafness, autosomal recessive 6, 600971 |
| TMLHE | 37.7 | 86% | 77% | Epsilon-trimethyllysine hydroxylase deficiency, 300872 |
| TPMRSS15 | 101.4 | 100% | 99% | Enterokinase deficiency |
| TPMRSS3 | 91.3 | 100% | 96% | Deafness, autosomal recessive 8/10, 601072 |
| TPMRSS6 | 72.9 | 96% | 92% | Iron-refractory iron deficiency anemia, 206200 |
| TNC | 130.3 | 100% | 99% | Deafness, autosomal dominant 56, 615629 |
| TNFRSF10B | 91.0 | 100% | 99% | Squamous cell carcinoma, head and neck, 275355 |
| TNFRSF11A | 101.8 | 96% | 94% | Osteolysis, familial expansile, 174810 Paget disease of bone, 602080 Osteopetrosis, autosomal recessive 7, 612301 |
| TNFRSF11B | 181.2 | 100% | 100% | Paget disease, juvenile, 239000 |
| TNFRSF13B | 60.5 | 100% | 92% | Immunoglobulin A deficiency 2, 609529 Immunodeficiency, common variable, 2, 240500 |
| TNFRSF13C | 51.2 | 100% | 73% | Immunodeficiency, common variable, 4, 613494 |
| TNFRSF1A | 69.3 | 94% | 91% | Periodic fever, familial, 142680 {Multiple sclerosis, susceptibility to, 5}, 614810 |

| | | | | |
|---------|-------|------|------|---|
| TNFSF11 | 145.1 | 100% | 100% | Osteopetrosis, autosomal recessive 2, 259710 |
| TNNC1 | 106.7 | 100% | 100% | Cardiomyopathy, dilated, 1Z, 611879 Cardiomyopathy, familial hypertrophic, 13, 613243 |
| TNNI2 | 76.2 | 100% | 98% | Arthrogryposis multiplex congenita, distal, type 2B, 601680 |
| TNNI3 | 77.4 | 100% | 92% | Cardiomyopathy, familial hypertrophic, 7, 613690 Cardiomyopathy, familial restrictive, 115210 Cardiomyopathy, dilated, 2A, 611880 Cardiomyopathy, dilated, 1FF, 613286 |
| TNNT1 | 89.7 | 96% | 93% | Nemaline myopathy 5, Amish type, 605355 |
| TNNT2 | 94.0 | 100% | 96% | Cardiomyopathy, familial hypertrophic, 2, 115195 Cardiomyopathy, dilated, 1D, 601494 Cardiomyopathy, familial restrictive, 3, 612422 Left ventricular noncompaction 6, 601494 |
| TNNT3 | 80.5 | 100% | 90% | Arthrogryposis, distal, type 2B, 601680 |
| TNXB | 7.6 | 25% | 9% | Ehlers-Danlos syndrome, autosomal recessive, due to tenascin X deficiency, 606408 Ehlers-Danlos syndrome, autosomal dominant, hypermobility type, 130020 |
| TOP1 | 104.5 | 100% | 96% | DNA topoisomerase I, camptothecin-resistant |
| TOP2A | 128.0 | 99% | 95% | DNA topoisomerase II, resistance to inhibition of, by amsacrine |
| TOPORS | 159.3 | 100% | 100% | Retinitis pigmentosa 31, 609923 |
| TP53 | 77.3 | 100% | 99% | Colorectal cancer, 114500 Li-Fraumeni syndrome, 151623 Hepatocellular carcinoma, 114550 Osteosarcoma, 259500 Choroid plexus papilloma, 260500 Nasopharyngeal carcinoma, 607107 Pancreatic cancer, 260350 Adrenal cortical carcinoma |
| TP63 | 128.7 | 100% | 100% | Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 Split-hand/foot malformation 4, 605289 Hay-Wells syndrome, 106260 ADULT syndrome, 103285 Limb-mammary syndrome, 603543 Rapp-Hodgkin syndrome, 129400 Orofac |
| TPI1 | 68.0 | 100% | 97% | Hemolytic anemia due to triosephosphate isomerase deficiency |

| | | | | |
|---------|-------|------|------|---|
| TPK1 | 80.1 | 100% | 100% | Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 |
| TPM1 | 85.7 | 100% | 97% | Cardiomyopathy, familial hypertrophic, 3, 115196 Cardiomyopathy, dilated, 1Y, 611878 Left ventricular noncompaction 9, 611878 |
| TPM2 | 99.8 | 100% | 100% | Arthrogryposis multiplex congenita, distal, type 1, 108120 Arthrogryposis, distal, type 2B, 601680 Nemaline myopathy 4, autosomal dominant, 609285 CAP myopathy 2, 609285 |
| TPM3 | 68.3 | 82% | 80% | Nemaline myopathy 1, autosomal dominant or recessive, 609284 CAP myopathy 1, 609284 Myopathy congenital, with fiber-type disproportion, 255310 |
| TPMT | 95.7 | 100% | 100% | 6-mercaptopurine sensitivity, 610460 |
| TPO | 78.6 | 98% | 95% | Thyroid dyshormonogenesis 2A, 274500 |
| TPP1 | 135.3 | 100% | 100% | Ceroid lipofuscinosis, neuronal, 2, 204500 |
| TPRN | 48.1 | 82% | 78% | Deafness, autosomal recessive 79, 613307 |
| TRAPP11 | 116.5 | 100% | 99% | Muscular dystrophy, limb-girdle, type 2S, 615356 |
| TRAPP2 | 29.9 | 75% | 49% | Spondyloepiphyseal dysplasia tarda, 313400 |
| TRAPP9 | 68.6 | 98% | 91% | Mental retardation, autosomal recessive 13, 613192 |
| TRDN | 80.2 | 100% | 94% | Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 |
| TREM2 | 100.0 | 100% | 100% | Nasu-Hakola disease, 221770 |
| TREX1 | 127.4 | 100% | 100% | Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 Chilblain lupus, 610448 Vasculopathy, retinal, with cerebral leukodystrophy, 192315 {Systemic lupus erythematosus, susceptibility to}, 152700 |
| TRHR | 150.4 | 100% | 100% | Thyrotropin-releasing hormone resistance, generalized |
| TRIM24 | 95.5 | 99% | 98% | Thyroid carcinoma, papillary, 188550 |
| TRIM32 | 106.2 | 100% | 100% | Muscular dystrophy, limb-girdle, type 2H, 254110 Bardet-Biedl syndrome 11, 209900 |
| TRIM33 | 97.8 | 97% | 88% | Thyroid carcinoma, papillary, 188550 |
| TRIM37 | 105.0 | 100% | 98% | Mulibrey nanism, 253250 |
| TRIOBP | 93.9 | 95% | 91% | Deafness, autosomal recessive 28, 609823 |
| TRIP11 | 132.1 | 99% | 98% | Achondrogenesis, type IA, 200600 |
| TRMU | 75.4 | 100% | 99% | {Deafness, mitochondrial, modifier of}, 580000 Liver failure, transient infantile, 613070 |

| | | | | |
|---------|-------|------|------|---|
| TRPA1 | 67.7 | 83% | 79% | Episodic pain syndrome, familial, 615040 |
| TRPC6 | 79.3 | 94% | 89% | Glomerulosclerosis, focal segmental, 2, 603965 |
| TRPM1 | 129.2 | 98% | 98% | Night blindness, congenital stationary (complete), 1C, autosomal recessive, 613216 |
| TRPM4 | 82.4 | 100% | 99% | Progressive familial heart block, type IB, 604559 |
| TRPM6 | 121.0 | 99% | 98% | Hypomagnesemia 1, intestinal, 602014 |
| TRPS1 | 136.2 | 100% | 100% | Trichorhinophalangeal syndrome, type I, 190350 Trichorhinophalangeal syndrome, type III, 190351 |
| TRPV3 | 99.3 | 99% | 94% | Olmsted syndrome, 614594 |
| TRPV4 | 93.1 | 100% | 99% | Brachyolmia type 3, 113500 Spondylometaphyseal dysplasia, Kozlowski type, 184252 Metatropic dysplasia, 156530 Hereditary motor and sensory neuropathy, type IIc, 606071 Scapuloperoneal spinal muscular atrophy, 181405 [Sodium serum level] |
| TSC1 | 95.7 | 99% | 97% | Otosclerosis 1 (2) |
| TSC1 | 95.7 | 99% | 97% | Tuberous sclerosis-1, 191100 Lymphangioleiomyomatosis, 606690 Focal cortical dysplasia, Taylor balloon cell type, 607341 |
| TSC2 | 85.9 | 99% | 95% | distal to PKD1 Tuberous sclerosis-2, 613254 Lymphangioleiomyomatosis, somatic, 606690 |
| TSEN2 | 121.3 | 100% | 100% | Pontocerebellar hypoplasia type 2B, 612389 |
| TSEN34 | 66.2 | 100% | 93% | Pontocerebellar hypoplasia type 2C, 612390 |
| TSEN54 | 105.5 | 98% | 96% | Pontocerebellar hypoplasia type 2A, 277470 Pontocerebellar hypoplasia type 4, 225753 |
| TSFM | 102.7 | 96% | 94% | Combined oxidative phosphorylation deficiency 3, 610505 |
| TSG101 | 107.3 | 100% | 100% | Breast cancer, somatic, 114480 |
| TSHB | 171.4 | 100% | 100% | Hypothyroidism, congenital, nongoitrous 4, 275100 |
| TSHR | 157.0 | 100% | 98% | Hypothyroidism, congenital, nongoitrous, 1 275200 Thyroid adenoma, hyperfunctioning, somatic Hyperthyroidism, nonautoimmune, 609152 Thyroid carcinoma with thyrotoxicosis Hyperthyroidism, familial gestational, 603373 |
| TSHZ1 | 124.1 | 99% | 98% | Aural atresia, congenital, 607842 |
| TSPAN12 | 117.9 | 100% | 100% | Exudative vitreoretinopathy 5, 613310 |
| TSPAN7 | 43.6 | 95% | 71% | Mental retardation, X-linked 58, 300210 |
| TSPEAR | 120.9 | 100% | 99% | Deafness, autosomal recessive 98, 614861 |

| | | | | |
|---------|-------|------|------|---|
| TSPYL1 | 191.4 | 100% | 100% | Sudden infant death with dysgenesis of the testes syndrome, 608800 -3 |
| TTBK2 | 131.5 | 100% | 100% | Spinocerebellar ataxia 11, 604432 |
| TTC19 | 72.4 | 87% | 77% | Mitochondrial complex III deficiency, nuclear type 2, 615157 |
| TTC21B | 112.5 | 99% | 98% | Nephronophthisis 12, 613820 Asphyxiating thoracic dystrophy 4, 613819 |
| TTC37 | 116.5 | 100% | 100% | Trichohepatoenteric syndrome 1, 222470 |
| TTC7A | 65.2 | 95% | 95% | Intestinal atresia, multiple, 243150 |
| TTC8 | 107.1 | 100% | 100% | Bardet-Biedl syndrome 8, 209900 Retinitis pigmentosa 51, 613464 |
| TTI2 | 112.9 | 100% | 100% | Mental retardation, autosomal recessive 39, 615541 |
| TTN | 149.1 | 98% | 97% | Cardiomyopathy, familial hypertrophic, 9, 613765 Cardiomyopathy, dilated, 1G, 604145 Tibial muscular dystrophy, tardive, 600334 Muscular dystrophy, limb-girdle, type 2J, 608807 Myopathy, proximal, with early respiratory muscle involvement, |
| TTPA | 94.5 | 98% | 92% | Ataxia with isolated vitamin E deficiency, 277460 |
| TTR | 87.4 | 100% | 99% | Amyloidosis, hereditary, transthyretin-related, 105210 [Dystransthyretinemic hyperthyroxinemia], 145680 Carpal tunnel syndrome, familial, 115430 |
| TUBA1A | 20.1 | 84% | 50% | Lissencephaly 3, 611603 |
| TUBA8 | 100.5 | 100% | 99% | Polymicrogyria with optic nerve hypoplasia, 613180 |
| TUBB1 | 142.2 | 100% | 100% | Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 |
| TUBB2A | 50.8 | 100% | 94% | Cortical dysplasia, complex, with other brain malformations 5, 615763 |
| TUBB2B | 54.4 | 98% | 92% | Polymicrogyria, symmetric or asymmetric, 610031 |
| TUBB3 | 80.2 | 81% | 79% | Fibrosis of extraocular muscles, congenital, 3A, 600638 Cortical dysplasia, complex, with other brain malformations 1, 614039 |
| TUBB4A | 62.8 | 85% | 72% | ?Dystonia 4, torsion, autosomal dominant, 128101 Leukodystrophy, hypomyelinating, 6, 612438 |
| TUBG1 | 109.0 | 83% | 81% | Cortical dysplasia, complex, with other brain malformations 4, 615412 |
| TUBGCP6 | 116.4 | 100% | 98% | Microcephaly and chorioretinopathy with or without mental retardation, 251270 |
| TUFM | 100.7 | 99% | 94% | Combined oxidative phosphorylation deficiency 4, 610678 |
| TULP1 | 84.8 | 100% | 93% | Retinitis pigmentosa 14, 600132 Leber congenital amaurosis 15, 613843 |
| TUSC3 | 126.6 | 100% | 99% | Mental retardation, autosomal recessive 7, 611093 |

| | | | | |
|---------|-------|------|------|---|
| TWIST1 | 99.1 | 100% | 99% | Saethre-Chotzen syndrome, 101400 Saethre-Chotzen syndrome with eyelid anomalies, 101400 Craniosynostosis, type 1, 123100 Robinow-Sorauf syndrome, 180750 |
| TWIST2 | 74.9 | 100% | 96% | Focal facial dermal dysplasia 3, Setleis type, 227260 |
| TYK2 | 84.3 | 99% | 95% | Tyrosine kinase 2 deficiency, 611521 |
| TYMP | 91.2 | 99% | 92% | Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 |
| TYR | 132.9 | 74% | 74% | Albinism, oculocutaneous, type IA, 203100 Waardenburg syndrome/albinism, digenic, 103470 Albinism, oculocutaneous, type IB, 606952 [Skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 {Melanoma, cutaneous malignant, susceptibi |
| TYROBP | 62.5 | 100% | 100% | Nasu-Hakola disease, 221770 |
| TYRP1 | 126.0 | 100% | 100% | Albinism, oculocutaneous, type III, 203290 Skin/hair/eye pigmentation, variation in, 11 (Melanesian blond hair), 612271 |
| UBA1 | 66.0 | 100% | 98% | Spinal muscular atrophy, X-linked 2, infantile, 301830 |
| UBE2A | 60.0 | 100% | 100% | Mental retardation, X-linked syndromic, Nascimento-type, 300860 |
| UBE3A | 102.8 | 99% | 99% | Angelman syndrome, 105830 |
| UBE3B | 107.4 | 99% | 98% | Blepharophimosis-ptosis-intellectual disability syndrome, 615057 -3 |
| UBIAD1 | 94.4 | 100% | 100% | Corneal dystrophy, Schnyder type, 121800 |
| UBQLN2 | 78.6 | 100% | 100% | Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 |
| UBR1 | 104.7 | 100% | 99% | Johanson-Blizzard syndrome, 243800 |
| UGT1A1 | 146.5 | 100% | 98% | Crigler-Najjar syndrome, type I, 218800 [Gilbert syndrome], 143500 Crigler-Najjar syndrome, type II, 606785 Hyperbilirubinemia, familial transient neonatal, 237900 [Bilirubin, serum level of, QTL1], 601816 |
| UMOD | 80.8 | 99% | 96% | Hyperuricemic nephropathy, familial juvenile 1, 162000 Medullary cystic kidney disease 2, 603860 Glomerulocystic kidney disease with hyperuricemia and isosthenuria, 609886 |
| UMPS | 111.2 | 100% | 100% | Orotic aciduria, 258900 |
| UNC13D | 151.8 | 100% | 100% | Hemophagocytic lymphohistiocytosis familial 3 |
| UNC93B1 | 41.3 | 55% | 54% | Herpes simplex encephalitis, susceptibility to, 1, 610551 |
| UNG | 77.5 | 94% | 92% | Immunodeficiency with hyper IgM, type 5, 608106 |

| | | | | |
|--------|-------|------|------|---|
| UPB1 | 110.4 | 100% | 100% | Beta-ureidopropionase deficiency, 613161 |
| UPF3B | 58.0 | 98% | 87% | Mental retardation, X-linked, syndromic 14, 300676 |
| UQCRCB | 114.1 | 100% | 100% | Mitochondrial complex III deficiency, nuclear type 3, 615158 |
| UQCRC2 | 88.5 | 97% | 94% | Mitochondrial complex III deficiency, nuclear type 5, 615160 |
| UQCRCQ | 63.3 | 100% | 99% | Mitochondrial complex III deficiency, nuclear type 4, 615159 |
| UROC1 | 73.3 | 98% | 83% | Urocanase deficiency, 276880 |
| UROD | 84.5 | 97% | 90% | Porphyria cutanea tarda, 176100 Porphyria, hepatoerythropoietic, 176100 |
| UROS | 71.7 | 99% | 89% | Porphyria, congenital erythropoietic, 263700 |
| USB1 | 59.4 | 93% | 88% | Poikiloderma with neutropenia |
| USH1C | 79.4 | 99% | 92% | Acadian and Samaritan variety Usher syndrome, type 1C, 276904 Deafness, autosomal recessive 18A, 602092 |
| USH1G | 98.7 | 95% | 88% | Usher syndrome type 1G |
| USH2A | 116.3 | 100% | 99% | Usher syndrome, type 2A, 276901 Retinitis pigmentosa 39, 613809 -3 |
| USP9Y | 66.9 | 99% | 95% | Spermatogenic failure, Y-linked, 2, 415000 |
| UVSSA | 66.7 | 100% | 96% | UV-sensitive syndrome 3, 614640 |
| VANGL1 | 145.3 | 100% | 100% | Caudal regression syndrome, 600145 Neural tube defects, 182940 -3 |
| VANGL2 | 103.4 | 100% | 95% | Neural tube defects, 182940 |
| VAPB | 153.5 | 100% | 93% | Amyotrophic lateral sclerosis 8, 608627 Spinal muscular atrophy, late-onset, Finkel type, 182980 |
| VAX1 | 79.7 | 100% | 92% | Microphthalmia, syndromic 11, 614402 |
| VCAN | 146.6 | 100% | 100% | Wagner syndrome 1, 143200 |
| VCL | 101.2 | 96% | 92% | Cardiomyopathy, dilated, 1W, 611407 Cardiomyopathy, familial hypertrophic, 15, 613255 |
| VCP | 111.2 | 99% | 96% | Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320 Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, 613954 |
| VDR | 87.1 | 100% | 100% | Rickets, vitamin D-resistant, type IIA, 277440 ?Osteoporosis, involutional, 166710 (1) |
| VHL | 128.4 | 100% | 100% | von Hippel-Lindau syndrome, 193300 Renal cell carcinoma, somatic, 144700 Pheochromocytoma, 171300 Hemangioblastoma, cerebellar, somatic Erythrocytosis, familial, 2, 263400 |

| | | | | |
|---------|-------|------|------|--|
| VIM | 97.7 | 100% | 100% | Cataract 30, pulverulent, 116300 |
| VIPAS39 | 115.0 | 100% | 97% | Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 |
| VKORC1 | 120.2 | 100% | 100% | Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 Warfarin resistance, 122700 |
| VLDLR | 117.9 | 100% | 100% | Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 |
| VPS13A | 122.9 | 100% | 98% | Choreoacanthocytosis, 200150 |
| VPS13B | 113.3 | 99% | 98% | Cohen syndrome, 216550 |
| VPS33B | 102.6 | 100% | 97% | Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 |
| VPS35 | 78.0 | 96% | 90% | Parkinson disease 17, 614203 |
| VPS37A | 84.0 | 100% | 97% | Spastic paraplegia 53, autosomal recessive, 614898 |
| VPS45 | 104.4 | 99% | 97% | Neutropenia, severe congenital, 5, autosomal recessive, 615285 |
| VRK1 | 133.6 | 100% | 100% | Pontocerebellar hypoplasia type 1A, 607596 |
| VSX1 | 55.8 | 99% | 88% | Keratoconus 1, 148300 Corneal dystrophy, hereditary polymorphous posterior, 122000 Craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 |
| VSX2 | 62.5 | 100% | 94% | Microphthalmia with coloboma 3 |
| VWF | 59.3 | 78% | 71% | von Willebrand disease, types 2A, 2B, 2M, and 2N, 613554 von Willebrand disease, type 1, 193400 von Willibrand disease, type 3, 277480 |
| WAS | 27.3 | 89% | 69% | Wiskott-Aldrich syndrome, 301000 Thrombocytopenia, X-linked, 313900 Neutropenia, severe congenital, X-linked, 300299 Thrombocytopenia, X-linked, intermittent, 313900 |
| WDPCP | 93.8 | 100% | 99% | Bardet-Biedl syndrome 15 |
| WDR11 | 93.9 | 100% | 99% | Hypogonadotropic hypogonadism 14 with or without anosmia, 614858 |
| WDR19 | 123.9 | 100% | 100% | Asphyxiating thoracic dystrophy 5, 614376 Nephronophthisis 13, 614377 Cranioectodermal dysplasia 4, 614378 |
| WDR34 | 88.2 | 100% | 97% | Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 |
| WDR35 | 121.8 | 99% | 97% | Cranioectodermal dysplasia 2, 613610 Short rib-polydactyly syndrome, type V, 614091 |
| WDR36 | 121.3 | 99% | 95% | Glaucoma 1, open angle, G, 609887 |
| WDR45 | 42.3 | 100% | 89% | Neurodegeneration with brain iron accumulation 5, 300894 |
| WDR60 | 101.9 | 99% | 98% | Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 |

| | | | | |
|---------|-------|------|------|--|
| WDR62 | 100.3 | 98% | 94% | Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317 |
| WDR72 | 111.0 | 96% | 96% | Amelogenesis imperfecta, hypomaturation type, IIA3, 613211 |
| WDR81 | 112.3 | 99% | 98% | Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2, 610185 |
| WFS1 | 145.6 | 100% | 98% | Wolfram syndrome, 222300 Deafness, autosomal dominant 6/14/38, 600965 Wolfram-like syndrome, autosomal dominant, 614296 {Diabetes mellitus, noninsulin-dependent, association with}, 125853 |
| WHSC1L1 | 120.2 | 99% | 96% | Leukemia, acute myeloid, 601626 |
| WIPF1 | 92.9 | 100% | 97% | Wiskott-Aldrich syndrome 2, 614493 |
| WISP3 | 125.0 | 100% | 100% | Arthropathy, progressive pseudorheumatoid, of childhood, 208230 Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 |
| WNK1 | 144.2 | 100% | 99% | Pseudohypoaldosteronism, type IIC, 614492 Neuropathy, hereditary sensory and autonomic, type II, 201300 |
| WNK4 | 114.7 | 100% | 99% | Pseudohypoaldosteronism, type IIB, 614491 |
| WNT1 | 144.6 | 100% | 96% | Osteogenesis imperfecta, type XV, 615220 {Osteoporosis, early-onset, susceptibility to, autosomal dominant}, 615221 |
| WNT10A | 71.2 | 90% | 85% | Odontoonychodermal dysplasia, 257980 Schopf-Schulz-Passarge syndrome, 224750 Tooth agenesis, selective, 4, 150400 |
| WNT10B | 92.9 | 100% | 97% | Split-hand/foot malformation 6, 225300 |
| WNT3 | 137.2 | 97% | 94% | Tetra-amelia, autosomal recessive, 273395 |
| WNT4 | 141.9 | 92% | 92% | SERKAL syndrome, 611812 Mullerian aplasia and hyperandrogenism, 158330 |
| WNT5A | 106.6 | 100% | 99% | Robinow syndrome, autosomal dominant, 180700 |
| WNT7A | 132.1 | 100% | 100% | Ulna and fibula, absence of, with sever limb deficiency, 276820 Fuhrmann syndrome, 228930 |
| WRAP53 | 125.9 | 100% | 99% | Dyskeratosis congenita, autosomal recessive 3, 613988 |
| WRN | 140.5 | 100% | 99% | Werner syndrome |
| WT1 | 61.3 | 100% | 98% | Wilms tumor, type 1, 194070 Denys-Drash syndrome, 194080 Nephrotic syndrome, type 4, 256370 Frasier syndrome, 136680 Meacham syndrome, 608978 |

| | | | | |
|---------|-------|------|------|--|
| | | | | Mesothelioma, somatic, 156240 |
| WWOX | 105.4 | 100% | 98% | Esophageal squamous cell carcinoma, 133239 |
| XDH | 89.2 | 100% | 99% | Xanthinuria, type I, 278300 |
| XIAP | 69.4 | 84% | 76% | Lymphoproliferative syndrome, X-linked, 2, 300635 |
| XK | 60.0 | 100% | 84% | McLeod syndrome with or without chronic granulomatous disease, 300842 |
| XPA | 87.6 | 100% | 98% | Xeroderma pigmentosum, group A, 278700 |
| XPC | 122.8 | 100% | 98% | Xeroderma pigmentosum, group C, 278720 |
| XPNPEP3 | 130.7 | 100% | 99% | Nephronophthisis-like nephropathy 1, 613159 |
| YAP1 | 84.1 | 97% | 89% | Coloboma, ocular, 120433 Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or mental retardation, 120433 |
| YARS | 107.6 | 100% | 97% | Charcot-Marie-Tooth disease, dominant intermediate C, 608323 |
| YARS2 | 106.9 | 100% | 100% | Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 |
| ZAP70 | 88.5 | 87% | 87% | Selective T-cell defect, 269840 |
| ZBTB16 | 124.4 | 100% | 98% | Leukemia, acute promyelocytic, PL2F/RARA type Skeletal defects, genital hypoplasia, and mental retardation, 612447 |
| ZBTB24 | 163.9 | 100% | 100% | Immunodeficiency-centromeric instability-facial anomalies syndrome-2, 614069 |
| ZC4H2 | 54.5 | 100% | 98% | Wieacker-Wolf syndrome, 314580 |
| ZDHHC9 | 36.6 | 97% | 83% | Mental retardation, X-linked syndromic, Raymond type, 300799 |
| ZEB1 | 146.4 | 98% | 97% | Corneal dystrophy, posterior polymorphous, 3, 609141 Corneal dystrophy, Fuchs endothelial, 6, 613270 |
| ZEB2 | 154.5 | 100% | 99% | Mowat-Wilson syndrome, 235730 |
| ZFP57 | 16.5 | 82% | 30% | Diabetes mellitus, transient neonatal, 1, 601410 |
| ZFPM2 | 183.8 | 98% | 98% | Tetralogy of Fallot, 187500 Diaphragmatic hernia 3, 610187 |
| ZFYVE26 | 88.6 | 96% | 93% | Spastic paraplegia 15, autosomal recessive, 270700 |
| ZFYVE27 | 78.6 | 96% | 91% | Spastic paraplegia 33, autosomal dominant, 610244 |
| ZIC2 | 58.5 | 93% | 86% | Holoprosencephaly-5, 609637 |
| ZIC3 | 54.2 | 100% | 97% | Heterotaxy, visceral, 1, X-linked 306955 Congenital heart defects, nonsyndromic, 1, X-linked, 306955 VACTERL association, X-linked, 314390 |

| | | | | |
|----------|-------|------|------|--|
| ZMPSTE24 | 162.4 | 100% | 100% | Mandibuloacral dysplasia with type B lipodystrophy, 608612 Restrictive dermopathy, lethal, 275210 |
| ZMYND10 | 96.6 | 100% | 92% | Ciliary dyskinesia, primary, 22, 615444 |
| ZNF335 | 82.1 | 98% | 94% | Microcephaly 10, primary, autosomal recessive, 615095 |
| ZNF423 | 127.9 | 100% | 99% | Nephronophthisis 14, 614844 Joubert syndrome 19, 614844 |
| ZNF469 | 94.6 | 100% | 99% | Brittle cornea syndrome, 229200 |
| ZNF513 | 99.1 | 100% | 96% | Retinitis pigmentosa 58, 613617 |
| ZNF592 | 114.5 | 94% | 92% | Spinocerebellar ataxia, autosomal recessive 5, 606937 |
| ZNF644 | 168.2 | 100% | 100% | Myopia 21, autosomal dominant, 614167 |
| ZNF711 | 82.6 | 100% | 100% | Mental retardation, X-linked 97, 300803 |
| ZNF750 | 122.9 | 100% | 99% | Seborrhea-like dermatitis with psoriasiform elements, 610227 |
| ZNF81 | 46.3 | 99% | 96% | Mental retardation, X-linked 45, 300498 |

Gene symbols used follow HGNC guidelines Genomics 79(4):464-470 (2002) updated February 2014

Median Coverage describes the average number of reads seen across 50 exomes

% Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x

% Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x

OMIM release used for OMIM disease identifiers and descriptions : 31 october 2014

Ad 1. "No OMIM phenotype" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors